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 5 
Introduction 
 
 
“Διαιτήμασί τε χρήσομαι ἐπ᾽ ὠφελείῃ καμνόντων κατὰ δύναμιν καὶ κρίσιν ἐμήν, 
ἐπὶ δηλήσει δὲ καὶ ἀδικίῃ εἴρξειν.” 
 
 
“I will apply, for the benefit of the sick, all measures which are required, 
avoiding those twin traps of overtreatment and therapeutic nihilism.” 
 
 
The quote mentioned above is part of 
a modern translation of the oath of 
Hippocrates (460 BC – 370 BC). Even 
though the original Hippocratic oath 
has been highly debated throughout 
the years, in particular regarding 
abortion and euthanasia,1 it is unlikely 
that any physician will disagree with 
the moral value behind the 
highlighted quote. This quote implies 
that the outcome of patients is 
continuously monitored and new 
measures that benefit the sick are 
proactively investigated. In this 
thesis, we investigate new measures 
to accurately monitor patients with 
ANCA associated vasculitis for disease 
activity during follow-up. These 
findings may in the future be used to 
guide maintenance therapy in order to 
reduce overtreatment and therapeutic 
nihilism. 
Before we continue to recent findings 
and new insights regarding ANCA 
associated vasculitis, we shall first 
describe the history of research in the 
field of ANCA associated vasculitis in 
order to appreciate our findings in the 
correct context. 
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A historical perspective
Periarteritis nodosa 
In 1866, Kussmaul and Maier reported 
a 27-year old journeyman tailor who 
developed fever, myalgia, 
mononeuritis multiplex, abdominal 
pain and proteinuria. The disease 
progressed rapidly and he died 5 
weeks later.2 At autopsy the 
involvement of medium-sized vessels 
was observed with the naked eye: 
“Peculiar mostly nodular thickening of 
countless arteries of and below the 
calibre of the liver artery and the 
major branches of the coronary 
arteries of the heart, principally in the 
bowel, stomach, kidneys, spleen, 
heart and voluntary muscles, and, to 
a lesser extent, also in the liver, 
subcutaneous cell tissue, and in the 
bronchial and phrenic arteries.”2 
According to Kussmaul and Maier, the 
vascular abnormalities originated 
from foci of fibrinoid necrosis and 
inflammation in the perivascular 
sheaths and resulted in small 
aneurysms along the course of the 
vessel wall. Hence, they described 
their observations as periarteriitis 
nodosa.2 Ferrari later observed that 
the necrotizing vascular lesions were 
transmural and not only limited to the 
perivascular sheaths and reasoned 
that the term polyarteritis [acuta] 
nodosa was more appropriate.3 
 
After the original report of Kussmaul 
and Maier of polyarteritis nodosa, 
defined by the gross macroscopic 
abnormalities of the vasculature, 
several other cases were reported 
with large heterogeneity in clinical 
and histopathologic features. In fact, 
by 1938 an estimated 395 cases were 
reported according to Boyd.4 Some 
authors argued that ‘the term 
[periarteritis nodosa] had gradually 
encompassed a wide variety of 
vascular conditions, some of which 
had little in common with those 
lesions for which the name was 
originally coined.”5 Several cases of 
subvariants of periarteritis nodosa are 
highlighted below that formed the 
basis of the nomenclature that we use 
in the present time.  
 
Microscopic Polyangiitis 
The involvement of various sizes of 
arteries and venules was subject to 
debate. While macroscopic nodular 
abnormalities along the course of the 
wall of arteries were observed in most 
reported cases with polyarteritis 
nodosa, in some patients vascular 
inflammation was detectable only by 
microscope.6 In his article ‘Uber die 
nur mikroskopisch erkennbare form 
der periarteriitis nodosa’, Wohlwill 
introduced the term microscopic 
periarteriitis nodosa.7 Davson et al. 
highlighted the renal lesions of 
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segmental necrotizing 
glomerulonephritis as a form of 
microscopic periarteritis nodosa.8 
At that time, microscopic necrotizing 
arteritis was increasingly recognized 
as a manifestation of 
hypersensitivity.5,9 Similar lesions of 
microscopic necrotizing arteritis were 
sometimes observed after 
administration of the antibiotic drug 
sulphonamide, as well as in patients 
with serum sickness. In addition, it 
was claimed by several authors that 
similar lesions could be induced in 
animal models by administration of 
various substances, including horse 
serum, egg white, bacterial toxin and 
other non-specific proteins. Zeek 
argued that patients with microscopic 
necrotizing arteritis should be 
distinguished from the classic 
periarteritis nodosa and categorized 
them as hypersensitivity angiitis 
because she assumed that the lesions 
were most likely induced by a foreign 
agent, such as sulphonamide. In 
addition, she reasoned that the term 
angiitis would be more appropriate 
because abnormalities were observed 
in arteries as well as venules.  
 
Allergic Granulomatosis 
Jacob Churg and Lotte Strauss had 
read the same cases as Zeek 
regarding the causal role of 
hypersensitivity with polyarteritis 
nodosa. However, they were most 
intrigued by the relationship between 
allergy, such as severe asthma, and 
the development of polyarteritis 
nodosa, as had been reported among 
others by Rackemann and Greene in 
1939 and later emphasized by 
Harkavy.10-12 In their seminal paper in 
1951, 13 cases of polyarteritis nodosa 
were presented with severe asthma 
which they named Allergic 
Granulomatosis. Other symptoms 
included fever, hypereosinophilia, 
cardiac involvement, in particular 
pericarditis, peripheral neuropathy 
and all patients had signs of renal 
damage in the form of hematuria and 
albuminuria. At autopsy, macroscopic 
nodular abnormalities along the 
course of arteries were observed in 
the majority of patients. In addition, 
extravascular lesions in the 
connective tissue were present in the 
form of necrotizing granulomas 
associated with or replacing an 
inflammatory exudate. While this was 
also observed in cases with Wegener’s 
Granulomatosis, the common 
denominator in the presented cases 
was the presence of eosinophils in the 
exudate as well as in the necrotic core 
of the granuloma (which they 
subsequently called the allergic 
granuloma). Different stages could be 
identified from the composition of the 
exudate:  
”In the acute stage the predominant 
cell was the eosinophilic leukocyte, 
which constituted as much as 70 or 
80% of the exudate. The number of 
eosinophils decreased as the acute 
Introduction 
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inflammation subsided, but they were 
seldom entirely absent. Further 
characteristic elements were 
macrophages and giant cells […], 
these became more prominent as the 
process tended towards the subacute 
and chronic stages. In addition, there 
were varying numbers of plasma cells, 
lymphocytes and neutrophils.”12 
 
While renal involvement was 
observed in most cases, histologic 
evidence frequently consisted of 
diffuse or focal interstitial nephritis 
with influx of eosinophils. Glomerular 
lesions were seen in most of the 
cases, but mostly focal and rarely 
affecting the majority of glomeruli. 
Churg and Strauss hypothesized that 
the presence of the allergic granuloma 
was a separate histopathologic entity, 
while the presence of angiitis was its 
most malignant expression.12 
Churg and Strauss agreed with Zeek 
that hypersensitivity angiitis most 
likely was a separate disease entity as 
compared to the classic polyarteritis 
nodosa. Interestingly, one of the 
patients presented by Zeek as 
hypersensitivity angiitis had severe 
asthma, similar to the cases of Churg 
and Strauss. Churg and Strauss 
argued that an allergic etiology of 
necrotizing arteritis was clearly 
proven in their case series and that it 
also should be regarded as a separate 
disease entity. The terms allergic and 
hypersensitivity have later been 
abandoned by others because even 
though a sensitivity phenomenon is 
involved, there is no unequivocal 
evidence of hypersensitivity or allergy 
in all cases.13-15 
 
Wegener’s Granulomatosis 
Another variant of periarteriitis 
nodosa of importance was first 
described by Klinger in 1931. He 
reported a patient who presented with 
severe sinusitis with inflammatory 
upper respiratory tract lesions, 
proptosis and arthralgia and 
eventually died due to renal failure.16 
Thereafter, Wegener reported several 
patients with similar disease 
manifestations and proposed that 
they form an entity separable from 
the usual forms of periarteriitis 
nodosa on the basis of clinical and 
histopathological evidence.17,18 
Histologic evaluation was 
characterized by necrotizing angiitis 
and glomerulonephritis, but also by 
granuloma formation in the upper 
respiratory tract, often necrotic and 
usually containing giant cells. The 
term Wegener’s Granulomatosis was 
first coined by Godman and Churg, 
who formulated the following 
criteria:14  
“(1) necrotizing granulomatous 
lesions in the upper air passages, 
lower respiratory tract or both, (2) 
generalized focal necrotizing 
vasculitis involving both arteries and 
veins, almost always present in the 
lungs and more or less widely 
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disseminated in other sites, and (3) 
glomerulitis, characterized by 
necrosis and thrombosis of loops or 
lobes of the capillary tuft, capsular 
adhesions and evolution as a 
granulomatous lesion.” 
 
Similar to the diagnosis of 
polyarteritis nodosa, the prognosis of 
these patients was morbid:19 
“The duration is brief, six months on 
the average, and the outcome in 
recognized cases would appear to be 
fatal. At times the illness runs an 
intermittent or subacute course for 
two or more years.” 
 
Making sense of nomenclature 
Differences in histopathology have led 
to considerable nosological 
confusion.15 A particular definition 
could describe such a heterogeneous 
group of features (e.g. periarteritis 
nodosa), while a particular feature 
was described by various definitions 
(e.g. hypersensitivity and microscopic 
angiitis). The following comment of 
Fienberg captured the associated 
frustration strikingly:  
“It can hardly be doubted that this 
plethora of terms has added to the 
confusion regarding this disease.”15 
Several attempts were made to 
classify patients in different forms of 
vasculitis with unconvincing results, 
which led to even more classification 
schemes. This is not surprising, as 
stated by Lie: “For a group of 
conditions that lack pathognomonic 
clinical features, diagnostic laboratory 
tests, or a uniform histopathologic 
expression, and with unknown or 
incompletely understood etiology and 
pathogenesis for all of them save few, 
the classification of vasculitis 
according to a schema with universal 
acceptance is virtually an impossible 
task.”13 
 
Lack of standardisation in diagnostic 
terms and definitions was a major 
problem in order to establish the 
clinical significance of the 
histopathologic features. Therefore, a 
group of clinicians sought consensus 
during the Chapel Hill Conference 
(CHCC) in 1994 regarding the 
nomenclature.20 Small vessel 
vasculitis was divided in Wegener’s 
Granulomatosis if granulomatous 
inflammation and necrotizing 
vasculitis was observed, Churg-
Strauss Syndrome if tissue 
eosinophilia, hypereosinophilia or 
asthma was also present and 
Microscopic Polyangiitis (MPA) if 
necrotizing vasculitis was observed 
but not granulomatous inflammation. 
The CHCC nomenclature was revised 
during the next Chapel Hill Consensus 
Conference in 2012.21 In particular, 
there was a gradual shift from naming 
diseases in honour of the first 
person(s) who described them in 
greater detail, to a terminology based 
on pathology or etiology. In addition, 
evidence was found that Friedrich 
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Wegener was a member of the Nazi 
party before and during the Second 
World War.22 Therefore, Wegener’s 
Granulomatosis was renamed to 
Granulomatosis with Polyangiitis 
(GPA) and Churg Strauss Syndrome 
to Eosinophilic Granulomatosis with 
Polyangiitis (EGPA)(see Table 1-1).21
 
 
Name Definition 
Granulomatosis with 
Polyangiitis (Wegener’s) 
Necrotizing granulomatous inflammation usually 
involving the upper and lower respiratory tract, 
and necrotizing vasculitis affecting 
predominantly small to medium vessels (e.g., 
capillaries, venules, arterioles, arteries and 
veins). Necrotizing glomerulonephritis is 
common. 
Microscopic Polyangiitis Necrotizing vasculitis, with few or no immune 
deposits, predominantly affecting small vessels 
(i.e., capillaries, venules, or arterioles). 
Necrotizing arteritis involving small and medium 
arteries may be present. Necrotizing 
glomerulonephritis is very common. Pulmonary 
capillaritis often occurs. Granulomatous 
inflammation is absent 
Eosinophilic 
Granulomatosis with 
Polyangiitis (Churg 
Strauss) 
Eosinophil-rich and necrotizing granulomatous 
inflammation often involving the respiratory 
tract, and necrotizing vasculitis predominantly 
affecting small to medium vessels, and 
associated with asthma and eosinophilia. ANCA 
is more frequent when glomerulonephritis is 
present. 
Table 1-1. Definitions for small vessel vasculitis adopted by the 2012 International 
Chapel Hill Consensus Conference (CHCC2012). 
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The double-edged sword known as 
cyclophosphamide 
Most of the clinicians involved in the 
diseases described above were of the 
opinion that the etiology was most 
likely related to hypersensitivity.14,15 
Hence, several immunosuppressive 
therapies were tried, such as 
corticosteroids, azathioprine, 
methotrexate and 
cyclophosphamide.23-27 The effect of 
cyclophosphamide in particular 
seemed promising, as reported by 
several case reports in the 1970s.26-29 
A single-centre cohort study showed 
that cyclophosphamide therapy 
resulted in the complete resolution of 
symptoms of active disease in 79 of 
85 (93%) patients.29 As a result, 
cyclophosphamide became the 
cornerstone of induction therapy in 
patients with Granulomatosis with 
Polyangiitis.  
At that time, the treatment protocol 
consisted of cyclophosphamide, 
2mg/kg bodyweight, and prednisone, 
1mg/kg bodyweight. Prednisone 
regimen was gradually tapered, 
starting with an alternate-day 
regimen after 1 to 2 months, while 
cyclophosphamide was continued for 
at least one full year after the patient 
was in complete remission. In the 
initial cohort study, 23 (27%) patients 
were completely off therapy. 
However, 25 (29%) patients who had 
initially achieved remission 
experienced symptoms related to 
active disease during follow-up, in 
particular when cyclophosphamide 
was tapered. Immunosuppressive 
therapy was restarted in these 
patients and symptoms quickly 
resolved.30 
Unfortunately, immunosuppressive 
therapy, in particular 
cyclophosphamide, was associated 
with serious side-effects; patients 
were at risk of leukopenia and 
susceptible to potentially life-
threatening infections.31 Gonadal 
dysfunction was invariably linked to 
the treatment, as well as 
haemorrhagic cystitis.30,32,33 In 
addition, long-term effects were 
sobering; patients treated with 
cyclophosphamide had a 2.4-fold 
overall increase in malignancies, in 
particular an increased risk for 
bladder cancer and lymphomas.34 
Immunosuppressive therapy was 
effective against active disease, but 
not against vasculitic damage. As 
such, almost all patients suffered from 
morbidity related to the disease 
and/or treatment, including end-
stage renal failure.34 These results 
ushered in a new era in which patients 
are no longer diagnosed with a fatal 
disease, but they suffer from a chronic 
disease instead. In this new era, 
clinicians were looking for strategies 
to decrease treatment-related side-
effects, while keeping the disease 
activity under control. 
 
Introduction 
12 
A spectrum of disease severities 
After the establishment of 
cyclophosphamide induction therapy, 
it was hypothesized that 
immunosuppressive therapy could be 
reduced in patients with less severe 
disease activity in order to avoid 
treatment-related side-effects. At the 
time of the first classification 
schemes, the insidious onset of 
Granulomatosis with Polyangiitis was 
already appreciated.14,15 In 1956, 
Leggat and Walton presented an 
illustrative case of a 42-year old 
women with necrotizing granulomas 
that were limited to the respiratory 
tract and no signs of renal 
involvement. During follow-up, 7 
months after initial presentation, 
hematuria and albuminuria was 
observed and her condition 
deteriorated shortly thereafter. At 
autopsy, glomerulonephritis was 
uncovered amongst other findings of 
Granulomatosis with Polyangiitis.35 It 
was postulated that a diagnosis in the 
early stage of the disease was 
possible in which the lesions are 
confided to the respiratory tract.35 In 
addition, a diagnosis of 
Granulomatosis with Polyangiitis was 
debated in several cases with 
pulmonal lesions with similar 
histopathology and no renal 
involvement, but the diagnosis of 
Granulomatosis with Polyangiitis was 
at that time rejected because they did 
not fulfil the full triad of criteria as 
described by Godman and Churg.15,36-
38  
In 1966, Carrington and Liebow 
presented 16 patients with pulmonary 
lesions identical to Granulomatosis 
with Polyangiitis, but with absent or 
limited lesions elsewhere.39 
Importantly, no signs of 
glomerulonephritis were observed. 
The authors proposed that these 
patients suffered from a limited form 
of Granulomatosis with Polyangiitis as 
there was no means at the time to 
distinguish them at the onset from the 
classic disease. The outcome in these 
patients was more favourable but 
nevertheless grave as approximately 
one third died within a year. 
Promisingly, several patients 
responded to corticosteroid 
monotherapy, which was not the case 
in patients with generalized forms of 
Granulomatosis with Polyangiitis. 
 
Not everyone agreed with the 
sentiment to reduce treatment in 
patients with limited forms of the 
disease. Fienberg observed the 
development of renal failure and 
mutilation of the face in a series of 12 
patients because cytotoxic therapy 
was not started at the onset of 
symptoms, often because of a lack of 
proper interpretation of histologic 
details.40 He described the earliest 
lesions that should warn pathologists 
for Granulomatosis with Polyangiitis 
as: 
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“Very small foci consisting of a 
granular type of necrosis or fibrinoid 
degeneration without neutrophils or 
vascular participation. These foci at 
first [...] possessed few or no 
palisading histiocytes at the 
periphery, but as they became older 
and larger they developed well 
defined palisading margins. In some 
older foci of fibrinoid degeneration the 
affected collagen became smudged 
and then disintegrated, but 
occasionally necrotic bundles 
remained intact within the margin of 
palisaded cells.”  
Interestingly, necrotizing angiitis was 
absent in 4 of the 12 cases. As such, 
Fienberg was reluctant to define 
limited forms of vasculitis as a 
separate disease entity but at the 
same time refuted the necessity of a 
full triad of criteria as described by 
Godman and Churg.  
 
Nevertheless, the European Vasculitis 
Society (EUVAS) set out in the 
nineties to harmonize treatment 
strategies for the different stages of 
disease. It was agreed that the 
immunosuppressive treatment should 
reflect the severity of the disease.41 
The EUVAS group arbitrarily 
categorized patients in localised, early 
systemic, generalised, renal severe or 
refractory disease.41 This 
classification tries to reflect the 
postulated (natural) progress of the 
disease, although refractory disease is 
included as well and it is clear that 
patients cannot be classified as such 
at presentation. 
Among others and not limited to the 
following examples, the efforts of the 
EUVAS group has resulted in 
randomized clinical trials that 
investigated the use methotrexate in 
early systemic disease (NORAM)42, 
oral versus intravenous 
cyclophosphamide as induction 
therapy (CYCLOPS)43 and 
azathioprine (CYCAZAREM)44 or 
Mycophenolate mofetil (IMPROVE)45 
as maintenance therapy. Most 
recently, an induction therapy based 
primarily on Rituximab, a monoclonal 
antibody targeted against B-cells, was 
found to be non-inferior as compared 
to an induction therapy based on 
cyclophosphamide (RITUXVAS).46 
The Wegener's Granulomatosis 
Etanercept Trial (WGET) group later 
classified their patients as "limited" in 
the absence of disease features that 
pose immediate threats to either a 
critical individual organ or to the 
patient’s life and as "severe" 
otherwise.47,48 The WGET group 
classified patients based on the need 
of directly initiating maximal therapy, 
which may be more pragmatic for the 
clinician who needs to decide between 
aggressive (i.e. cyclophosphamide or 
Rituximab) or a milder form of 
treatment (i.e. methotrexate).47,48 
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The discovery of anti-neutrophil 
cytoplasmic antibodies 
The occurrence of antibodies directed 
against neutrophils had already been 
described in the 1960s.49,50 In those 
early days, granulocyte-specific 
antinuclear antibodies (GS-ANA) were 
defined as antinuclear antibodies 
reacting specifically with granulocyte 
nuclei or when reactivity with 
granulocytes was higher than 
reactivity with other cell nuclei (by at 
least two dilution steps).51 These 
antibodies were most often found in 
patients with rheumatoid arthritis 
and/or Felty’s syndrome. 
Unfortunately, attempts to discover 
the antigen failed repeatedly.51 In 
1982, the occurrence of anti-
neutrophil cytoplasmic antibodies in 8 
patients with segmental necrotizing 
glomerulonephritis was described by 
Davies et al.52 ANCA were detected by 
the staining of neutrophil leukocytes 
after formalin fixation by indirect 
immunofluorescence (IIF), which 
resulted in a cytoplasmic pattern (C-
ANCA). Thereafter, it was recognized 
that ANCA was observed in GPA53 and 
that the target antigen of ANCA in 
these patients was proteinase 3. 
Furthermore, MPO was found to be 
the target antigen in patients with 
PR3-ANCA negative GPA, MPA and/or 
EGPA.54-56 Indirect 
immunofluorescence using ethanol 
dissolves the myeloperoxidase from 
the granules, which subsequently 
attaches to the cell nucleus, resulting 
in a perinuclear staining pattern (P-
ANCA).55 This is not the case with 
proteinase 3, which remains 
cytoplasmic after ethanol fixation and 
thereby keeping the C-ANCA pattern 
as a result. Importantly, patients with 
necrotizing glomerulonephritis are 
nearly always ANCA positive,54,56 
while ANCA are not always found in a 
subgroup of patients with more 
limited disease.57,58  
 
The pathogenicity of MPO-ANCA was 
confirmed using a mouse model in 
2002 by Xiao et al.59 In this study, 
antibodies against MPO were first 
produced in MPO-deficient mice that 
were immunized by mouse MPO. 
These antibodies subsequently 
induced focal necrotizing crescentic 
glomerulonephritis one week after 
injection into wild-type C57BL/6 
mice.59 Vasculitis has, subsequently, 
been induced by MPO-ANCA in several 
other mouse models, thereby 
emphasizing the pathogenicity of the 
autoantibody.60 Induction of vasculitis 
by PR3-ANCA in mice has proven to be 
difficult, in part because proteinase 3 
is not expressed on peripheral blood 
leukocytes in mice.61 Immunisation 
with chimeric human/mouse 
proteinase 3 led to an autoantibody 
response but not to gross pathological 
abnormalities in rats and mice.62 Little 
et al. circumvented the lack of 
proteinase 3 on mice neutrophils by 
using chimeric mice that were 
generated by injecting human 
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haematopoietic stem cells into 
irradiated mice. Injection of human 
IgG from patients with PR3-ANCA in 
these mice subsequently led to mild 
proliferative glomerulonephritis and 
punctate bleeding on the surface of 
lungs.63 63,64 Importantly, vasculitis 
has readily been induced by ANCA in 
mice but not granuloma formation. It 
has been suggested but not proven 
that “[MPO-ANCA] can cause severe 
extravascular granulomatous 
inflammation in mice if they have 
predisposing characteristics of their 
innate immune system and 
synergistic inflammation.”65  
Furthermore, results from animal 
studies have led to new insights in the 
pathophysiology of ANCA associated 
vasculitis. The priming of neutrophils 
by bacterial lipopolysaccharide is 
required for anti-proteinase-3 
antibody-induced alveolar 
haemorrhage and 
glomerulonephritis63 and aggravates 
anti-myeloperoxidase antibody-
induced glomerulonephritis.64 These 
findings have resulted in the “second 
hit” hypothesis, which postulates that 
ANCA-induced (severe) disease 
reactivation is enabled by or 
aggravated by a “second hit”, such as 
a bacterial infection. Next to 
microorganisms, several other 
candidates for a second hit have been 
postulated, such as environmental 
factors66,67, and/or other auto-
antibodies.68,69  
 
The presence of PR3- or MPO-ANCA in 
ANCA-associated vasculitis has since 
been undisputed and has been 
incorporated in the current 
classification schemes.21,70 The 
association between ANCA and the 
diagnosis of GPA, MPA or EGPA was 
not yet fully elucidated at the time of 
the first Chapel Hill Consensus 
Conference and was therefore not 
included.20 The revised CHCC in 2012 
has incorporated the presence of PR3- 
or MPO-ANCA in small vessel 
vasculitis, but still requires 
histological evidence.21 The European 
Medical Agency developed and 
validated another classification 
scheme that replaces the need for 
histology if positive serology for PR3- 
or MPO-ANCA is present and 
surrogate markers for GPA or renal 
vasculitis are present.70 
 
The association between serial ANCA 
measurements and disease activity 
Soon after the discovery of ANCA as a 
diagnostic marker for GPA, it was 
recognized that ANCA titer rises were 
associated with disease relapses 
during follow-up.71 In one of the initial 
studies, 35 patients with GPA were 
prospectively followed. Patients were 
evaluated every month for signs and 
symptoms attributable to disease 
activity and blood was drawn for 
ANCA testing using IIF. Most 
importantly, physicians were blinded 
to the results of the ANCA tests. 
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Relapses were subdivided in minor or 
major, depending on whether the 
relapse was potentially organ- or life 
threatening or not. Eight major 
relapses and 9 minor relapses were 
observed during the study period of 
16 months. All relapses were 
preceded by an ANCA rise. Only one 
patient demonstrated ANCA rises that 
were not followed by relapses.71 This 
observation led to a multitude of 
studies to investigate the value of 
serial ANCA measurements to predict 
disease activity.72,73 If an ANCA rise is 
indeed followed by a relapse of 
disease activity, then 
immunosuppressive therapy may be 
pre-emptively started to prevent the 
relapse to occur.74 However, such a 
strategy is hampered by potential 
unnecessary exposure to treatment-
related side-effects in patients in 
whom no relapse would occur after an 
ANCA rise. Therefore, the use of serial 
ANCA measurements to guide therapy 
has been controversial and subject to 
debate.72,73  
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The present state of ANCA associated vasculitis
The prognosis of patients with ANCA 
associated vasculitis has improved 
dramatically over the years. This is 
not only related to the introduction of 
immunosuppressive therapy in the 
1960s, as survival rates increased 
even further in the next decades. 
Results from a single centre inception 
cohort of 181 patients from the 
Limburg Renal Registry have shown 
that patients diagnosed in the period 
1979-1989 had a 3.9 times higher 
mortality rate as compared to patients 
diagnosed in the period 2001-2009.75 
An analysis on the long term outcome 
of a combined cohort of EUVAS trials 
observed a 1-, 2- and 5-year survival 
of 88%, 85% and 78%, 
respectively.76 The major prognostic 
factors for mortality at the time of 
diagnosis are advanced age, worse 
kidney function and higher disease 
activity using the Birmingham 
Vasculitis Activity Score (BVAS) at 
presentation.77 Most deaths occur in 
the first year after the initiation of 
treatment and are most often caused 
by treatment-related side-effects, 
such as infections (50%), rather than 
active vasculitis (14%).78 After the 
first year, mortality rates markedly 
improve but remain slightly higher 
than the general population and are 
most often caused by cardiovascular 
events, malignancy and infection.76 
Cardiovascular disease remains an 
important issue during follow-up, 
since patients with ANCA associated 
vasculitis have a two- to fourfold 
increased risk of coronary artery 
disease as compared to the general 
population,79,80 independent of classic 
cardiovascular risk factors.81 
 
Multiple factors may have resulted in 
the markedly improved survival rate 
in patients with ANCA associated 
vasculitis. First, discovery of ANCA 
has significantly helped to establish 
the correct diagnosis. This is evident 
in the reduction in the delay between 
the diagnosis and the first onset of 
symptoms. A Finnish study reported a 
decrease in diagnostic delay from a 
median of 17 months in the period of 
1981-1985 to only 4 months in the 
period of 1996-2000.82 An earlier 
survey amongst GPA in North America 
observed similar results and observed 
a decrease in number of physicians 
seen by the patient prior to the 
diagnosis from 5.5 in the 1970s to 4.4 
in the 1990s, a number that is still in 
need of improvement.83  
Second, clinical trials from the last 
decades have resulted in treatment 
strategies that requires less 
cyclophosphamide to induce 
remission. This is most evident 
considering the reported 
cyclophosphamide exposure was an 
average of 40 months in the original 
study of Fauci et al.29, while the 
cyclophosphamide exposure is 
currently kept to a minimum of 3 to 6 
months. The reduction in 
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cyclophosphamide has subsequently 
resulted in a decrease of treatment-
related side-effects, in particular the 
incidence of malignancy. While a 
recent meta-analysis concluded that 
patients treated with 
cyclophosphamide are still at 
increased risk of late-occurring 
malignancies84, malignancy risk 
reduces significantly with lower 
exposure to cyclophosphamide.85 
Most importantly, patients treated 
with rituximab do not have an 
increased risk of a malignancy as 
compared to the general population.86  
 
Relapses were less of a concern at the 
time of the introduction of 
cyclophosphamide. The reduction in 
mortality was a major improvement 
and patients were simply given more 
cyclophosphamide when symptoms 
returned.30 However, with the advent 
of immunosuppressive sparing 
treatment protocols, relapses have 
become a major concern. A 
systematic review in 2008 observed a 
relapse rate of 18 to 40% at 24 
months and a time to first relapse of 
15 to 29 months.87 The combined 
cohort of EUVAS trials reported an 
overall relapse risk of 38% at 5 
years.88 Relapses during follow-up are 
associated with the occurrence of 
irreversible damage.89-93 While most 
damage occurs at initial 
presentation94, patients are still at risk 
of developing further damage at a 
subsequent relapse.90 The reduction 
of damage occurring at relapse versus 
diagnosis can most likely be 
accredited to the vigilance of expert 
physicians, since most patients are 
referred to a centre of excellence once 
the diagnosis has been made. A 
further analysis of occurring relapses 
show that relapses with renal 
involvement lead to more damage, in 
particular renal failure.89 Damage 
during long term follow-up most often 
consists of disease related damage 
caused by relapses, e.g. reduced 
renal function, nasal blockage and 
hearing loss, although treatment-
related damage also occurs, such as 
osteoporosis, malignancy and 
diabetes.95  
These observations have led to the 
proposal to classify patients based on 
relapse risk rather than the 
histopathology, disease severity at 
diagnosis or serology.96-99 However, 
no consensus has been reached yet 
regarding such a classification 
system. Moreover, as we will further 
describe in this thesis, these 
classification systems do not yet fully 
incorporate the biologic behavior of 
the disease and are in need of 
improvement. Such a classification 
system may in the future be used to 
guide maintenance therapy in 
patients with ANCA associated 
vasculitis. 
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Aim of the current thesis
From the historical perspective it is 
apparent that physicians have 
continuously searched for the optimal 
strategy to avoid those twin traps of 
overtreatment and therapeutic 
nihilism. However, evidence from the 
present state of ANCA associated 
vasculitis emphasizes the need for 
further improvement on this regard. 
The aim of the current thesis is to 
provide physicians tools to predict 
future disease activity in order to 
guide maintenance therapy in 
patients with ANCA associated 
vasculitis. These tools may in the 
future be used to prevent morbidity 
and mortality related to active 
disease, while minimizing treatment-
related side-effects. 
 
Serial ANCA measurements have 
been at the centre of attention in 
predicting disease activity since the 
discovery of ANCA, as reviewed in 
Chapter 3. However, the predictive 
value of an ANCA rise for a relapse 
could not be confirmed in several 
other studies, possibly due to 
considerable methodological and 
clinical heterogeneity.72,73 History has 
shown ANCA associated vasculitis 
consists of a spectrum of diseases 
based on differences in 
histopathology, disease severity and 
laboratory test results. Moreover, 
animal studies have shown that ANCA 
can readily induce vasculitis but not 
granulomatous disease. In addition, 
ANCA are nearly always found in 
severe disease, but not always in 
limited disease. Therefore, we 
hypothesized in Chapter 1 that ANCA 
rises may be highly associated with a 
relapse of capillaritis, in particular 
necrotizing glomerulonephritis, but 
not with a relapse of granulomatous 
disease. 
While several risk factors for a relapse 
have been described in the literature 
at the time of remission, no analyses 
have been performed at the time of an 
ANCA rise. In Chapter 2, we set out to 
investigate risk factors for a relapse at 
the time of an ANCA rise. In 
particular, we hypothesize that a 
second hit may be required to create 
a pro-inflammatory environment that 
enables the ANCA to become 
pathogenic. In the “second hit” 
hypothesis, ANCA-induced (severe) 
disease reactivation is enabled by or 
aggravated by an as yet unidentified 
“second hit”. 
 
Previous studies have only looked at 
the quantity of ANCA in relation to 
disease activity. We hypothesize that 
the pathogenicity of an ANCA rise is 
modulated by the quality of the 
autoantibody. Several characteristics 
of the autoantibody are worth 
mentioning. First, antibodies are 
separated in isotypes, of which 
immunoglobulin G is the most 
abundant. Immunoglobulin G consists 
of four subclasses, ranging from IgG1 
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to IgG4, based on the heavy-chain 
structure, resulting in different 
effector functions.100 In particular 
immunoglobulin G3 is effective in the 
induction of effector functions. 
Therefore, a prospective study 
investigated whether serial ANCA 
testing of the IgG3 subtype was more 
predictive of a relapse, but this could 
not be confirmed.101  
Second, not every ANCA targeted 
against PR3 or MPO reacts to the 
same epitope of PR3 or MPO, 
respectively. Antibodies may react to 
different epitopes of the antigen, 
ranging from a linear sequence of 
amino acids to a discontinuous 
complex of amino acids that come 
together in a three-dimensional 
conformation. In patients with ANCA 
associated vasculitis, it has been 
demonstrated that a substantial 
diversity of MPO-ANCA epitopes is 
present and some epitopes are 
exclusive to active disease.102 
Third, antibodies and antigen bind 
together to form an antigen-antibody 
complex. This complex is reversible 
and the strength of the complex may 
vary between antibody and antigens, 
which is expressed as the avidity. In 
Chapter 4, we explore whether the 
avidity of PR3-ANCA changes during 
follow-up. Importantly, we 
hypothesize that the avidity of the 
autoantibody is higher in relapsing 
patients compared to non-relapsing 
patients. 
Fourth, the effector function of the 
antibody is dependent on the glycan 
structure attached to the fragment 
crystallizable region. The 
glycosylation profile of the 
crystallizable fragment (Fc) of the 
immunoglobulin G (IgG) is 
characterized by a single N-linked 
glycan attached to each heavy chain 
at the asparagine-297.103 In Chapter 
5, we investigate the predictive value 
of the glycosylation profile at the PR3-
ANCA rise for a relapse. 
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Abstract 
The value of measuring anti-neutrophil cytoplasmic antibodies (ANCA) during 
follow-up to predict a relapse is controversial. Based on recently obtained 
pathophysiological insights, we postulated that measuring ANCA in patients with 
renal involvement is useful but less valuable in patient with non-renal disease. 
One-hundred-and-sixty-six consecutive patients with ANCA-associated 
vasculitis, positive for either PR3- or MPO-ANCA were included in our study, 
followed at regular intervals, and tested for PR3- and MPO-ANCA. One-hundred-
and-four patients had renal involvement (72 PR3-ANCA, 32 MPO-ANCA) and 62 
patients had non-renal disease (36 PR3-ANCA, 26 MPO-ANCA). During an 
average (±SD) follow-up of 49±33 months and 19±14 ANCA measurements, 89 
ANCA rises and 74 relapses were recorded. An ANCA rise is related with relapses 
in patients who present with renal involvement (HR 11.09 [95%-Cl 5.01-24.55]), 
while ANCA rises are only weakly associated with relapses in patients who 
present with non-renal disease (HR 2.79 [95%-Cl 1.30-5.98]). In conclusion, 
longitudinal ANCA measurements are useful in patients with renal involvement 
but less valuable in patients with non-renal disease. 
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Anti-neutrophil cytoplasmic 
antibodies (ANCA) play an important 
role in the pathophysiology of ANCA-
associated vasculitis (AAV).104 The 
value of measuring ANCA to predict 
disease activity, however, is 
controversial.71-73,105 A recent meta-
analysis calculated a pooled positive 
likelihood ratio of 2.8 (95% CI 1.7-
4.9), concluding that serial ANCA 
measurements are of limited value.73 
The interpretation of this meta-
analysis is, however, difficult since the 
published studies are very 
heterogeneous and prospective and 
retrospective studies are lumped 
together. Based on pathophysiological 
insights104, we hypothesize that serial 
measuring ANCA is useful in patients 
with renal involvement but less 
valuable in patients with non-renal 
disease. In mouse models it has been 
demonstrated that ANCA induce 
glomerulonephritis but require more 
modification to induce granulomatous 
lesions.65 Furthermore, ANCA is 
nearly always found in patients with 
renal involvement whereas a 
subgroup of patients with non-renal 
disease are clearly ANCA 
negative.57,105 Therefore, we 
investigated the relationship of an 
ANCA rise with a relapse in our cohort 
and divided our patients in those with 
and without renal involvement. 
 
Between January 1, 2000 and 
November 1, 2011, 201 patients 
visited our University hospital with a 
diagnosis of ANCA-associated 
vasculitis21 and were positive for 
either MPO- or PR3-ANCA.106 Twenty-
eight patients were excluded because 
we could not obtain follow-up data. 
Seven patients were refractory to 
treatment and did not reach stable 
clinical remission; these patients were 
also excluded. Of the remaining 166 
patients, 74 (44.6%) patients did not 
experience a relapse during an 
average (±SD) follow-up of 7.5±5.9 
years. All other patients had one or 
more relapses: 1, 2, 3, 4, or 5 
relapses in 42 (25.3%), 31 (18.7%), 
7 (4.2%), 4 (2.4%) and 8 (4.8%) 
patients, respectively. The relapse 
frequency was on average 0.17±0.21 
per year for patients with PR3-ANCA 
and 0.11±0.18 for patients with MPO-
ANCA (p=0.06).  
 
ANCA as a predictor of a relapse 
26 
 
Total Renal Non-renal 
Patients 166 104 62 
Characteristics at time of previous disease activity 
Age in years 56.7±14.5 56.2±14.8 57.5±13.9 
Men/women 99/67 71/33 28/34 
PR3/MPO 108/58 72/32 36/26 
GPA/MPA/EGPA 126/23/17 83/19/2 43/4/15 
BVAS 14 [8-20] 18 [14-21] 8 [6-11] 
C-reactive protein 60.5 [15-144] 60 [17-144] 64 [12-135] 
Serum creatinine 108 [85-195] 148 [100-334] 87 [77-95] 
Organ involvement 
Arthralgia 76 49 27 
Cutaneous 41 31 10 
Eyes 30 20 10 
Ear, nose, throat 122 75 47 
Lung 124 74 50 
Cardiovascular 12 9 3 
Renal 104 104 0 
Dialysis 15 15 0 
Abdominal 11 10 1 
Central nervous system 5 2 3 
Peripheral nervous system 28 16 12 
Induction treatment resulting in remission 
Cyclophosphamide + GC 111 77 34 
Rituximab + GC 7 7 0 
Methotrexate + GC 13 6 7 
Mofetil mycophenolate + GC 10 8 2 
Azathioprine + GC 4 0 4 
GC monotherapy 16 3 13 
Other 5 3 2 
Plasmapheresis 30 29 1 
Characteristics during follow-up 
Time in months 48.6±33.0 48.1±34.4 49.6±13.7 
Measurements 17.9±14.0 19.0±14.7 16.1±12.7 
Non-persistently ANCA positive 116 73 43 
ANCA rise 89 60 29 
Major relapse 26 21 5 
Minor relapse 48 23 25 
Chapter 1 
27 
Table 1-1 (previous page). Patient characteristics. Values are expressed as mean 
± SD or median [inter-quartile range, IQR] or as the total. GC, glucocorticoids; PR3, 
proteinase-3; MPO, myeloperoxidase; GPA, granulomatosis with polyangiitis; MPA, 
microscopic polyangiitis; EGPA, eosinophilic GPA. 
 
 
 
To study the association of an ANCA 
rise with a relapse, the 166 patients 
were included when they entered their 
first remission after visiting our 
Hospital. Hundred and twenty-six 
patients (75.9%) were included 
during remission after diagnosis and 
40 patients during remission after a 
relapse. Baseline patient 
characteristics are presented in Table 
1-1. During an average follow-up of 
49±33 months and an average of 
18±14 ANCA measurements, 74 
patients relapsed: 26 major and 48 
minor. Eighteen patients included 
after a relapse and 74 patients 
included after diagnosis remained in 
remission. Seven patients died after a 
median follow-up of 3.3 year (1.2-
5.3), causes of death were unknown 
(n=4), cardiovascular (2), malignancy 
(2), infection (1) or cerebral (1). Five 
patients were lost to follow-up after a 
median follow-up of 3.3 years (1.8-
4.1). During follow-up, 89 ANCA rises 
were identified. These rises were 
observed after an average of 20±17 
months since the previous period of 
disease activity. After an ANCA rise, a 
relapse was diagnosed in 2 (2.2%), 
26 (29.2%), 35 (39.3%) and 45 
(50.6%) patients after <1, 6, 12 and 
18 months since the rise, 
respectively. The median (IQR) time 
elapsed between the ANCA rise and 
last follow-up visit in the patients that 
did not relapse was 41.5 months 
(30.3-51.0). 
At the time of relapse, all 26 patients 
with a major relapse were ANCA 
positive. In 24 (92%) patients the 
relapse was preceded by an ANCA 
rise. In contrast, only 32 of 48 
patients (67%) with a minor relapse 
were ANCA positive at the time of 
relapse and in only 28 (58%) patients 
the relapse was preceded by an ANCA 
rise. In patients who became ANCA 
negative during follow-up, all major 
relapses were preceded by an ANCA 
rise (see Figure 1-1).
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Figure 1-1. Flowchart of the included patients. As shown, patients who had become 
ANCA negative during follow-up did not experience a major relapse if an ANCA rise 
had not occurred. 
 
In the entire cohort, an ANCA rise is 
significantly associated with a relapse 
(HR 5.84 [95%-Cl 3.44-9.92], 
p<0.001). A rise is strongly related to 
a relapse in patients with renal 
involvement (HR 11.09 [95%-Cl 5.01-
24.55], p<0.001), while an ANCA rise 
is only weakly associated with a 
relapse in patients with non-renal 
disease (HR 2.79 [95%-Cl 1.30-5.98], 
p=0.008). Also, a rise is strongly 
related with a relapse in patients with 
non-renal severe48 disease (4 relapses 
in 16 patients, HR 13.08 [95%-Cl 
1.03-166.7], p=0.043), but not in 
patients with non-renal limited48 
disease (26 relapses in 46 patients, 
HR 2.09 [95%-Cl 0.92-4.78], 
p=0.078). Sampling interval 
(categorized as ≥4 measurements per 
year or fewer) and ANCA pattern 
(categorized as persistently ANCA 
positive or not) were additional 
factors that influenced the 
relationship of an ANCA rise with a 
relapse (see Figure 1-2 and 
supplementary data). 
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Figure 1-2. The predictive value of an ANCA rise as determined by the antigen-
specific solid-phase ANCA method in the entire cohort and subgroups of patients with 
AAV. A differentiation was made in renal involvement, sampling interval (<4 versus 
≥4 per year), ANCA pattern (persistently positive or non-persistently positive) and 
ANCA serotype (MPO-ANCA versus PR3-ANCA). Hazard ratios are shown with 95% 
confidence intervals. The area up to a hazard ratio of 1 marks the border of 
significance. 
 
How can our results be translated to 
daily practice? Firstly, in patients who 
became ANCA negative during follow-
up, the risk to develop a major relapse 
is extremely low as long as no rise in 
ANCA level occurs. Secondly, an ANCA 
rise in a patient with previous renal 
involvement should warn the clinician 
for a relapse since the probability of a 
relapse occurring after the rise is 
more than eleven times higher 
compared to the period before the 
rise. Thirdly, measuring serial ANCA 
levels in patients without renal 
involvement, especially when severe 
vasculitic manifestations are lacking, 
is of limited value.107 An ANCA rise 
should, however, not be used to pre-
emptively treat the patient74,108, since 
only less than half of the patients with 
an ANCA rise will experience a relapse 
within a year. Serial ANCA 
measurement is an important factor, 
but not the only factor that should be 
considered during follow-up in 
patients with ANCA-associated 
vasculitis.109,110 
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In 2006, a meta-analysis on the value 
of ANCA measurements to predict 
relapses concluded that no firm 
conclusions could be drawn because 
of considerable methodological 
heterogeneity in the different 
studies.72 In contrast, another meta-
analysis based on a more selected 
subgroup of these studies concluded 
that there is limited use to serial ANCA 
measurements.73 We found that the 
proportion of patients with renal 
involvement dictates the conclusion 
whether ANCA measurements are of 
value during follow-up. Furthermore, 
we found that the association of an 
ANCA rise with a relapse was 
influenced by the ANCA method (see 
supplementary data), sampling 
interval and persistence of ANCA. 
Interestingly, we did not find a 
difference between MPO-ANCA and 
PR3-ANCA as previously 
suggested.73,109,111,112 We analyzed 
the articles that were in the latest 
meta-analysis and specified the 
study-level variables that may have 
influenced the results (Table 3-1, 
page 65).73 Studies with a high 
prevalence of renal or 'severe' 
disease48 tended to have higher 
likelihood ratios, although variation in 
other study-level variables such as 
the ANCA method used or the 
definition of an ANCA rise may 
obscure this association. This 
suggests that spectrum bias is 
involved.113 
The presence of ANCA is, however, 
not the only factor that is required for 
disease re-activation, since many 
rises are not followed by a 
relapse.71,101,110 This suggests that 
other qualities, such as epitope 
specificity and the sialylation ratio, 
may determine the pathogenicity of 
ANCA.102,105,114 Otherwise, the 
association may be stronger when 
newer generation ANCA methods are 
used.105,106,115 Lastly, a second hit may 
be required after the occurrence of an 
ANCA rise before the patient truly 
develops a relapse. The importance of 
a second hit has been demonstrated 
in a mouse model of MPO-ANCA64, but 
remains elusive in humans. Possible 
candidates are microorganisms116, 
environmental factors,66,67 and/or 
other auto-antibodies.68 
Our study suffers from several 
limitations. In daily practice,71,101 time 
between ANCA measurements varies 
as was found in our study. We 
resolved this issue by using the slope 
of a rise, thereby taking into account 
the time between measurements. In 
our current study, physicians were not 
blinded to ANCA results71,101, which 
could have had an effect in diagnosing 
relapses. This may have influenced 
the association between an ANCA rise 
and a relapse in the entire cohort but 
could not explain the marked 
difference between patients with and 
without renal involvement. A minority 
of patients suffered from MPA or 
EGPA, making any conclusion on 
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ANCA testing in these diseases less 
valid. Renal involvement may be a 
proxy for severe vasculitic disease as 
we found in non-renal patients with 
severe disease that an ANCA rise was 
also associated with a relapse in this 
small subgroup of patients. Finally, 5 
of 62 patients who were initially 
diagnosed with non-renal disease 
developed a renal relapse, suggesting 
that we should probably focus on 
markers of the biologic behavior of 
the disease in patients that initially 
present with non-renal disease in 
order to predict the value of serial 
ANCA measurements in this subgroup 
of patients.117  
In summary, we have demonstrated 
in the largest published cohort with 
longitudinal ANCA measurements that 
an ANCA rise is related to a relapse in 
patients with renal involvement, but 
less in patients with non-renal 
disease.  
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Concise methods
Renal involvement was determined by 
a renal biopsy showing pauci-immune 
necrotizing glomerulonephritis.118 
However, the presence of hematuria 
in combination with red cell casts, 
dysmorphic erythrocytes (>10) 
and/or proteinuria sufficed (a renal 
biopsy was not performed in twelve 
patients with renal involvement).70 
Disease activity was scored using the 
BVAS v3.119 Patients were treated 
according to the European League 
Against Rheumatism (EULAR) 
guidelines as previously described.118 
Maintenance therapy was given for at 
least 18 months and tapered within 24 
months according to protocol in newly 
diagnosed patients.120 Patients who 
previously relapsed and/or relapsed 
during our study while using 
maintenance therapy were offered 
long term maintenance therapy. 
Remission was defined as absence of 
disease activity attributable to active 
disease during maintenance 
immunosuppressive therapy of a 
prednisone dosage of 7.5mg or 
lower.121 A relapse was defined as 
reoccurrence or new onset of disease 
attributable to active disease 
combined with an increase or addition 
of immunosuppressive 
treatment.74,101,120,121 Relapses were 
further subdivided in minor or major, 
depending on whether the relapse 
was potentially organ- or life 
threatening or not.121 For a renal 
relapse, the (re)occurrence of 
hematuria in combination with a rise 
in serum creatinine of 25% was 
required to be characterized as a 
major relapse.  
Solid-phase ANCA tests were used to 
detect and quantify PR3-ANCA and 
MPO-ANCA.105,106 For quantitation of 
MPO- and PR3-ANCA the samples 
were diluted 1:50 in PBS as instructed 
by the manufacturer. Results were 
calculated in arbitrary units by a 
standard curve. Patient samples with 
results above the highest standard 
were further tested in two-fold 
dilutions as appropriate. For the 
detection of an ANCA rise, the ANCA 
value was compared with the value 
measured in the samples obtained in 
the 6 months prior to the current 
sample. We defined a rise using the 
slope of an increase, for which a 
receiver operating characteristics 
(ROC) curve was calculated to 
determine the optimal cut-off value 
(see supplementary data).101 The 
association between an ANCA rise and 
relapse was investigated using a Cox 
regression model with an ANCA rise 
included as a time-dependent, binary, 
nonreversible predictor.101,122  
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Abstract 
Introduction 
Granulomatosis with Polyangiitis (GPA; formerly Wegener's) and Microscopic 
Polyangiitis (MPA) are inflammatory disease entities affecting small to medium 
vessels. They are characterized by the presence of anti-neutrophil cytoplasmic 
antibodies (ANCA) and are frequently grouped together with Eosinophilic 
Granulomatosis with Polyangiitis (EGPA; formerly Churg Strauss Syndrome) 
under the term ANCA-associated Vasculitis (AAV). Due to effective 
immunosuppressive therapy that was introduced more than 45 years ago, AAV 
has become a chronic disease in which relapses occur frequently during 
maintenance treatment or later on after all immunosuppressive therapy is 
stopped. Since relapses are associated with morbidity and mortality, early 
detection and prevention of relapses is of great importance.  
Areas covered  
This review focuses on the potential strategies to guide maintenance therapy in 
patients with GPA or MPA, with an emphasis on patient classifications and the 
role of serial ANCA measurements. 
Expert opinion 
Risk factors for relapses, e.g., genetic background of the patient, have been 
studied during the last three decades. Only few of these risk factors directly 
influence the management of patients. One potentially important factor that may 
influence therapeutic decisions in AAV patients is serial measurement of ANCA. 
Recently, it became clear that serial ANCA measurement is an attractive 
approach in AAV patients with (a history of) capillaritis, e.g., renal involvement 
or alveolar haemorrhage, but not in patients with more limited disease. Whether 
ANCA rises can be used to guide therapy and –hence- to prevent relapses has 
been a great debate during the last three decades. At present, we conclude that 
small studies do support such an approach but that these findings require further 
validation in larger randomized clinical trials.  
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Introduction
Granulomatosis with Polyangiitis 
(GPA; formerly Wegener's) and 
Microscopic Polyangiitis (MPA) are 
inflammatory disease entities 
affecting small to medium vessels.104 
They are characterized by the 
presence of anti-neutrophil 
cytoplasmic antibodies (ANCA) and 
are frequently grouped together with 
Eosinophilic Granulomatosis with 
Polyangiitis (EGPA; formerly Churg 
Strauss Syndrome) under the term 
ANCA-associated Vasculitis (AAV). 
ANCA can be detected using indirect 
immunofluorescence (IIF), upon 
which a perinuclear pattern (P-ANCA) 
or a cytoplasmic pattern (C-ANCA) 
can be observed.105 In addition, 
antigen-specific tests are available for 
myeloperoxidase (MPO), which is 
typically found with a perinuclear 
pattern, and proteinase 3 (PR3), 
which is associated with a cytoplasmic 
pattern.105 
The paradigm of AAV changed from a 
fatal diagnosis to a chronic disease 
after the introduction of 
immunosuppressive therapeutics.29 
The majority of patients, however, 
experience relapses during treatment 
or at remission. Since relapses are 
associated with morbidity89 and 
mortality, early detection and 
prevention of relapses is of great 
importance. The therapeutic agents 
used to maintain remission and the 
clinical evidence thereof have been 
extensively reviewed elsewhere.144-146 
In this review, we will focus on 
potential strategies to guide 
maintenance therapy in patients with 
GPA or MPA, with an emphasis on 
patient classifications and the role of 
serial ANCA measurements.
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The classification of patients to guide maintenance therapy
Patient classifications – the old-
fashioned way 
Godman and Churg described in their 
seminal paper in 1954 the triad of 
pathological features that 
characterized patients with GPA: 
systemic necrotizing angiitis, 
necrotizing granulomatous 
inflammation of the respiratory tract 
and necrotizing glomerulonephritis.14 
Thereafter, several systems have 
been described to classify patients 
based on clinical characteristics, 
histopathological and serological 
evidence.13 The American College of 
Rheumatology developed criteria 
based on clinical and histopathological 
evidence in 1990 to classify patients 
as GPA, EGPA or polyarteritis nodosa 
(PAN). At that time, the association of 
ANCA to necrotizing vasculitis was not 
yet widely accepted in the USA147 and 
was therefore not included as a 
classification criterion.  
In 1994, the Chapel Hill Consensus 
Conference (CHCC) aimed to 
standardize the nomenclature of the 
various individual vasculitic diseases 
and focused mainly on the 
histopathological evidence.20 The 
typical histopathological finding of 
AAV is necrotizing vasculitis of small 
to medium sized vessels with few or 
no immune deposits, wherein GPA is 
distinguished by granulomatous 
inflammation (vascular and/or 
extravascular), while EGPA is 
characterized by eosinophil-rich 
inflammation.21 The size of the 
involved vessels dictated the 
classification of patients according to 
the 1994 CHCC nomenclature, while 
in the revised CHCC criteria of 2012 
overlap of vessel involvement was 
acknowledged in the various disease 
entities.21 Novel findings using 2-
[18F]fluoro-D-glucose (FDG) positron 
emission tomography (PET) scanning 
support this notion, since AAV 
patients with renal involvement have 
similar values of aortic FDG uptake as 
patients with large vessel vasculitis, 
reflecting aortic inflammation.148 The 
CHCC also formulated definitions for 
MPA and single-organ vasculitis, 
thereby acknowledging the possibility 
of necrotizing angiitis without the 
occurrence of granuloma formation, 
or vasculitis in a particular organ 
without systemic involvement, such 
as renal-limited vasculitis.54  
In 2007, the European Medicines 
Agency (EMA) developed a 
classification system that combined 
the CHCC and ACR criteria.70 
Importantly, seropositivity for PR3- or 
MPO-ANCA was included in this 
algorithm. This allows physicians to 
classify patients who do not (yet) 
have biopsy-proven vasculitis and do 
not fulfill the ACR criteria. When these 
patients are seropositive for PR3-
ANCA or MPO-ANCA and surrogate 
markers for AAV are available they 
can be classified as well as either GPA, 
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MPA, or EGPA. Importantly, it is 
acknowledged in the EMA 
classification scheme that 
histopathological evidence is not 
always available in clinical practice. It 
should be noted, however, that the 
described classification criteria and 
nomenclature were developed to 
enable comparison between different 
disease groups in epidemiological 
studies and that these criteria are, in 
general, more stringent diagnostic 
criteria.21,70 
In addition, patients within clinical 
entities such as GPA and MPA have 
been categorized based on the 
severity of disease activity.117 Organ 
involvement at the time of active 
disease and the severity thereof has 
been summarized in the Birmingham 
vasculitis activity score (BVAS),119 
while the extent of the disease is 
summarized by the disease extent 
index (DEI).149 The European 
Vasculitis Society (EUVAS) classified 
patients as having localized, early 
systemic, generalized, renal severe or 
refractory disease.41 Otherwise, the 
Wegener’s Granulomatosis 
Etanercept Trial (WGET) group 
classified patients as having severe or 
limited disease, depending on 
whether there are disease features 
present that pose immediate threats 
either to a critical organ or the 
patient’s life.48 The purpose of these 
classification systems is to provide a 
framework to tailor induction therapy 
based on the severity of the disease 
at the initial presentation.41,47 During 
the last decade it became clear that 
these systems are of limited 
prognostic value since they only 
reflect the severity of disease at initial 
presentation and do not take the 
clinical follow-up into account.117 
Therefore, these classification 
systems are limited in the guidance of 
maintenance therapy.123 
 
Definitions of remission and relapse 
Remission and relapse are arbitrary 
definitions that reflect the disease-
specific outcome of vasculitis. In order 
to harmonize these definitions, the 
European League against 
Rheumatism (EULAR) analysed the 
various definitions used in previously 
published studies and formulated 
definitions based on expert opinion 
that should be used in future 
studies.121 Patients are in remission 
when there is complete absence of 
active clinical disease. In addition, the 
EULAR proposed that patients may 
still use a glucocorticoid dose of less 
than or equal to 7.5mg per day. A 
relapse was defined as the 
reoccurrence or new onset of disease 
activity attributable to active 
inflammation. Moreover, a 
differentiation was made between 
major and minor relapses, depending 
on whether the relapse is potentially 
organ- or life-threatening.  
The EULAR recommendations allow us 
to compare results obtained during 
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clinical trials. At present, however, 
many differences still remain making 
comparisons between trials and 
published cohort studies difficult.150 
For example, both the RITUXVAS and 
the RAVE trial studied the efficacy of 
rituximab to induce remission in 
patients with AAV.46,151 However, 
sustained remission was defined by 
the RITUXVAS trial as BVAS = 0 
maintained for at least 6 months, 
while the RAVE trial defined complete 
remission as BVAS/WG = 0 and being 
off glucocorticoid therapy.46,151 
Moreover, the definitions by the 
EULAR are still open to subjective 
interpretation. For example, it can be 
difficult to differentiate minor 
symptoms, such as fever or arthralgia 
that are caused by vasculitis from 
symptoms that are caused by an 
infection. Therefore, in our studies, a 
minor relapse was diagnosed only if 
symptoms were refractory to 
appropriate antibiotic therapy.124 In 
addition, a relapse was defined as 
reoccurrence or new onset of disease 
attributable to active disease 
combined with an increase or addition 
of immunosuppressive treatment. The 
increase of glucocorticoid therapy 
almost always consisted of at least 
20mg per day. This is not always the 
case in other studies, in which 
relapses can occur that were treated 
with an increase of glucocorticoid 
therapy of only 2.5mg per day.152 
 
Risk factors for a relapse 
Several studies have investigated 
potential risk factors for a relapse. 
Positivity for PR3-ANCA has 
repeatedly been identified as an 
independent risk factor for a relapse 
during follow-up.75,88,96,120,151,153-155 A 
diagnosis of GPA, as well as lung 
involvement or upper respiratory tract 
involvement is related to a higher 
relapse risk.97,153,154,156,157 Patients 
with a high serum creatinine level 
(e.g. >200 μmol/l) tend to relapse 
less often than patients with a lower 
serum creatinine level.88,157 
Cardiovascular involvement has been 
identified as a predictor of a relapse.88 
In a small study, infection has been 
reported to be a risk factor for GPA.158 
In a larger study, however, we could 
not confirm this.157 Nasal carriage of 
staphylococcus aureus has been 
associated with a higher relapse rate 
and the addition of co-trimoxazole 
protects against relapses in patients 
with (limited) GPA.137,157 The 
assessment of chronic nasal carriage 
of s. aureus is, however, at present in 
clinical practice hindered by the use of 
antibiotics such as used for 
prophylaxis against pneumocystis 
pneumonia. Another risk factor for 
relapses is the presence of an 
increased waist circumference or the 
presence of metabolic syndrome.159 
Whether exposure to silica is also a 
risk factor for a relapse is at present 
not well studied.160  Finally, several 
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genetic factors may predispose to 
relapses.161-163  
 
Patient classifications - based on the 
chance to relapse 
Given previously described risk 
factors for a relapse, several attempts 
have been made to generate a 
classification system that stratifies 
patients according to their chance of a 
relapse.96,97 Using a cluster analysis 
approach in a population of 673 
patients, five subgroups of patients 
were identified with distinct 
differences in relapse rate: 
cardiovascular AAV (highest relapse 
risk), non-renal AAV, renal AAV with 
PR3-ANCA, renal AAV without PR3-
ANCA and gastrointestinal AAV 
(lowest risk).97 However, studies 
concerning cardiovascular 
involvement are hampered due to 
differences in applied diagnostic 
methods and lack of a clear definition 
of cardiovascular involvement due to 
vasculitis. In a prospective study with 
extensive cardiac screening including 
cardiac magnetic resonance imaging, 
it has been shown that 61% of 
patients with GPA have cardiac 
involvement, independent of clinical 
symptoms.164 In a study with 502 
patients, it was shown that ANCA 
specificity predicted relapses better 
than clinical diagnosis based on CHCC 
or EMA classification.96 Importantly, 
no difference in the relapse risk 
between GPA and MPA was observed 
if patients were stratified according to 
their ANCA specificity. These findings, 
in addition to distinct genetic 
differences between PR3-ANCA and 
MPO-ANCA positive patients but less 
between patients with GPA and 
MPA165, lead to the suggestion that 
patients should be classified based on 
ANCA specificity and not the disease 
entity.99,105,166 Differences between 
PR3-ANCA and MPO-ANCA associated 
vasculitis have been extensively 
reviewed elsewhere.99 
The risk to develop a relapse is not 
only associated with clinical or 
serological phenotypes, differences in 
the genetic background may also play 
a role.161-163 Carriage of HLA-
DPB1*04:01 (DPB4) has recently 
been identified as a strong 
independent risk factor for a 
relapse.163 Patients that are 
homozygous for DPB4 relapsed more 
often than heterozygous patients, 
while noncarriers relapsed less often 
compared to homozygous or 
heterozygous patients. PR3-ANCA 
positive patients were more often 
carrier of DPB4 (55.7% homozygous, 
34.5% heterozygous) compared to 
MPO-ANCA positive patients (25.3% 
homozygous, 41.3% heterozygous), 
as was previously observed in a 
genome-wide association study in 
patients with AAV.165 Most 
importantly, carriage of DPB4 was 
associated with a relapse independent 
of ANCA specificity. Therefore, DPB4 
homozygous patients are prone to 
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relapse also when they are MPO-ANCA 
positive. The incorporation of these 
findings into a classification system 
may lead to a classification that is 
focused on the biologic behavior of 
the disease and may in the future be 
used to guide maintenance therapy in 
patients with AAV.117
 
Serial ANCA measurements to guide maintenance therapy
Serial ANCA measurements – a 
historical perspective 
The occurrence of antibodies directed 
against neutrophils had already been 
described in the Sixties.49 In those 
early days, granulocyte-specific 
antinuclear antibodies (GS-ANA) were 
defined as antinuclear antibodies 
reacting specifically with granulocyte 
nuclei or when reactivity with 
granulocytes was higher than 
reactivity with other cell nuclei (by at 
least two dilution steps).51  These 
antibodies were most often found in 
patients with rheumatoid arthritis 
and/or Felty’s syndrome. 
Unfortunately, attempts to discover 
the antigen failed repeatedly.51 In 
1982, the occurrence of anti-
neutrophil cytoplasmic antibodies in 8 
patients with segmental necrotizing 
glomerulonephritis was described by 
Davies et al. 52 Thereafter, it was 
recognized that ANCA was observed in 
GPA53 and that the target antigen of 
ANCA in these patients was proteinase 
3. Furthermore, MPO was found to be 
the target antigen in patients with 
PR3-ANCA negative GPA, MPA and/or 
EGPA.54-56 Importantly, patients with 
necrotizing glomerulonephritis are 
nearly always ANCA positive54,56 while 
ANCA are not always found in a 
subgroup of patients with more 
limited disease.57,58 The presence of 
PR3- or MPO-ANCA in ANCA-
associated vasculitis has been 
undisputed and has been incorporated 
in the current classification 
schemes.21,70  
Soon after the discovery of ANCA as a 
diagnostic marker for GPA, it was 
recognized that ANCA titer rises were 
associated with disease relapses 
during follow-up.71 In one of the initial 
studies, 35 patients with GPA were 
prospectively followed. Patients were 
evaluated every month for signs and 
symptoms attributable to disease 
activity and blood was drawn for 
ANCA testing using IIF. Eight major 
relapses and 9 minor relapses were 
observed during the study period of 
16 months. All relapses were 
preceded by an ANCA rise. Only one 
patient demonstrated ANCA rises that 
were not followed by relapses.71 This 
observation led to a multitude of 
studies to investigate the value of 
serial ANCA measurements to predict 
disease activity.72,73 If an ANCA rise is 
indeed followed by a relapse of 
disease activity, then 
immunosuppressive therapy may be 
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pre-emptively started to prevent the 
relapse to occur.74 However, such a 
strategy is hampered by potential 
unnecessary exposure to treatment-
related side-effects in patients in 
whom no relapse would occur after an 
ANCA rise. Therefore, the use of serial 
ANCA measurements to guide therapy 
has been controversial and subject to 
debate.72,73  
 
Persistence of ANCA positivity 
Several characteristics can be derived 
from longitudinal ANCA 
measurements. Although the ANCA 
levels usually decrease from the start 
of induction therapy to the moment of 
sustained remission, this is not always 
the case.71,167 A reduction or complete 
disappearance of ANCA is therefore 
not required to achieve sustained 
remission. Several studies have 
investigated a potential increased risk 
of relapse in patients who are 
persistently ANCA positive, with 
various results.111,157,168-175 A meta-
analysis observed a relatively low but 
significant positive likelihood ratio of a 
relapse of 1.97 (95% confidence 
interval [CI] 1.43-2.70).73 A different 
approach was undertaken by Slot et 
al, who investigated the risk for a 
relapse in patients who were ANCA 
positive or ANCA negative when 
cyclophosphamide was switched to 
azathioprine.120 In this study, patients 
who were C-ANCA positive at the time 
of switch had a significantly higher 
chance for a relapse compared to 
patients who were ANCA negative 
(relative risk 2.6 [95% CI 1.1-
8.0]).120 Recently, however, these 
results could not be reproduced in a 
prospective study.176  
 
The predictive value of an ANCA rise 
for a relapse 
In 2006, a meta-analysis concluded 
that the presence of considerable 
methodological heterogeneity 
precludes firm conclusions concerning 
serial ANCA measurements for 
monitoring disease activity from the 
available literature.72 Another meta-
analysis, which included several newly 
published studies and excluded 
multiple other studies, concluded that 
there is limited use to serial ANCA 
measurements to guide maintenance 
therapy.73 An overview of published 
studies regarding the association 
between an ANCA rise and disease 
activity is presented in Table 3-1 and 
Table 3-2. Several studies were 
excluded from this table either 
because the predictive value of a rise 
in ANCA was not investigated, or 
because treatment changes were 
based on ANCA titer, because of 
inclusion of patients with PAN or 
various other 
reasons.57,74,108,110,141,157,168,174,177,178   
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Article Total 
(severe) 
Relapse 
(major) 
Design Relapses 
per patient 
Statistics Interval 
 
n (%) n (%) 
 
  Months 
Tervaert  
(1989)71 
35 
(100%) 
17 
(47%) 
pro Multiple Cross tabulation 1 
Specks  
(1989)179 
65 
(35%) 
4 (NA) retro Single Cross tabulation NA 
Egner  
(1990)180 
10 
(100%) 
6 (NA) pro Multiple Cross tabulation NA 
Halma  
(1990)181 
23 
(87%) 
3 (NA) retro Single Cross tabulation NA 
Pettersson  
(1992)169 
20 
(100%) 
6 
(100%) 
retro Single Cross tabulation 2 
Kerr  
(1993)182 
68 
(~63%) 
45 (NA) pro Single Cross tabulation 1 to 3 
Chan  
(1993)183 
10 
(~70%) 
11 (NA) retro Multiple Cross tabulation <1 to 4 
Davenport  
(1995)184 
37 (NA) 44 (NA) retro Multiple Cross tabulation 2.4 
(median) 
De’Oliviera  
(1995)185 
56 27 retro Multiple Cross tabulation NA 
Jayne  
(1995)170 
60 
(~65%) 
23 
(~43%) 
retro Single Cross tabulation 1 
Ara  
(1999)186 
25 
(100%) 
4 
(100%) 
NA Multiple Cross tabulation 4 
Kyndt  
(1999)171 
43 
(~72%) 
52 (NA) pro Multiple Cross tabulation 1 to 3 
Boomsma  
(2000)101 
100 (NA) 37 
(73%) 
pro Single Cox regression 
(time-dependent) 
1.7 
Girard  
(2001)172 
50 23 (NA) pro Multiple Cross tabulation 1 to 4 
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Article Total 
(severe) 
Relapse 
(major) 
Design Relapses 
per patient 
Statistics Interval 
 n (%) n (%)    Months 
Nowack  
(2001)173 
18 
(78%) 
35 (NA) retro Multiple Cross tabulation 1.8 
(median) 
Gisslen  
(2002)187 
10 
(90%) 
29 (NA) retro Multiple Cross tabulation 3 to 4 
Segelmark  
(2003)188 
13 
(100%) 
13 (NA) retro Multiple Cross tabulation NA 
Damoiseaux  
(2005)106§ 
46 
(100%) 
23 (NA) retro Single Cross tabulation 3 
Finkielman  
(2007)122 
101 
(~71%) 
46 
(~19%) 
pro Single Cox regression 
(time-dependent) 
2 to 6 
Damoiseaux  
(2009)115 § 
46 
(100%) 
23 (NA) retro Single Cross tabulation 3 
Terrier  
(2009)111 
38 
(~68%) 
11 
(~45%) 
retro Single Cross tabulation NA 
Kemna  
(2015)124 
166 
(72%) 
74 
(26%) 
retro single Cox regression 
(time-dependent) 
3 to 6 
Alberici  
(2015)189 
69 (NA) 28 
(12%) 
retro single Cross tabulation 3 to 4 
Verstockt  
(2015)190 
43 
(86%) 
43 (NA) retro multiple Cross tabulation 3 to 9 
Fussner  
(2016)191 
93 
(100%) 
55 
(76%) 
pro single Cox regression 
(time-dependent) 
3 to 6 
 
Table 3-1. An analysis of published studies that investigate the predictive value of 
an ANCA rise for a relapse. The severity of the included cohort and/or relapses is 
preceded by a tilde if the exact proportion was not described in the article, but an 
indication could be derived (from organ involvement for example). If multiple ANCA 
rises and/or relapses from one patient were included, the total amount of ANCA rises 
and relapses are shown. § References 106,115 analyze different ANCA methods on the 
same cohort. Retro, retrospective; pro, prospective; NA, Not available. 
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Serial ANCA measurements – 
heterogeneity between studies 
Several differences between 
published studies should be taken into 
consideration when interpreting the 
results. First, differences in the 
definition between relapse and 
remission may be present. Second, 
the method of ANCA testing may 
influence the usefulness of serial 
ANCA measurements.105,106 Indirect 
immunofluorescence was mostly used 
in the initial studies, a technique that 
is at present infrequently used for 
quantification of ANCA levels. 
Subsequently, most studies were 
performed using a direct ELISA (a so-
called first-generation antigen-
specific test). At present, second 
(capture ELISA) and third (anchor 
ELISA) generation tests are 
available.105 For serial ANCA 
measurements, an ANCA rise as 
measured by ELISA is a stronger 
predictor of a relapse compared to a 
rise as measured by IIF.101,124 One 
study found that a combination of a 
rise of PR3-ANCA and C-ANCA was 
most predictive of a relapse.101 
However, this was not confirmed by a 
later study.124 Preliminary results 
suggest that the second and third 
generation tests predict relapses 
better than IF tests and/or first 
generation tests.105,115 Monitoring 
ANCA of the IgG3 subtype does not 
warrant additional benefits,101,173 nor 
does the detection of ANCA targeted 
against the proenzyme of PR3.122 
Third, more frequent sampling may 
result in a higher association of an 
ANCA rise with a relapse.73 A higher 
association was observed in patients 
who were tested at least 4 times per 
year (HR 6.40 [95% CI 3.45-11.88]) 
compared to patients who were tested 
less frequently (HR 2.13 [95% CI 
0.67-6.77]).124 However, more 
frequent sampling may not always be 
feasible.192 
Fourth, large variations exist between 
the definitions used for an ANCA rise. 
Initial studies used a relatively high 
cut-off value, such as quadrupling of 
the previous result.71 Other studies 
have used a lower cut-off value that 
may be less specific for a relapse. A 
definition that is only determined by 
the relative increase of an ANCA titer 
compared to the previous sample(s) is 
unreliable if there is a large variability 
in the time between samples. To 
resolve this issue, ANCA rises have 
previously been defined using the 
slope of the rise (e.g. doubling of the 
ANCA rise in 3 months).124,192 Another 
study has retrospectively calculated 
the peak of the ANCA rise, which 
cannot be used in a prospective 
study.141 Several studies have used a 
receiver operating characteristic 
curve to define the most optimal cut-
off value.101,115,124 Usually, the cut-off 
value closest to the upper left corner 
is chosen (the cut-off value closest to 
100% sensitivity and 100% 
specificity). A different approach that 
is not yet applied is to use two 
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different cut-off values for an ANCA 
rise: one definition with a low cut-off 
value that is highly sensitive and one 
definition with a high cut-off value 
that is highly specific. Whether such 
an approach offers additional value 
should be investigated in future 
studies. 
Fifth, there are differences in the 
interpretation of the clinical 
usefulness of an ANCA rise that is 
detected concomitant to clinical 
symptoms of a relapse. Since the 
intention of serial ANCA 
measurements is to prevent relapses, 
an ANCA rise concomitant to a relapse 
is of limited value. Therefore, some 
researchers define these ANCA rises 
as false-negative results.191 However, 
this occurrence may be caused by a 
lack of frequent ANCA sampling. 
Moreover, these ANCA rises may still 
be of value in order to differentiate a 
relapse from an infection. The 
concomitant occurrence of a relapse 
and an ANCA rise underline the tight 
relationship of ANCA with disease 
activity. It should be further 
investigated why some ANCA rises are 
directly followed by a relapse while 
other ANCA rises are not. The 
pathogenicity of an ANCA rise may be 
determined by other qualities of the 
autoantibody, such as the avidity, 
glycosylation profile or epitope 
specificity.102,193-195 
Sixth, some studies include multiple 
relapses from a single patient, while 
other studies only include the first 
relapse of a patient. The results of the 
first type of studies are prone to be 
biased since the association between 
an ANCA rise and a relapse may be 
specific to a particular subset of 
patients. Therefore, one patient that 
frequently relapses shortly after 
several ANCA rises may therefore 
(incorrectly) skew the results of the 
study toward a high association 
between ANCA rises and a relapse. 
Seventh, different statistical methods 
have been used. Serial ANCA 
measurements can be approached 
with cross tabulation, after which the 
sensitivity, specificity and positive and 
negative likelihood ratios can be 
derived.196 This method increases the 
clinical usefulness of ANCA testing to 
diagnose AAV197, but has several 
limitations when used for serial ANCA 
measurements. First, this method 
does not take the duration of follow-
up into account. A second limitation of 
this approach is that the association 
of a negative ANCA titer with 
sustained remission is negated if an 
ANCA rise occurs. Another limitation 
of this method is that the method is 
unable to deal with patients that are 
lost to follow-up. A different approach 
is using the Cox regression with an 
ANCA rise as a time-dependent, 
binary, non-reversible 
predictor.122,124,191,198 This approach 
elegantly deals with the limitations of 
the previous approach but is more 
difficult to apply. A major drawback of 
the Cox regression is that a high 
Maintaining remission in GPA and MPA patients 
68 
hazard ratio does not necessarily 
mean that a relapse will shortly occur 
after an ANCA rise. For example, the 
hazard ratio will also be high if no 
relapses occur in patients in whom no 
ANCA rise has been detected. As such, 
the Cox regression investigates the 
association of an ANCA rise with a 
relapse and not the predictive value of 
an ANCA rise for a relapse. Therefore, 
a combination of both approaches will 
give the most optimal representation 
of the clinical usefulness of serial 
ANCA measurements.  
Last, it is important to note that a 
prospective study design and blinding 
of the physicians to the ANCA titers is 
present in only a minority of 
previously published studies71,74,101 
which are essential requirements to 
ensure strong internal validity.72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-2 (next page). The results of published studies that investigate the 
predictive value of an ANCA rise for a relapse. Positive likelihood ratios are shown 
only if self-reported or sensitivity and specificity were reported. *The cut-off value 
was determined using a receiver operating characteristic curve. ± The ELISA was not 
specific for PR3 or MPO, instead the antigen was obtained by lysing granules of 
normal donor granulocytes.181 HR, hazard ratio; LR+, positive likelihood ratio; NA, 
Not available. 
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Article Method Definition 
ANCA rise 
True 
positive 
False 
positive 
False 
negative 
HR or 
LR+ 
  
% n n n  
Tervaert  
(1989)71 
IIF 400% 17 5 0  
Specks  
(1989)179 
IIF NA 4 3 0  
Egner  
(1990)180 
IIF NA 6 2 0  
Halma  
(1990)181 
IIF 800% 3 10 3  
ANCA-ELISA± NA 3 NA 3  
Pettersson  
(1992)169 
IIF, ELISA appearance 2 1 4  
Kerr  
(1993)182 
IIF 400% 9 6 30  
Chan  
(1993)183 
IIF, ELISA >10 units 9 6 2  
Davenport  
(1995)184 
IIF 400% or 
appearance 
19 63 25  
De’Oliviera  
(1995)185 
Direct ELISA NA 9 2 28  
Jayne  
(1995)170 
Direct ELISA 130 17 10 10  
Ara  
(1999)186 
IIF, ELISA Appearance 
or ‘increase’ 
4 1 0  
Kyndt  
(1999)171 
IIF 200% 8 6 NA  
Direct ELISA NA 21 10 NA  
Boomsma  
(2000)101 
IIF 400% 17 13 20 4.59 
Direct ELISA 175%* 30 11 7 18.6 
Girard  
(2001)172 
IIF Appearance 8 NA 6  
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Article Method Definition 
ANCA rise 
True 
positive 
False 
positive 
False 
negative 
HR or 
LR+ 
  % n n n  
Nowack  
(2001)173 
IIF 400% NA NA NA 1.29 
Direct ELISA 150% NA NA NA 1.47 
Capture ELISA 150% NA NA NA 0.86 
Gisslen  
(2002)187 
Direct ELISA 200% 23 2 6  
Capture ELISA 200% 29 6 0  
Segelmark  
(2003)188 
IIF 400% 10 NA 3  
Direct ELISA 150% 10 NA 3  
Capture ELISA 150% 13 NA 0  
Damoiseaux  
(2005)106§ 
IIF 200%* 15 9 8 1.7 
Direct ELISA 150%* 17 7 6 2.4 
Capture ELISA 300%* 16 5 7 3.2 
FEIA 200%* 18 8 5 2.3 
Finkielman  
(2007)122 
Capture ELISA 200% 15 18 31 0.8 
Damoiseaux  
(2009)115 § 
Capture ELISA 200%* 20 8 3 2.5 
Hn ELISA 200%* 16 8 7 4.3 
Hr ELISA 250%* 14 5 9 5.6 
Hn-hr ELISA 175%* 19 8 4 8.9 
Terrier  
(2009)111 
Direct ELISA appearance 9 1 2  
Kemna  
(2015)124 
IIF 400 NA NA NA 3.81 
Direct ELISA 2.56 %/day* 52 37 22 5.84 
Alberici  
(2015)189 
Direct ELISA appearance 10 3 14  
Verstockt  
(2015)190 
Direct ELISA 175% or 
appearance 
NA NA NA 3.43 or 
4.43 
Fussner  
(2016)191 
Direct ELISA 200%, ≥40 
if negative 
39 19 16 2.24 
Capture ELISA 200% NA NA NA 1.15 
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An ANCA rise is highly associated with 
a relapse in a subgroup of patients 
Patients with renal involvement are 
almost always ANCA positive, 
whereas a positive ANCA is not always 
present in patients with localized 
disease.57,105 Also, animal models 
have shown that necrotizing vasculitic 
lesions are readily induced by ANCA, 
while granulomas are more difficult to 
induce.65,99 These observations led to 
the hypothesis and the ensuing 
observation that serial ANCA 
measurements are highly associated 
with a relapse in patients with renal 
involvement (HR 11.09 [95% CI 5.01-
24.55]) but not in patients with non-
renal disease (HR 2.79 [95% CI 1.30-
5.98]).124 Renal involvement may be 
a proxy for severe vasculitic activity, 
since an ANCA rise was also highly 
associated with a relapse in patients 
with non-renal severe disease (HR 
13.08 [95% CI 1.03-166.7]). This 
observation was confirmed in the 
RAVE trial, wherein an ANCA rise was 
highly associated with a severe 
relapse in patients with renal 
involvement (HR 7.94 [95% CI 2.72-
29.18]) or alveolar haemorrhage (HR 
24.19 [95% CI 3.05-447.2]).191 
Whether ANCA rises are indeed highly 
associated with vasculitic disease but 
not granulomatous disease should be 
further investigated in future studies. 
The classification of granulomatous 
versus vasculitic disease is difficult, 
since both types of lesions can be 
simultaneously present.199 The study 
by Fussner et al. also observed a good 
association between an ANCA rise 
with a severe relapse in patients that 
were treated with Rituximab (HR 5.80 
[95% CI 2.06-19.77]), but not in 
patients that were treated with 
cyclophosphamide (HR 2.84 [94%-CI 
0.87-11.40]).191 This finding should 
be further investigated in other 
cohorts. 
 
Therapy based on ANCA levels 
Few studies have investigated the 
therapeutic potential to guide therapy 
based on serial ANCA 
measurements.74,108,176,178 In the 
initial study performed in the 1980s, 
57 patients were followed and ANCA 
was monthly measured.74 Nine of a 
total of 20 patients with ANCA rises 
were randomly assigned to receive a 
9-month course of cyclophosphamide 
and a short course of prednisolone at 
the time of an ANCA rise, while no 
changes in immunosuppressive 
therapy were made in the remaining 
11 patients. Nine of 11 untreated 
patients with ANCA rises relapsed, 
while all patients who were pre-
emptively treated remained in 
remission. Importantly, the 
cumulative cyclophosphamide and 
prednisolone dose was higher in 
initially untreated patients at the time 
of the ANCA rise compared to the 
patients who were pre-emptively 
treated.74 A similar - but 
nonrandomized – study was 
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performed in 2003, in which all 8 
patients relapsed in whom no 
treatment changes were made after a 
quadrupling of the ANCA titer, while 
only 2 of 11 patients relapsed if 
immunosuppressive therapy was pre-
emptively increased at the time of the 
ANCA rise (azathioprine was 
increased in 7 patients, 
cyclophosphamide increased in 2 
patients, azathioprine was switched to 
cyclophosphamide in one patient and 
the prednisone dose was increased in 
all patients with a mean of 10mg).108 
In a third study, only one of 22 
patients relapsed that were pre-
emptively treated with glucocorticoids 
monotherapy after a MPO-ANCA rise, 
while 29 of 35 patients relapsed in 
whom no change in 
immunosuppressive therapy was 
made.178  
These studies were all performed 
using the traditional therapeutic 
regimens using cyclophosphamide 
induction therapy and azathioprine 
maintenance therapy. Recent studies, 
however, have demonstrated that a 
rituximab-based regimen is non-
inferior to a cyclophosphamide-
azathioprine-based regimen for 
remission induction and 
maintenance.46,151,192,200 As the 
duration of response to a cycle of 
Rituximab is, however, variable 
among patients, the timing of 
repeating Rituximab cycles is at 
present unknown and is being 
investigated in the MAINRITSAN2 trial 
(ClinicalTrials.gov Identifier: 
NCT01731561), in which individually 
timed retreatment based on ANCA 
rise or B cell reconstitution is 
compared with fixed interval dosing of 
Rituximab.  
Finally, in another clinical trial 
patients were randomized when they 
were C-ANCA positive at the time of 
switch of therapy from 
cyclophosphamide to azathioprine to 
receive either an extended (i.e. up to 
48 months after diagnosis) or 
standard (i.e. up to 24 months after 
diagnosis) period of azathioprine 
maintenance therapy in order to 
prevent relapses. It was concluded 
that extended azathioprine 
maintenance therapy does not result 
in a longer period of sustained 
remission.176  
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Conclusion
AAV has become a chronic disease in 
which relapses occur frequently 
during maintenance treatment or 
later on after all immunosuppressive 
therapy is stopped. Since relapses are 
associated with morbidity and 
mortality, early detection and 
prevention of relapses is of great 
importance. Risk factors for relapses, 
for example genetic background of 
the patient, have been studied during 
the last three decades. Only few of 
these risk factors directly influence 
the management of patients. One 
potentially important factor that may 
influence therapeutic decisions in AAV 
patients is serial measurement of 
ANCA. Recently, it became clear that 
serial ANCA measurement is an 
attractive approach in AAV patients 
with (a history of) capillaritis, e.g. 
renal involvement or alveolar 
haemorrhage, but not in patients with 
more limited disease. Whether ANCA 
rises can be used to guide therapy and 
hence to prevent relapses has been a 
great debate during the last three 
decades. At present, we conclude that 
small studies do support such an 
approach but that these findings 
require further validation in larger 
randomized clinical trials.  
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Expert opinion
The ultimate goal regarding the 
guidance of maintenance therapy in 
ANCA-associated vasculitis is to 
reduce the incidence of relapses and 
concomitantly reduce the exposure to 
immunosuppressive therapy, thereby 
reducing the incidence of vasculitic 
damage and the mortality rate, while 
minimizing treatment-related side-
effects. Another goal, which is equally 
important, yet often overlooked, is to 
increase the quality of life of patients 
suffering from ANCA-associated 
vasculitis during follow-up.201 
Especially the latter should get more 
attention amongst researchers and 
clinicians in the future. In addition, 
the active involvement of the patient 
may result in a better prediction 
model for disease reactivation, as 
simply asking the patient how active 
he believes his disease has been in 
the past month is predictive of a 
future relapse.202 
Current research is hampered due to 
the heterogeneity between studies in 
the study protocol, used definitions 
and methodology as described above. 
Clinical research in ANCA-associated 
vasculitis can therefore be 
strengthened by the harmonization 
and standardization of the used 
methodology, ranging from 
autoantibody testing to the definitions 
used to define relapse and remission. 
Indeed, the standardization of 
autoantibody testing may be the most 
difficult challenge to achieve105,203, 
although significant steps have been 
made.204 The methodology behind 
serial ANCA measurements may also 
be further fine-tuned, including an in-
depth analysis regarding the 
definition used to characterize an 
ANCA rise.192 Major limitation of 
current research, however, remains 
the limited number of included 
patients in trials, which is inherent to 
the low incidence of the disease. 
Previous collaborations, such as the 
EUVAS and the French Vasculitis 
Study Group (FVSG) have been highly 
effective to solve this issue. We 
expect that intensive collaboration 
between research groups resulting in 
multicenter studies will most likely 
generate a large body of data that can 
be used to better predict relapses 
during follow-up. 
Even though a large number of 
studies have already been published 
in which the presence of ANCA to 
predict relapses was studied, the role 
of serial ANCA measurements during 
follow-up remains at present 
uncertain. In recent years, studies 
that have been published showed that 
an ANCA rise is closely associated with 
a relapse in specific subsets of 
patients, such as patients with 
necrotizing glomerulonephritis or 
alveolar haemorrhage. These findings 
suggest a close association between 
ANCA and vasculitic but not with 
granulomatous disease activity. 
However, this hypothesis needs to be 
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tested in future prospective studies 
that are not only highly powered but 
are also capable to accurately define 
granulomatous and vasculitic disease 
activity. The latter prerequisite may in 
particular be difficult since it is 
unpractical (and unethical) to obtain 
histological evidence of every lesion. 
A first step toward a better 
classification in granulomatous and 
vasculitic lesions, however, has 
recently been made.199 Such studies 
may better specify the subsets of 
patients in whom serial ANCA 
measurements can help guide 
maintenance therapy during follow-
up.  
In addition, studies that characterize 
patients that relapse while ANCA are 
not detectable may give new insights 
regarding the role of ANCA in disease 
reactivation. To our knowledge, no 
studies have been published that 
investigated these ANCA negative 
relapses in previously ANCA positive 
patients. In our own experience124, 
these ANCA negative relapses 
predominantly occur in patients with 
non-renal disease and are 
characterized by granulomatous 
inflammation of the respiratory tract, 
but this should be further 
investigated.  
Future studies that are focused on 
novel biomarkers that better predict 
disease (re)activation may also yield 
new findings that can be used to guide 
maintenance therapy during follow-up 
(e.g. urinary soluble CD163 in active 
renal vasculitis205). Obvious targets to 
study more intensively concerning 
ANCA as a predictor of relapse are the 
avidity, glycosylation profile or 
epitope specificity of ANCA.102,193-195 
In addition, biomarkers that are not 
(necessarily) related to ANCA may 
also be relevant, such as markers 
reflecting inflammation, injury and 
repair.206 Multiple studies have 
already shown an association of such 
a biomarker206,207, but the number of 
included patients restrict the analysis 
to the predictive value of a single 
biomarker. Future collaborations may 
increase the number of included 
patients and will enable us to analyze 
the predictive value of a panel of 
biomarkers to better predict relapses. 
As previously stated, these results 
may subsequently lead to a 
classification system that is focused 
on the biologic behavior of the disease 
and may in the future be used to 
guide maintenance therapy in 
patients with AAV.117  
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Abstract 
Objective 
The objective of this study is to investigate whether the avidity of PR3-ANCA 
changes during follow-up in different subgroups of patients with Granulomatosis 
with Polyangiitis (GPA). 
Methods 
We selected 10 patients with renal relapsing GPA, 10 patients with renal non-
relapsing GPA and 10 patients with non-renal relapsing GPA. In all patients, an 
ANCA rise occurred during remission. The avidity was measured using a 
chaotropic approach at the time of an ANCA rise and at the time of a relapse in 
relapsing patients or time-matched during remission in non-relapsing patients. 
Results 
No difference was observed in the avidity at the ANCA rise between renal 
relapsing patients (26.2% [15.5-47.5]), renal patients without a relapse (39.6% 
[21.2-63.4]) and non-renal relapsing patients (34.2% [21.6-59.5]). In renal 
relapsing patients, the avidity significantly increased from the moment of the 
ANCA rise to the relapse (difference 6.4% [0.0–17.1], p=0.0273). The avidity 
did not increase after an ANCA rise in renal non-relapsing patients (difference 
3.5 [-6.0–10.1], p=0.6250) or in non-renal relapsing patients (difference -3.1% 
[-8.0–5.0], p=0.5703).  
Conclusion 
The avidity of PR3-ANCA increases after an ANCA rise during follow-up in renal 
relapsing patients but not after an ANCA rise in renal patients who remain in 
remission or in non-renal relapsing patients.  
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Introduction
Granulomatosis with Polyangiitis 
(GPA; formerly Wegener's), 
Microscopic Polyangiitis (MPA) and 
Eosinophilic Granulomatosis with 
Polyangiitis (EGPA; Churg Strauss 
Syndrome) are inflammatory disease 
entities affecting small to medium 
vessels. They are characterized by the 
presence of anti-neutrophil 
cytoplasmic antibodies (ANCA) 
against myeloperoxidase (MPO) or 
proteinase-3 (PR3) and are frequently 
grouped together under the term 
ANCA-associated vasculitis (AAV).104  
Since the eighties it has been 
advocated that ANCA rises predict 
disease reactivation.71 However, the 
relation between ANCA rise and 
relapse of the disease is far from 
absolute since many ANCA rises are 
not followed by a relapse and relapses 
may occur without a preceding ANCA 
rise.73,101 Recently, we have 
demonstrated that longitudinal ANCA 
measurements are highly predictive 
for disease activity in patients with 
renal involvement, but not in patients 
with non-renal disease.124 At present, 
it is clear that not every ANCA rise is 
pathogenic, since only a subset of 
patients who have an ANCA rise will 
experience disease reactivation within 
a period of 12 months. Our hypothesis 
is that the pathogenicity of an ANCA 
rise is determined by the quality of the 
autoantibodies, such as the avidity, 
glycosylation profile or epitope 
specificity. 
The clinical relevance of the avidity of 
an autoantibody has been 
demonstrated in patients with anti-
phospholipid syndrome (APS), in 
which patients with high avidity anti-
β2-glycoprotein I antibodies (anti-β2-
GPI) have a higher risk of thrombosis 
compared to patients with low or 
heterogeneous avidity anti-β2-GPI.208 
In systemic lupus erythematosus 
(SLE), high avidity anti-dsDNA 
antibodies are more closely 
associated with renal involvement 
and/or disease activity than low or 
intermediate avidity anti-dsDNA 
antibodies.209-212 Lastly, 
determination of the avidity of anti-
viral antibodies is useful to 
differentiate a primary infection from 
reactivation.213-215  
Several published studies 
investigated the avidity of MPO-
ANCA.194,216-220 The avidity from 
natural auto-antibodies against MPO 
in healthy controls is lower compared 
to the avidity of MPO-ANCA in patients 
with primary AAV.216 The avidity of 
MPO-ANCA antibodies reduces during 
remission in patients with vasculitis 
induced by propylthiouracil (PTU), but 
remains constant in primary ANCA-
associated vasculitis.217-219 Patients 
with high avidity MPO-ANCA generally 
suffer from severe vasculitis disease 
activity, while patients with low 
avidity more often suffer from mild 
vasculitis activity.194 To our 
knowledge, no studies have currently 
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been published on the avidity of PR3-
ANCA. 
The primary objective of this study is 
to evaluate whether the avidity of 
PR3-ANCA changes during follow-up 
in patients with GPA. The secondary 
objective is to determine whether the 
avidity of PR3-ANCA differs in patients 
with renal involvement compared to 
patients without renal involvement 
during follow-up. 
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Materials and methods
Patient inclusion 
In our cohort of patients with GPA124, 
we defined three different subgroups 
and we selected 10 patients from each 
subgroup: 10 patients with renal 
involvement with a relapse during 
follow-up (i.e., ‘renal relapsing’), 10 
patients without renal involvement 
with a relapse during follow-up (i.e., 
‘non-renal relapsing’) and 10 patients 
with renal involvement without a 
relapse during follow-up (i.e., ‘renal 
non-relapsing’).  
All selected patients fulfilled the 
following criteria: (1) patients were 
diagnosed with biopsy-proven GPA 
according to the EMA classification 
system70, (2) patients were positive 
for PR3-ANCA106, (3) remission was 
induced after the initiation of 
immunosuppressive induction 
therapy123, (4) an ANCA rise occurred 
during follow-up124 and (5) serum was 
available as described below. Serum 
was obtained for clinical purpose and 
patients did not object to the 
(anonymous) use of surplus serum for 
the purpose of research. Therefore, 
the requirement of ethical approval 
was waived according to the Dutch 
law. 
 
Classification of patients 
Renal involvement was determined by 
a renal biopsy showing pauci-immune 
necrotizing glomerulonephritis.118 
Disease activity was scored using the 
BVAS v3.119 Patients were treated 
according to the European League 
against Rheumatism (EULAR) 
guidelines as previously 
described.118,123 Remission was 
defined as absence of disease activity 
attributable to active disease during 
maintenance immunosuppressive 
therapy of a prednisone dosage of 7.5 
mg or lower.121  
 
Follow-up 
Patients were routinely screened for 
potential symptoms of a relapse and 
blood was drawn.124 Antigen-specific 
solid-phase ANCA tests were 
performed for the detection and 
quantification of PR3-ANCA. An ANCA 
rise was defined as described 
previously.124 A relapse was defined 
as reoccurrence or new onset of 
disease attributable to active disease 
combined with an increase or addition 
of immunosuppressive 
treatment.74,101,120,121,124  
 
Serum selection 
In all patients, a serum sample (‘T1’) 
was selected at the time of an ANCA 
rise.124 In renal relapsing and non-
renal relapsing patients, a second 
serum sample (‘T2rel’) was selected 
prior to the start of the 
immunosuppressive induction therapy 
at the time of the relapse. In renal 
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non-relapsing patients, a second 
serum sample (‘T2rem’) was selected 
after the ANCA rise whereas the time 
since the ANCA rise was matched with 
the time between the ANCA rise and 
the relapse of the renal relapsing 
patients. 
If available, we also included a 
diagnostic sample prior to the start of 
the immunosuppressive induction 
therapy at diagnosis. 
 
Determination of the avidity of PR3-
ANCA 
Sera were tested using the PR3-hn-hr 
ELISA (Euroimmun AG, Luebeck, 
Germany).115 Briefly, 100 µl of serum 
diluted 1:101 in sample buffer was 
added to each of three wells coated 
with PR3 antigen. After incubation for 
30 min at room temperature (+18 °C 
to +25 °C) and washing, wells were 
exposed to 200 µl of either a 5 M urea 
solution, a 3 M urea solution or 
phosphate buffered saline (PBS) for 
10 min. After washing three times, 
wells were incubated with 100 µl 
peroxidase-labeled anti-human IgG 
for 30 min at room temperature, 
followed again by three washing 
cycles. 100 µl of a chromogenic 
substrate solution was added, and the 
reactions were stopped after 15 min 
by the addition of 100 µl stop solution 
per well. The reactions were read 
immediately at a wavelength of 450 
nm using a reference wavelength of 
650 nm. A highly positive index 
patient serum was used to generate a 
standard curve consisting of three 
calibrators (2, 20 and 200 relative 
units (RU)/ml). RU were calculated by 
this standard curve.115 A relative 
avidity index (RAI) was calculated for 
each specimen and was expressed as 
the percentage of reactivity remaining 
in the urea-treated wells.215 The inter- 
and intra-assay coefficients of 
variability of the PR3-hn-hr ELISA 
were 3.4% and 2.1% when using PBS, 
4.4% and 2.9% when using 3 M urea 
and 4.2% and 4.3% when using 5 M 
urea. 
 
Statistics 
Numerical variables were expressed 
as median [interquartile range] and 
categorical variables as numbers 
(percentages). Continuous variables 
were correlated with the Spearman 
test. Three unpaired variables were 
compared with the Kruskal-Wallis H 
test and post-hoc with the Mann 
Whitney U test. Two paired variables 
were compared with the Wilcoxon 
matched-pairs signed rank test. For 
the main research question regarding 
the change of avidity over time, we 
also applied a sensitivity analysis 
using a linear mixed model with time 
(1=ANCA rise, 2=relapse or time-
matched during remission), group 
(1=renal relapsing, 2=renal non-
relapsing and 3=non-renal relapsing) 
and time x group as fixed factor and 
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an unstructured covariance structure 
for the repeated measurements.  
All statistical analyses were 
performed using GraphPad Prism 
version 6.04 for Windows (GraphPad 
Software, La Jolla California USA) and 
SPSS statistics for Windows, version 
23.0 (IBM, Armonk, NY). A p-value 
<0.05 was considered significant.
 
        
Figure 4-1 (a; upper left). The correlation of the relative avidity index as measured 
with a urea concentration of 5 M and 3 M. (b; upper right) The correlation of the 
ANCA level as measured in PBS with the relative avidity index as measured with a 
urea concentration of 3 M. (c; below) The correlation of the ANCA level as measured 
in PBS with the relative avidity index as measured with a urea concentration of 5 M. 
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Results
Description of the cohort 
Thirty patients were included: 10 
renal relapsing patients, 10 renal non-
relapsing patients and 10 non-renal 
relapsing patients (see Table 4-1).  
 
Avidity as measured with different 
urea concentrations 
The median PR3-ANCA level as 
measured with PBS was 142 [82-247] 
RU/ml. One sample in a non-renal 
relapsing patient at the time of a 
minor relapse tested negative for 
PR3-ANCA and this sample was 
excluded for the evaluation of avidity. 
The relative avidity index (RAI) as 
measured with 3 M and 5 M urea was 
59.3% [45.8-73.3] and 35.6% [24.5-
49.9], respectively. A strong 
correlation between the relative 
avidity index as measured with 3M 
and the relative avidity index as 
measured with 5 M existed (R=0.951, 
p<0.001, see Figure 4-1a). In 
addition, the PR3-ANCA level as 
measured with PBS correlated with 
the relative avidity index as measured 
with 3 M and 5 M (R=0.432, p<0.001 
and R=0.296, p<0.001, respectively, 
see Figure 4-1b and Figure 4-1c). The 
relative avidity index as measured 
with 5M urea was used in all further 
analyses. 
 
Avidity at the time of the ANCA rise 
No difference was observed in the 
avidity of PR3-ANCA if obtained at the 
time of an ANCA rise between renal 
relapsing patients (26.2% [15.5-
47.5] Kruskal-Wallis p=0.4756), renal 
patients without a relapse (39.6% 
[21.2-63.4]) and non-renal relapsing 
patients (34.2% [21.6-59.5], see  
Figure 4-2).
 
 
 
 
 
 
Table 4-1 (next page). Patient characteristics. Values are expressed as median 
[inter-quartile range, IQR] or as the total. GC, glucocorticoids; PR3, proteinase-3; 
MPO, myeloperoxidase.  
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 Renal 
relapse 
Renal 
remission 
Non-renal 
relapse 
Patients 10 10 10 
Characteristics at time of previous disease activity 
Included at diagnosis 7 9 9 
Age in years 58 [52-72] 50 [31-54] 56 [49-63] 
Women 0 4 5 
BVAS 17 [13-21] 21 [16-24] 7 [5-11] 
C-reactive protein 68 [15-157] 87 [16-120] 121 [24-162] 
Serum creatinine 388 [127-489] 114 [79-274] 87 [78-102] 
Organ involvement at previous disease activity 
Arthralgia 8 6 7 
Cutaneous 3 2 1 
Eyes 2 3 2 
Ear, nose, throat 9 8 8 
Lung 8 9 8 
Cardiovascular 1 0 0 
Renal 10 10 0 
Central nervous system 1 0 0 
Peripheral nervous system 1 2 0 
Induction treatment resulting in remission 
Cyclophosphamide + GC 7 7 5 
Rituximab + GC 1 2 0 
Methotrexate + GC 0 0 3 
Mofetil mycophenolate + GC 0 1 0 
Gusperimus + GC 2 0 1 
GC monotherapy 0 0 1 
Characteristics during follow-up 
Time between previous 
disease activity and ANCA 
rise in months 
12.0 [8.5-24.5] 19.6 [13.1-
44.2] 
12.4 [8.6-14.4] 
Time between ANCA rise and 
relapse/remission in months 
7.2 [1.9-9.9] 7.4 [2.8-12.9] 14.5 [5.6-17.5] 
Persistently ANCA positive 3 3 3 
Major relapse 8 0 3 
Minor relapse 2 0 7 
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Changes in avidity during follow-up 
In renal relapsing patients, the avidity 
significantly increased from the 
moment of the ANCA rise to the 
relapse (difference 6.4% [0.0–17.1], 
p=0.0273). This was not the case in 
renal non-relapsing patients, in whom 
the avidity was similar at the ANCA 
rise and time-matched during 
remission (difference 3.5 [-6.0–10.1], 
p=0.6250) or in non-renal relapsing 
patients, in whom the avidity was 
similar at the ANCA rise and at the 
relapse (difference -3.1% [-8.0–5.0], 
p=0.5703, see Figure 4-3). The 
sensitivity analysis using a linear 
mixed model gave similar results as 
the Wilcoxon matched-pairs signed 
rank test (p=0.012, p=0.662 and 
p=0.453 for renal relapsing, renal 
non-relapsing and non-renal relapsing 
patients). Concomitantly, in renal 
relapsing patients the ANCA level 
significantly increased from the 
moment of the ANCA rise (140 [102-
201]) to the relapse (222 [123-340], 
p=0.0488), while ANCA levels did not 
increase in renal non-relapsing 
patients and in non-renal relapsing 
patients (data not shown). 
No significant differences were 
observed at the relapse or time-
matched in remission in the avidity of 
PR3-ANCA between renal relapsing 
patients (35.8% [22.2-70.5], 
Kruskall-Wallis p=0.5912), renal 
patients without a relapse (41.1% 
[31.3-51.2], post-hoc p=0.6706 
versus renal relapsing patients) 
and/or non-renal relapsing patients 
(27.2% [23.3-54.6], post-hoc 
p=0.6447 versus renal relapsing 
patients). 
 
Avidity at the time of diagnosis 
Finally, we examined the avidity at 
the time of diagnosis to investigate 
whether there are differences in 
avidity in the early stages of disease 
process. A diagnostic sample was 
available in 7 renal relapsing patients, 
9 renal non-relapsing patients and 7 
non-renal relapsing patients. 
No significant differences were 
observed in the avidity at the 
diagnosis between renal relapsing 
patients (49.1% [29.3-60.2], 
Kruskal-Wallis p=0.1653), renal 
patients without a relapse (34.5% 
[15.2-43.9], post-hoc p=0.0712 
versus renal relapsing patients) and 
non-renal relapsing patients (37.1% 
[28.9-61.6], post-hoc p=0.6894 
versus renal relapsing patients).
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Figure 4-2. The relative avidity index in renal relapsing patients, renal non-relapsing 
patients and non-renal relapsing patients at the ANCA rise (T1). Post-hoc p-values 
from the Mann Whitney U test are shown.
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Figure 4-3. The relative avidity index during follow-up in renal relapsing patients in 
renal patients who remain in remission and in non-renal relapsing patients. P-values 
of the Wilcoxon matched-pairs signed rank test are shown.  
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Discussion
In this study, we report the results of 
avidity measurement of PR3-ANCA in 
patients with GPA. Most importantly, 
the avidity increases in patients with 
renal involvement who relapse during 
follow-up, while it remains constant in 
renal patients who do not relapse and 
in non-renal patients who relapse 
during follow-up. We did not find a 
difference in the avidity between 
patients with renal involvement 
compared to patients with non-renal 
disease at the time of the ANCA rise 
and/or the time of diagnosis. 
 
The affinity of an antibody is defined 
as the binding energy of a monovalent 
antibody with a single epitope of the 
target antigen, while the avidity of an 
antibody represents the binding 
energy of the antibody with all 
available epitopes.221 The avidity of an 
antibody can be determined using two 
distinct approaches. The chaotropic 
method is based on the chemical 
dissociation of the antigen-antibody 
complex by a chaotropic agent, such 
as urea.214,215,222 Another approach is 
based on competitive inhibition of the 
binding site of the 
antibody.194,216,220,223,224 The results of 
the distinct approaches are similar, 
although assays employing a 
chaotropic agent may more often 
detect antibodies with inappropriately 
low avidity.225 The applied method to 
determine the avidity in this study has 
been extensively validated with large 
panels of characterized samples in the 
field of infectious serology.214,215 
 
Interestingly, the avidity increases in 
patients with renal involvement who 
relapse during follow-up, while it 
remains constant in renal patients 
who do not relapse and non-renal 
patients who relapse during follow-up. 
Similar results were found with an 
additional sensitivity analysis, thereby 
strengthening the observation. These 
changes in the avidity of PR3-ANCA 
may be linked to the fluctuating 
presence of the antigen source, as has 
been suggested in patients with MPO-
ANCA.217,220,226 In addition, the 
immune system in these patients may 
be skewed to a pro-inflammatory 
state, e.g. due to a chronic upper 
respiratory infection, which may 
contribute towards avidity 
maturation. 
 
This study was designed as a pilot 
study to gain insight in the avidity of 
PR3-ANCA during follow-up in 
patients with renal involvement and 
patients with non-renal disease. 
Importantly, we did not find a 
difference in the avidity level at the 
ANCA rise of patients with renal 
involvement compared to patients 
with non-renal disease. Therefore, we 
conclude that the avidity of PR3-ANCA 
does not explain why ANCA rises are 
highly associated with a relapse in 
patients with renal involvement but 
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not in patients with non-renal 
disease.124 The avidity index may be 
correlated with the ANCA level due to 
several reasons. First, low ANCA 
levels and low avidity may represent 
natural autoantibodies, while high 
avidity PR3-ANCA production may 
result in high ANCA levels that are 
pathogenic.216 Alternatively, the 
observed correlation between the 
avidity index and the ANCA level may 
be related to the method of avidity 
testing. Avidity assays have been 
shown to be less sensitive to changes 
in avidity in samples with a high 
concentration of antibodies.221 
Moreover, using a different assay but 
utilizing a similar test principle, 
Dangel et al. have shown that the 
avidity index varied between various 
dilutions of the same sample.227  
 
Our study suffers from several 
limitations. First, we tested only a 
small group of highly selected 
patients. The strength of our study is 
that patients are well characterized 
and the avidity of PR3-ANCA was 
determined at several moments 
during follow-up that are clinically 
relevant.124 Moreover, the avidity was 
determined using a method that has 
been extensively validated.214,215 
 
In conclusion, the avidity of PR3-
ANCA increases during follow-up in 
renal relapsing patients but not in 
renal patients who remain in 
remission or in non-renal relapsing 
patients. Whether the avidity of PR3-
ANCA is associated with more severe 
vasculitic disease activity at diagnosis 
should be further studied, as has been 
demonstrated for MPO-ANCA. 
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Abstract 
Objective 
The objective of our study is to investigate the Fc glycosylation profiles of both 
antigen-specific IgG targeted against proteinase 3 (PR3-ANCA) and total IgG as 
prognostic markers of relapse in patients with Granulomatosis with Polyangiitis 
(GPA). 
Methods 
Seventy-five patients with GPA and a PR3-ANCA rise during follow-up were 
included, of whom 43 patients relapsed within a median period of 8 (2-16) 
months. The N-glycan at Asn297 of affinity-purified and denatured total IgG and 
PR3-ANCA was determined by mass spectrometry of glycopeptides in samples 
obtained at the time of the PR3-ANCA rise and at the time of the relapse or time-
matched during remission. 
Results 
Patients with total IgG1 exhibiting low galactosylation or low sialylation were 
highly prone to relapse after an ANCA rise (HR 3.46 [95%-CI 1.73-6.96], 
p<0.0001 and HR 3.22 [95%-CI 1.52-6.83], p=0.002, respectively). 
In relapsing patients, total IgG1 galactosylation, sialylation and bisection 
significantly decreased and fucosylation significantly increased from the time of 
the PR3-ANCA rise to the relapse (p<0.0001, p=0.0087, p<0.0001 and 
p=0.0025), while the glycosylation profile remained similar in non-relapsing 
patients. PR3-ANCA IgG1 galactosylation, sialylation and fucosylation of PR3-
ANCA IgG1 decreased in relapsing patients (p=0.0073, p=0.0049 and 
p=0.0205), but also in non-relapsing patients (p=0.0007, p=0.0114 and 
p=0.0002), while bisection increased only in non-relapsing patients (P<0.0001). 
Conclusion 
While Fc glycosylation profiles have been associated with clinically manifest 
autoimmune diseases, in the present study we show that low galactosylation and 
sialyation in total IgG1 but not PR3-ANCA IgG1 predicts disease reactivation in 
patients with GPA who experience an ANCA rise during follow-up. We postulate 
that glycosylation profiles may be useful in pre-emptive therapy studies using 
ANCA rises as guideline. 
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Introduction
Granulomatosis with Polyangiitis 
(GPA; Wegener's), Microscopic 
Polyangiitis (MPA) and Eosinophilic 
Granulomatosis with Polyangiitis 
(EGPA; Churg Strauss Syndrome) are 
inflammatory disease entities 
affecting small to medium vessels. 
They are characterized by the 
presence of anti-neutrophil 
cytoplasmic antibodies (ANCA) 
against proteinase-3 (PR3) or 
myeloperoxidase (MPO) and are 
frequently grouped together under 
the term ANCA-associated vasculitis 
(AAV).104  
The pathogenic potential of ANCA to 
cause necrotizing glomerulonephritis 
(NCGN) is well established in mouse 
models.59,63,64 Patients with severe 
NCGN are almost always positive for 
either PR3- or MPO-ANCA54, while 
ANCA are less often detected in 
patients with localized forms of 
vasculitis.57,105 After remission 
induction, a rise in the ANCA titer is 
detected in some patients and disease 
reactivation may occur shortly 
thereafter.71 However, the relation 
between longitudinal ANCA 
measurements and disease 
reactivation is far from absolute since 
many ANCA rises are not followed by 
a relapse and relapses may occur 
without a preceding ANCA rise.72,101 
Recently, it has been shown that 
ANCA rises are highly predictive for 
disease activity in patients with 
severe vasculitic disease, e.g. NCGN 
or alveolar haemorrhage, but not in 
patients with limited granulomatous 
disease.124,178,191,192 Our current 
hypothesis is that the pathogenicity of 
an ANCA rise is modulated by the 
quality of the auto-antibody, for which 
the glycosylation profile is an 
important factor. 
The glycosylation profile of the 
crystallizable fragment (Fc) of the 
immunoglobulin G (IgG) is 
characterized by a single N-linked 
glycan attached to each heavy chain 
at the asparagine-297.103 The Fc N-
glycan composition affects Fcy 
receptor (FcγR) affinity103,228-230 and 
can influence complement 
activation.231 The lack of a core 
fucose, N-acetylneuraminic (sialic) 
acids and galactose residues on the Fc 
N-glycan have been found to increase 
the inflammatory capacity of IgG, at 
least in mice.232-234 The Fc N-glycan is 
essential for the pathogenicity of the 
antibody, since deglycosylation of 
MPO-ANCA significantly attenuates 
ANCA-mediated neutrophil activation 
and reduces glomerular crescent 
formation in a mouse model.235 
Already in the early eighties, it was 
recognized that total IgG in patients 
with rheumatoid arthritis (RA) 
contained less galactose and sialic 
acid at the non-reducing termini 
compared to healthy controls.236 A 
difference in the glycosylation profile 
of total IgG has since been 
demonstrated in patients with various 
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other auto-immune diseases when 
compared to healthy controls, 
including systemic lupus 
erythematosus, inflammatory bowel 
disease, myasthenic gravis, 
ankylosing spondylitis, primary 
Sjögren’s syndrome, psoriatic arthritis 
and multiple sclerosis.237-241 
Furthermore, significant differences 
have been observed in the 
glycosylation profile of total IgG and 
specific auto-antibodies, such as anti-
citrullinated protein antibodies 
(ACPA), anti-β2GP1 and anti-histone 
IgG.242-245 Finally, Fc glycosylation of 
auto-antibodies may change during 
disease development. For example, 
the glycosylation profile of ACPA 
changes prior to the onset of RA 
towards a more inflammation-
associated phenotype.243,246  
In patients with PR3-ANCA, it was 
previously shown with lectin assays 
that total IgG exhibits a lower degree 
of galactosylation when compared to 
healthy controls.247,248 In addition, the 
degree of sialylation of PR3-ANCA is 
lower during active disease compared 
to inactive disease.114 Recently, it has 
been shown with mass spectrometric 
IgG Fc glycosylation analysis that 
total IgG Fc of patients with severe 
AAV exhibits lower levels of 
galactosylation, sialylation and 
bisecting N-acetylglucosamine 
(GlcNAc) compared to healthy 
controls.193 This finding was more 
pronounced for PR3-ANCA compared 
to total IgG.193 Correlations were 
observed between the glycosylation 
profile of PR3-ANCA and several 
cytokine concentrations, suggesting 
that the glycosylation of ANCA may be 
driven by T-cell activation in an 
antigen-specific manner.193 Potential 
differences and similarities in the 
glycosylation profile of total IgG and 
antigen-specific IgG between patients 
with PR3-ANCA and patients with 
MPO-ANCA associated vasculitis have 
not yet been investigated. 
The objective of our study is to 
investigate differences in the 
glycosylation profile of both PR3-
ANCA and total IgG and the 
prognostic value at the time of a rise 
in PR3-ANCA in patients with GPA. The 
primary question is whether patients 
with a particular glycosylation profile 
are more prone to relapse. 
Furthermore, upon an ANCA rise, 
changes in glycosylation profiles 
associated with a relapse are 
examined. To increase the 
homogeneity of our cohort, we 
included only GPA patients that are 
PR3-ANCA positive, the disease 
subgroup that is most prevalent in our 
area. 
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Materials and methods
Inclusion criteria 
All patients who visited the clinic at 
the Maastricht University Medical 
Center (MUMC) between January 1, 
2000 and November 1, 2011 were 
evaluated. Inclusion criteria were a 
diagnosis of GPA according to the EMA 
classification system and a rise in 
PR3-ANCA during remission.70,121,124  
Clinical characteristics were recorded 
in all subjects according to the Dutch 
law on Medical Treatment Act 
(WGBO), the Personal Data Protection 
Act (Wbp) and the Code of Conduct 
for Health Research (Federa).134 
Ethics approval was waived by our 
local ethics committee. 
 
Classification of patients 
Renal involvement was preferably 
determined by a kidney biopsy 
showing pauci-immune necrotizing 
glomerulonephritis.118,131 However, 
surrogate markers such as hematuria 
in combination with red cell casts, 
dysmorphic erythrocytes (>10) 
and/or proteinuria sufficed.70 All 
patients have been treated according 
to the European League against 
Rheumatism (EULAR) 
guidelines.118,123 
The definitions recommended by the 
EULAR of 2007 were applied to define 
disease activity states.121 Remission 
was defined as absence of disease 
activity attributable to active disease 
during maintenance 
immunosuppressive therapy of a 
prednisone dosage of 7.5mg or lower. 
A relapse was defined as re-
occurrence or new onset of disease 
attributable to active disease 
combined with an increase or addition 
of immunosuppressive treatment. 
Relapses were further subdivided in 
'major' or 'minor' depending on 
whether the relapse was potentially 
organ- or life-threatening or not.121  
 
ANCA measurements 
Patients were routinely evaluated 
during follow-up, generally every 
three months during the first two 
years after diagnosis and/or a relapse 
and 2-3 per year later on. At every 
visit, patients were screened for 
potential symptoms of a relapse121 
and blood was drawn.  
Antigen-specific solid-phase ANCA 
tests were performed for the 
detection and quantification of PR3-
ANCA. Initially, commercially 
available direct PR3-ANCA enzyme 
linked immunosorbent assays (ELISA) 
were used (Euro Diagnostica, Malmö, 
Sweden).133 On October 1, 2005, this 
assay was replaced by a fluorescent-
enzyme immune-assay (FEIA) for 
PR3-ANCA (EliA, Thermo Fisher, 
Freiburg, Germany).106 During the 
transition, ANCA measurements were 
performed using both methods. 
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Definition of an ANCA rise 
For the detection of an ANCA rise, the 
ANCA titer was compared to all 
measurements made with the same 
assay in the past 6 months. We 
defined a rise using the slope of an 
increase as previously described124, 
thereby taking into account the 
relative increase (in %) and the time 
between measurements (in days). A 
receiver operating characteristics 
(ROC) curve was calculated to 
determine the optimal cut-off value of 
the slope. The chosen cut-off values 
as determined by the ELISA and FEIA 
method were 2.56 and 2.25 %/day, 
respectively. This is equivalent to a 
relative increase of 78% and 68% 
over one month or 233% and 205% 
over three months.  
To ensure that small elevations were 
above the intra-assay coefficient of 
variation, a rise had to constitute to a 
relative increase of at least 25% and 
an absolute increase equivalent to a 
doubling of the lowest value of a 
borderline result (at least 10 AU for 
the ELISA and 5 U/ml for the FEIA). 
Because our analysis is focused on 
patients in remission, only serum 
samples drawn at least 3 months after 
the previous disease activity were 
eligible for detection of an ANCA 
rise.124  
 
Serum selection 
In all 75 patients, a serum sample was 
selected at the time of an ANCA rise 
(‘T1’).124 In relapsing patients, either 
renal or non-renal, a second serum 
sample was selected prior to the start 
of the immunosuppressive induction 
therapy at the time of the relapse 
(‘T2rel’). In non-relapsing patients, a 
second serum sample was selected 
after the ANCA rise during remission 
(‘T2rem’), of which the time between 
the first and second sample was 
matched with the time between the 
first and second sample in the renal 
relapsing patients. For 4 relapsing 
patients no serum sample was 
available at the time of the relapse, 
and therefore only 71 T2 serum 
samples were analyzed. 
 
Total IgG purification  
For total IgG purification, the wells of 
two filter plates (Multiscreen filter 
plates with Durapore membrane, pore 
size 0.65 µm; Merck Millipore, 
Darmstadt, Germany) were filled with 
15 µl of Protein G Sepharose 4 Fast 
Flow beads (GE Healthcare, Uppsala, 
Sweden) in 200 µl PBS, followed by 
the addition of 2 µl of the serum 
samples. Furthermore, 10 of the 
serum samples were purified in 
duplicate. Fifteen wells were filled 
with 2 µl Milli-Q-purified water to 
serve as negative control and 20 wells 
were filled with 2 µl of the serum of a 
healthy donor to serve as positive 
control. The plates were incubated on 
a shaker at room temperature for 1 
hour. The samples were then washed 
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on a vacuum manifold with 4x 200 µl 
PBS and 3x 200 µl Milli-Q-purified 
water, followed by the addition of 100 
µl 100 mM formic acid (Fluka, 
Steinheim, Germany) for elution into 
a V-bottom 96-well plate (Greiner 
Bio-One, Frickenhausen, Germany), 
which has been shown to result in 
near-complete denaturation of IgG.249 
Eluates were dried in a centrifugal 
vacuum concentrator (Eppendorf, 
Hamburg, Germany) at 60 °C for 
approximately 2 hours.  
  
PR3-ANCA purification  
An ELISA kit (Wieslab PR3-ANCA; 
Euro Diagnostica) was used for 
purification of PR3-ANCA. Eighty µl 
diluent containing PBS (Wieslab kit) 
and 20 µl of the serum samples were 
added to two PR3-coated 96-well 
plates. Ten of the serum samples 
were purified in duplicate in separate 
wells. Fifteen wells were filled with 20 
µl Milli-Q-purified water to serve as 
negative control and 20 wells were 
filled with 20 µl of the serum of a 
healthy donor to serve as a further 
negative control. The samples were 
incubated on a shaker at room 
temperature for 1 hour, followed by 
washing 4x with 250 µl wash buffer 
(Wieslab kit) and 1x with 150 µl 50 
mM ammonium bicarbonate buffer 
(Sigma-Aldrich, St. Louis, MO). The 
PR3-ANCA was eluted by adding 100 
µl 100 mM formic acid to the wells and 
collected into a V-bottom 96-well 
plate. The samples were then dried in 
a centrifugal vacuum concentrator at 
60°C for approximately 2 hours.   
 
Trypsin digestion  
The dried total IgG and PR3-ANCA 
samples were resuspended in 20 µl 50 
mM ammonium bicarbonate and 
incubated on a shaker at room 
temperature for 15 minutes. Twenty 
µl of 0.01 µg/µl trypsin (sequencing 
grade modified trypsin, Promega, 
Madison, WI) was then added to each 
well. The samples were again 
incubated on a shaker at room 
temperature for 15 minutes, followed 
by overnight incubation at 37°C. 
Samples were stored at -20°C.  
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Figure 5-1. LC-MS spectra showing tryptic IgG1 glycopeptides for total IgG and PR3-
ANCA belonging to an AAV patient (#9; details in Supplemental Table 1) at the time 
of relapse. The peaks denoted with an asterisk belong to a co-enriched contaminant 
(an apolipoprotein O-glycopeptide). Pep=peptide. 
 
LC-MS/MS analysis 
The digested samples were analyzed 
by nanoLC-reversed phase (RP)-
electrospray ionization (ESI) –
quadrupole time-of-flight (qTOF)-MS 
on an Ultimate 3000 HPLC system 
(Dionex/Thermo Scientific, 
Sunnyvale, CA) coupled to a MaXis 
Impact (Bruker Daltonics, Bremen, 
Germany). The samples were 
concentrated on a Dionex Acclaim 
PepMap100 C18 trap column (particle 
size 5 µm, internal diameter 300 µm, 
length 5 mm) and separated on an 
Ascentis Express C18 nano column 
(2.7 µm HALO fused core particles, 
internal diameter 75 µm, length 50 
mm; Supelco, Bellefonte, PA). The 
following linear gradient was applied, 
with solvent A consisting of 0.1% 
trifluoroacetic acid (TFA; Fluka) and 
solvent B of 95% acetonitrile 
(Biosolve, Valkenswaard, The 
Netherlands): t=0 min, 3% solvent B; 
t=2, 6%; t=4.5, 18%; t=5, 30%; 
t=7, 30%; t=8, 1%; t=10.9, 1%. The 
sample was ionized in positive ion 
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mode with a CaptiveSprayer (Bruker 
Daltonics) at 1100 V. A nanoBooster 
(Bruker Daltonics) was used to enrich 
the nitrogen gas with acetonitrile to 
enhance the ionization efficacy. A 
mass spectrum was acquired every 
second (frequency of 1 Hz), with the 
ion detection window set at m/z 550-
1800. In between every 12 
measurements an external IgG 
standard was run.  
 
Data processing 
Mass spectrometric identification and 
processing of tryptic IgG glycopeptide 
data was done as described 
previously250, with a few differences 
as stated below, and was performed 
blindly in order to prevent bias. The 
LC-MS data files were examined in 
Compass Data Analysis 4.2 software 
(Bruker Daltonics). Negative controls 
were inspected and found to contain 
no significant intensity of IgG signals.  
First, the m/z axis of the mass spectra 
was calibrated internally using several 
known IgG glycopeptides masses. 
Next, the files were converted to the 
.mzXML data format using the 
MSconvert program from the 
ProteoWizard 3.0 suite.251 The m/z 
and retention times of all the tryptic 
IgG glycopeptides were manually 
determined using MZmine 2.10252 and 
can be found in supplemental table 
S1. The time axes were aligned based 
on a list of the most prominent IgG 
glycopeptide peaks and their 
retention times, using an alignment 
tool designed in-house.253 The 
intensity of the first three isotopes of 
every analyte was extracted using a 
window of ± 0.04 Thomson and ± 10 
s around the manually determined 
retention time. This was achieved 
using the in-house developed 3D Total 
Extractor (3DTE) program (software 
code can be found in the supplemental 
data). A list of analytes is provided to 
3DTE, which then uses a binary 
search to find the retention time and 
mass region around each analyte. 
Afterwards, the maximum intensity of 
each analyte is determined per mass 
spectrum that falls within the 
retention time window. The value that 
is reported for each analyte by 3DTE 
is the sum of the highest intensity 
values from the individual mass 
spectra. Lastly, the program 
generates a tab-separated output file 
that lists all the compositions and 
their respective total intensities. 
Background correction was optimized 
to minimize intensity biases in the 
determination of glycopeptide ratios. 
In Excel 14.0, the background-
corrected signal intensities of the 
three isotopic peaks in both 2+ and 
3+ charge state were summed to 
obtain a single value for each 
glycopeptide. IgG1 G2 and G2S2 were 
excluded because of overlap with 
contaminant peaks. Isotopic peaks for 
several other IgG1 glycopeptides 
were also excluded due to peak 
overlap, and these values were 
Glycosylation profile of PR3-ANCA 
102 
replaced by an estimate based on the 
remaining isotopic peaks and the 
theoretical isotopic pattern  (these 
isotopic peaks account for less than 
3% of the total glycopeptide signal 
intensity). Afucosylated IgG4 
glycopeptides were excluded due to 
peak overlap with IgG1 glycopeptides. 
In order to obtain a percentage value 
for each glycopeptide, this value was 
then divided by the sum of all signal 
intensities of glycopeptides, and this 
was done separately for IgG1, IgG2/3 
and IgG4. In Caucasian populations 
the tryptic glycopeptide of IgG3 
generally has the same peptide 
sequence as IgG2.254 Therefore it was 
not possible to distinguish between 
IgG2 and IgG3 glycopeptides with the 
methods we used, and these 
glycopeptides will be referred to as 
IgG2/3. The IgG percentage data can 
be seen in supplemental table S2. 
Several glycosylation features were 
calculated from this data: fucosylation 
(% of glycans bearing a core fucose), 
bisection (% of glycans with a 
bisecting GlcNAc), galactosylation (% 
of antennae carrying a galactose) and 
sialylation (% of antennae carrying a 
sialic acid, see supplemental data for 
the exact definitions). 
In order to guard the quality of the 
acquired data, an intensity threshold 
was set. If the sum of the signal 
intensities of G0F, G1F and G2F in 
triple charge state for an IgG subclass 
did not exceed this threshold, all data 
for that subclass was excluded. 
Additionally, data was excluded if the 
signal/background of the highest peak 
per subclass did not exceed 20. 
Finally, because of the chance of 
overlap between IgG4 glycopeptide 
peaks and later eluting IgG2/3 peaks, 
IgG2/3 data was excluded if more 
IgG4 was present than IgG2/3 (as 
determined by G0F+G1F+G2F (3+) 
signals). Lastly, we determined the 
average relative standard deviation 
(RSD) of eight prominent glycans 
(G0F, G1F, G2F, G0FN, G1FN, G2FN, 
G1FS and G2FS) to further examine 
the quality of the data.  
 
Statistical analysis 
Numerical variables were expressed 
as median (interquartile range [IQR]) 
and categorical variables as relative 
abundances (percentages). Two 
unpaired variables were compared 
with the Mann Whitney U test. Two 
paired variables were compared with 
the Wilcoxon signed rank test. 
Continuous variables were correlated 
with the Spearman test. 
Receiver operating characteristic 
(ROC) curves were constructed for 
galactosylation, sialylation, 
fucosylation and bisection at the time 
of an ANCA rise to discriminate 
relapsing patients from patients who 
remained in remission. If a trend 
towards significance was observed in 
an ROC curve, an optimal cut-off 
value was derived that was closest to 
the upper left corner (the cut-off value 
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with the highest sum of sensitivity and 
specificity). Patients were 
subsequently categorized as high 
(above or equal to the cut-off) or low 
(below cut-off) level for the 
concerning glycosylation trait. 
Differences in the time to relapse 
between high and low were assessed 
using the log-rank test. The time to 
relapse was estimated using the 
Kaplan-Meier method. An event was 
defined as a relapse at the time of the 
start or increase of 
immunosuppressive treatment. 
Subjects were censored at the time of 
last follow-up. Hazard ratios (HR) with 
the 95% confidence interval were 
derived using the Cox regression 
analysis, adjusted for age and sex. 
The proportional hazards assumption 
was assessed by visually inspecting 
log-log plots.  
All statistical analyses were 
performed using GraphPad Prism 
version 6.04 for Windows (GraphPad 
Software, La Jolla, California, USA) 
and SPSS statistics for Windows, 
version 23.0 (IBM, Armonk, NY, USA). 
Bonferroni corrections were applied to 
the statistical testing, in which a p-
value of <0.0125 was considered 
significant and <0.05 was considered 
as a trend.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1 (next page). Patient characteristics. The organ involvement refers the 
organ involvement during any previous periods of disease activity in the past (at the 
diagnosis or any previous relapse). The induction treatment refers to the treatment 
regimen that was used to induce remission during the most recent period of disease 
activity only. Abbreviations: SD, standard deviation. GC, glucocorticosteroid therapy. 
*This patient was included after a minor relapse which was treated with GC 
monotherapy, while remission was induced after diagnosis using cyclophosphamide 
+ GC. ±The follow-up time refers to the time from the most recent disease activity 
to the endpoint of the study (at the time of relapse or at the last time of follow-up).  
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Renal Non-renal 
 
Relapse 
(n=31) 
Remission 
(n=20) 
Relapse 
(n=12) 
Remission 
(n=12) 
Demographics 
Age (in years + SD) 58 (14) 55 (14) 58 (9) 66 (11) 
Male 23 (74%) 13 (65%) 6 (50%) 4 (33%) 
Organ involvement at previous disease activities 
Arthralgia 19 (61%) 10 (50%) 7 (58%) 5 (42%) 
Cutaneous 13 (42%) 3 (15%) 2 (17%) 0 (0%) 
Eyes 8 (226%) 5 (25%) 3 (25%) 3 (25%) 
Ear, nose, throat 26 (83%) 17 (85%) 10 (83%) 11 (92%) 
Lung 23 (74%) 14 (70%) 10 (83%) 10 (83%) 
Cardiovascular 1 (3%) 2 (10%) 0 (0%) 0 (0%) 
Renal 31 (100%) 20 (100%) 0 (0%) 0 (0%) 
Central nervous system 1 (3%) 0 (0%) 0 (0%) 1 (8%) 
Peripheral nervous system 7 (23%) 4 (20%) 1 (8%) 2 (17%) 
Induction treatment at previous disease activity resulting in remission 
Cyclophosphamide + GC 19 (61%) 14 (70%) 6 (50%) 10 (83%) 
Rituximab + GC 1 (3%) 3 (15%) 0 (0%) 0 (0%) 
Methotrexate + GC 5 (16 %) 0 (0%) 4 (33%) 1 (8%) 
Mofetil mycophenolate + GC 3 (10%) 3 (15%) 0 (0%) 0 (0%) 
Gusperimus + GC 2 (6%) 0 (0%) 1 (8%) 0 (0%) 
GC monotherapy 1 (3%)* 0 (0%) 1 (8%) 1 (8%) 
Immunosuppressive therapy at the time of the ANCA rise 
Immunosuppressive therapy 27 (87%) 16 (80%) 8 (67%) 8 (67%) 
None 4 (13%) 4 (20%) 4 (33%) 4 (33%) 
Follow-up 
Follow-up time (in months + 
SD) ± 
13 (20) 42 (21) 14 (16) 46 (35) 
Persistently ANCA positive 10 (32%) 6 (30%) 2 (17%) 3 (25%) 
Relapse 
Major 18 (58%) - 4 (33%) - 
Minor 13 (42%) - 8 (67%) - 
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Results
Patient characteristics 
Seventy-five patients with 
Granulomatosis with Polyangiitis 
positive for PR3-ANCA were included 
in this study, of whom 51 patients had 
renal involvement in the past and 24 
patients did not (see Table 5-1). 
Forty-three (57.3%) patients 
relapsed within a median time of 8 (2-
16) months since the ANCA rise.  
Out of 156 samples total (75 at the 
time of ANCA rise, 71 at a second time 
point, and 10 duplicates), PR3-ANCA 
IgG1 data was excluded in 16 
samples, total IgG1 data in 0 samples, 
total IgG2/3 data in 14 samples and 
total IgG4 in 20 samples. Because the 
signal intensity of PR3-ANCA IgG2/3 
and IgG4 in the majority of samples 
did not surpass the threshold, we 
excluded this data group altogether. 
For 8 prominent glycoforms, the 
external IgG standard run in between 
every 12 measurements showed an 
average RSD of 4.2% for IgG1, 4.0% 
for IgG2/3 and 7.1% for IgG4. The 
on-plate healthy donor serum-derived 
total IgG samples exhibited an 
average RSD of 4.0% for IgG1, 3.0% 
for IgG2/3 and 3.5% for IgG4. Finally, 
for the aforementioned 8 glycoforms, 
the 10 ANCA serum samples which 
were processed in duplicate showed 
an average RSD of 2.3%, 1.5% and 
1.3% for total IgG1, IgG2/3 and IgG4, 
and 3.1% for PR3-ANCA IgG1. Two 
LC-MS spectra of total IgG and PR3-
ANCA IgG, belonging to an AAV 
patient at the time of relapse, can be 
seen in Figure 5-1. 
For better readability, the results of 
total IgG1 and PR3-ANCA IgG1 are 
presented in the manuscript, while 
the results of total IgG2/3 and total 
IgG4, which exhibit the same general 
trend as total IgG1, can be found in 
the supplemental data. 
 
IgG1 Fc glycosylation of total IgG and 
PR3-ANCA at the time of the ANCA 
rise 
At the time of the ANCA rise, we 
analyzed whether there were 
differences in the glycosylation profile 
of total IgG1 and PR3-ANCA IgG1. The 
degree of galactosylation, sialylation 
and fucosylation of total IgG1 was 
lower compared to PR3-ANCA IgG1 
(46.0% [39.1-49.7%] versus 47.4% 
[40.4-57.5%], p=0.0175; 6.2% [5.2-
7.1%] versus 6.9 [5.1-9.0%]; 
p=0.0289 and 93.3% [89.9-95.5%] 
versus 98.4% [97.3-99.0%], 
p<0.0001, respectively). In contrast, 
the level of bisection of total IgG1 was 
higher compared to PR3-ANCA IgG1 
(19.0 [15.9-21.7%] versus 11.4% 
[10.1-13.9%], p<0.0001, see figure 
S1 in the supplemental data).
 
Glycosylation profile of PR3-ANCA 
106 
Figure 5-2. Time to relapse after an ANCA rise, (a) according to the degree of 
galactosylation of total IgG 1 Fc and (b) according to the degree of sialylation of total 
IgG 1 Fc.
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IgG1 Fc glycosylation as a predictor of 
a relapse at the time of an ANCA rise 
Thereafter, we investigated whether 
patients with a particular IgG1 Fc 
glycosylation profile at the time of an 
ANCA rise are more prone to relapse 
after an ANCA rise. The ROC curve of 
total IgG1 galactosylation and 
sialylation were found to differentiate 
relapsing patients from non-relapsing 
patients (supplemental figure S2; 
AUC 0.6533, p=0.02385 and AUC 
0.6563, p=0.02131, respectively). 
Total IgG1 bisection and fucosylation 
did not yield significant discrimination 
between relapsing and non-relapsing 
patients (p=0.9488 and p=0.9402, 
respectively; data not shown). The 
ROC curve of PR3-ANCA IgG1 was not 
significant for any of the glycosylation 
traits (data not shown). An optimal 
cut-off value was derived from the 
significant ROC curves, and patients 
were classified as ‘low galactosylation’ 
if the galactosylation rate of total 
IgG1 was lower than 46.1% and as 
‘low sialylation’ if the sialylation rate 
of total IgG1 was lower than 6.9% 
(see figure S2 in the supplemental 
data). 
Forty-one of 75 (54.7%) patients 
were classified as low galactosylation, 
of whom 30 (73.2%) patients 
relapsed within a median of 6 (1-15) 
months after the ANCA rise. In 
comparison, only 13 of 34 (38.2%) 
patients who were classified as high 
galactosylation relapsed in a median 
of 10 (2.5-17.5) months. Thus, 
patients with low galactosylation total 
IgG1 were highly prone to relapse 
after an ANCA rise (HR 3.46 [95%-CI 
1.73-6.96], p<0.0001, adjusted for 
age and sex, see Figure 5-2a).  
Similar results were found for the 
degree of sialylation. Forty-seven of 
75 (62.7%) patients were classified as 
low sialylation, of whom 34 (72.3%) 
patients relapsed within a median of 8 
(1-17) months after the ANCA rise. In 
comparison, only 9 of 28 (32.1%) 
patients with a high sialylation 
relapsed in a median of 7 (2-12) 
months. Low sialylation patients were 
highly prone to relapse after an ANCA 
rise (HR 3.22 [95%-CI 1.52-6.83], 
p=0.002, adjusted for age and sex; 
see Figure 5-2b).  
Because the degree of sialylation and 
galactosylation are highly correlated 
(terminal N-acetylneuraminic acid is 
attached to galactose), we in addition 
calculated the sialic acid per 
galactose. No association was 
observed between the sialic acid per 
galactose and the time to relapse (see 
figure S3 and S4 in the supplemental 
data). 
 
Changes in IgG1 Fc glycosylation 
during follow-up 
Next, we looked at potential changes 
of the glycosylation profile during 
follow-up. With regards to the total 
IgG1, the degree of galactosylation, 
sialylation and bisection significantly 
decreased and fucosylation 
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significantly increased in relapsing 
patients (p<0.0001, p=0.0087, 
p<0.0001 and p=0.0025, 
respectively), while the glycosylation 
profile remained similar in patients 
who remained in remission (see 
Figure 5-3 and figure S5 and S6 in the 
supplemental data). 
With regard to PR3-ANCA IgG1, in 
relapsing patients, a significant 
reduction in the degree of 
galactosylation and sialylation and a 
trend towards a reduction in 
fucosylation were observed from the 
ANCA rise to the time of the relapse 
(p=0.0073, p=0.0049 and p=0.0205, 
respectively, see Figure 5-4). 
Similarly, in patients who remained in 
remission, a significant reduction in 
the degree of galactosylation, 
sialylation and fucosylation was 
observed from the ANCA rise to the 
time of the second sample (p=0.0007, 
p=0.0114 and p=0.0002, 
respectively). Moreover, the 
proportion of bisection of PR3-ANCA 
IgG1 significantly increased from the 
ANCA rise to the time-matched 
sample during remission (p<0.0001).
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 (next page). The glycosylation profile of total IgG1 Fc at the time of an 
ANCA rise (T1) and at the time of a relapse (T2rel) in relapsing patients (black dots) 
and time-matched during remission (T2rem) in patients who remain in remission 
(gray dots). Dots represent individual patients, lines indicate corresponding pairs. 
The box represents the median with interquartile range, the whiskers delineate the 
min-max range. Significant differences were evaluated using the Wilcoxon signed 
rank test, P-values are shown if <0.10 and in bold if <0.0125.  
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IgG1 Fc glycosylation at the time of 
the relapse or time-matched during 
remission 
The changes in the glycosylation 
profile over time lead to significant 
differences between patients in 
relapse or in remission at the second 
time point. With regard to total 
IgG1, a significantly lower degree of 
galactosylation and sialylation and a 
trend towards a lower degree of 
bisection was observed in relapsing 
patients compared to patients who 
remain in remission (p=0.0015, 
p=0.0120 and p=0.0443, 
respectively, see Figure 5-5 and 
figure S7 in the supplemental data). 
Conversely, the glycosylation profile 
of PR3-ANCA was only significantly 
different with regard to bisection, 
which was lower in relapsing 
patients compared to patients who 
remained in remission (p=0.0009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 (next page). The glycosylation profile of antigen specific PR3-ANCA 
IgG1 Fc at the time of an ANCA rise (T1) and at the time of a relapse (T2rel) in 
relapsing patients (black dots) and time-matched during remission (T2rem) in 
patients who remain in remission (gray dots). Dots represent individual patients, lines 
indicate corresponding pairs. The box represents the median with interquartile range, 
the whiskers delineate the min-max range. Significant differences were evaluated 
using the Wilcoxon signed rank test, P-values are shown if <0.10 and in bold if 
<0.0125. 
  
Chapter 5 
111 
 
  
Glycosylation profile of PR3-ANCA 
112 
Discussion
In this study we investigate with mass 
spectrometry the changes in Fc 
glycosylation over time in both total 
IgG and PR3-ANCA of patients with 
AAV. In patients who were in clinical 
remission, a first serum sample was 
taken at the time of an ANCA rise, 
whereas a second sample was 
acquired either after relapse but 
before therapy was started, or for 
patients who remained in remission, 
after a similar length of time. Analysis 
of the two longitudinal samples 
revealed a significant reduction in 
galactosylation, sialylation and 
bisection and an increase in 
fucosylation in total IgG Fc of 
relapsing patients, while these 
glycosylation traits did not change 
significantly in patients who remain in 
remission. Most importantly, the Fc 
glycosylation profile of total IgG at the 
time of an ANCA rise predicts a 
relapse. Namely, patients with low 
galactosylation or low sialylation in 
total IgG are more prone to relapse 
compared to patients with high 
galactosylation or sialylation in total 
IgG. In addition, we observed that the 
level of sialylation and galactosylation 
of PR3-ANCA is decreased over time, 
both in relapsing and non-relapsing 
patients. Therefore, it appears that 
PR3-ANCA gains a more 
inflammation-associated phenotype 
during follow-up in both groups of 
patients, independent of disease 
course.  
While IgG with a low degree of 
galactosylation has repeatedly been 
found to be associated with pro-
inflammatory autoimmune responses, 
the underlying mechanisms are still 
largely elusive.255-258 In contrast, 
highly galactosylated IgG may confer 
anti-inflammatory activities through 
the association with the inhibiting 
receptor FcyRIIb and the C-type 
lectin-like receptor Dectin-1 in 
mice.233 This latter pathway has been 
shown to block C5a effector functions 
in vitro and C5a-dependent 
inflammatory responses in animal 
mouse models.233 This is highly 
relevant in AAV, since C5a plays a 
pivotal role in the 
pathophysiology.104,259 Mouse models 
have shown that the blocking of C5a 
or C5a receptor (C5aR) ameliorates 
anti-MPO induced necrotizing 
glomerulonephritis.260,261 The safety 
and efficacy in the treatment of non-
life-threatening AAV with CCX168, a 
C5aR inhibitor, is currently being 
tested in a phase 2 study (EudraCT 
Number: 2011-001222-15). The 
addition of galactose to the glycan 
structure also no longer enables the 
interaction of MBL with IgG, and may 
thereby block the lectin pathway.231 
The clinical relevance of the lectin 
pathway in AAV is questionable 
however, since mannose-binding 
lectin (MBL) deposition in the kidney 
was found in only a minority of 
patients and complement activation in 
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AAV occurs predominantly via the 
alternative pathway.259  
 
Sialylated IgG has been reported to 
have anti-inflammatory properties 
likely mediated through interaction 
with the murine C-type lectin receptor 
SIGN-R1 (a homologue of the human 
DC-SIGN) and FcyRIIb.234,262 In our 
study, we found that total IgG 
preserved an anti-inflammatory 
glycosylation profile in patients who 
remained in remission, but changed to 
an inflammation-associated 
phenotype in relapsing patients. It 
remains unclear whether this change 
merely represent a bystander acute-
phase reaction or whether the loss of 
anti-inflammatory effector function of 
total IgG enabled PR3-ANCA to induce 
disease reactivation. Notably, low 
galactosylation and sialylation at the 
ANCA rise predicts disease 
reactivation, suggesting that the 
change of total IgG towards an 
inflammation-associated phenotype 
precedes the onset of disease 
reactivation. We hypothesize that 
these anti-inflammatory mechanisms 
of total IgG are involved in the 
suppression of active disease in our 
AAV patients who remain in 
remission.  
 
One may wonder what causes the 
change of the glycosylation profile of 
total IgG from an anti-inflammatory 
towards a pro-inflammatory 
phenotype. One study observed an 
average reduction of total IgG 
sialylation by 40% upon antigenic 
challenge in a mouse model.234 Based 
on our findings, we speculate that a 
second hit that is not related to the 
presence of PR3-ANCA nor the 
glycosylation profile of PR3-ANCA is 
required for a relapse after an ANCA 
rise (the “first hit”). Several 
candidates for such a second hit have 
been postulated, such as 
microorganisms116, environmental 
factors66,67, and/or other auto-
antibodies.68 No functional data are 
currently available regarding the role 
of the glycosylation profile of total IgG 
and/or antigen-specific IgG in the 
capacity of PR3-ANCA to induce 
inflammation and this should be 
further studied. 
 
Figure 5-5 (next page). The glycosylation profile at the time of a relapse in 
relapsing patients and time-matched during remission in patients who remain in 
remission (gray dots). IgG1 Fc glycosylation of total IgG (left side, white background) 
and antigen specific PR3-ANCA (right side, yellow background) is shown. Dots 
represent individual patients. The box represents the median with interquartile range, 
the whiskers delineate the min-max range. Significant differences were evaluated 
using the Mann Whitney U test, P-values are shown if <0.10 and in bold if <0.0125. 
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A recent study reported a novel 
correlation between bisection of PR3-
ANCA and disease state.193 In our 
study we find a correlation between 
bisection and relapse/remission. The 
level of bisection of total IgG 
decreases significantly in relapsing 
patients, while it does not change in 
non-relapsing patients. In PR3-ANCA 
the level of bisection remains stable in 
relapsing patients, while it increases 
in non-relapsing patients. While the 
effect of a bisecting GlcNAc on IgG 
effector functions is minor compared 
to that of the other glycosylation 
features, it has been reported that 
bisection can enhance antibody-
dependent cellular cytotoxicity 
(ADCC) through increased FcγRIIIa 
affinity.263,264 Since a reduction in 
bisection is seen during AAV relapse, 
it is likely that the minor anti-
inflammatory effect of decreased 
bisection is overshadowed by effects 
of other changes in glycosylation and 
that ADCC may only play a minor role 
in the pathogenesis of AAV.265 A 
decrease in IgG bisection has not 
been reported for any other 
autoimmune disorders, while an 
increase in bisection has been 
observed for Lambert-Eaton 
Myasthenic Syndrome (LEMS).241 A 
slight increase in fucosylation over 
time was seen in total IgG of relapsing 
patients. In contrast, PR3-ANCA 
showed a minor decrease in 
fucosylation for both relapsing and 
non-relapsing patients. While the 
absence of a core fucose can greatly 
enhance the inflammatory properties 
of IgG through increased FcγRIIIa 
affinity, the differences in fucosylation 
in our study cohort are likely too small 
to be of much influence. 
Our findings regarding the 
glycosylation profile of total IgG 
compared to antigen-specific PR3 
markedly differ from those of a 
previous study, which reported a 
reduction of galactosylation, 
sialylation and bisection of PR3-ANCA 
as compared to total IgG, while we 
observe that bisection, but not 
galactosylation and sialylation is 
reduced in PR3-ANCA. These 
differences may be largely caused by 
the pronounced differences in study 
design.193 First, we included patients 
with severe AAV as well as patients 
with more limited forms of AAV, while 
the previous report only included 
patients with severe AAV.193 Second, 
our patients were in remission at the 
time of sampling, while the patients of 
Wuhrer et al. were sampled at the 
time of active disease.193 
Interestingly, both studies observe a 
lower degree of bisection in PR3-ANCA 
compared to total IgG.  
 
Our study is limited by the number of 
included patients, hence only the N-
glycan analysis was included in the 
statistical evaluation. Future 
validation in other, larger study 
cohorts is warranted in which the 
predictive value of a multitude of 
Glycosylation profile of PR3-ANCA 
116 
factors, in particular the IgG N-glycan 
analysis, should be evaluated using 
multivariate techniques, including 
principle components analysis. A 
strong aspect of our study is that our 
patients are highly characterized and 
we only included patients with GPA 
positive for PR3-ANCA. Yet differences 
still remain in organ involvement and 
immunosuppressive therapy. Our 
findings, however, may not apply to 
patients with MPA or patients positive 
for MPO-ANCA and this should be 
further investigated.  
 
Most importantly, we addressed the 
clinical value of the aberrant 
glycosylation which we observe in 
AAV patients. Changes in IgG 
glycosylation, especially 
galactosylation and sialylation, might 
be useful to screen patients for their 
risk of relapse. Our data indicates that 
analysis of total IgG would be 
sufficient for this purpose. Already in 
the first serum sample, acquired a 
median time of 8 months before the 
time of relapse, we could identify 
patients that are at risk for a future 
disease relapse. Differences in the 
glycosylation profile between 
relapsing and non-relapsing patients 
becomes more pronounced as the 
time of relapse approaches. 
Longitudinal acquisition of serum 
samples taken every few months 
would reveal changes in the personal 
glycosylation profile of each patient 
that could possibly help as a guide 
when to start treatment in these 
patients. It remains to be studied, 
however, whether treatment based on 
this information will be able to 
minimize tissue and organ damage.  
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General discussion 
 
In this thesis, we set out to provide physicians tools to predict future disease 
activity in order to guide maintenance therapy in patients with ANCA associated 
vasculitis. In the first section of the general discussion, we summarize the main 
findings as described in this thesis. Most importantly, our studies have further 
substantiated the evidence behind a classification system of patients based on 
the biologic behaviour of the disease to guide maintenance therapy in ANCA 
associated vasculitis. Our studies suffer from several limitations however, which 
are highlighted in the next paragraph. Furthermore, we propose 
recommendations for future research to realize a prediction model to accurately 
identify patients that are at risk of a relapse. We hypothesize that such a model 
can be constructed if a vast amount of patient data is collected in a standardized 
manner to allow for the application of artificial intelligence. While our studies 
have outlined factors that should be incorporated in the future model, other 
factors should be further investigated, which are highlighted in the last section. 
Ultimately, our recommendations will result in a prediction model that may in 
the future be used to prevent morbidity and mortality related to active disease, 
while minimizing treatment-related side-effects. 
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Summary of our findings
To accomplish our objectives, we 
analysed a cohort of patients with 
ANCA associated vasculitis that were 
closely monitored during follow-up in 
a tertiary referral hospital. In Chapter 
1, we analysed the association of 
serial ANCA measurements with 
disease activity during follow-up. In 
this study, we observed that ANCA 
rises are highly associated with a 
future relapse in patients with renal 
involvement, but not in patients with 
non-renal disease. Renal involvement 
may be a proxy for severe vasculitic 
disease as we found in a small 
subgroup of non-renal patients with 
severe disease were prone to relapse 
after an ANCA rise. This hypothesis is 
further substantiated by a later study 
in which ANCA rises were highly 
associated with disease activity in 
patients with a history of alveolar 
haemorrhage, a life-threatening 
vasculitic manifestation.191 
Not every ANCA rise leads to disease 
activation, however, since only 43.3% 
of our patients with renal involvement 
relapsed within a year after the ANCA 
rise. Therefore, we set out to identify 
additional risk factors for a relapse at 
the time of an ANCA rise in Chapter 2. 
We included all patients with renal 
involvement in whom an ANCA rise 
was detected during follow-up. We 
identified three independent risk 
factors for a relapse: previous 
induction therapy lacking 
cyclophosphamide or rituximab, an 
ANCA rise during the fall season and a 
perpetuating ANCA rise. An ANCA rise 
during the fall season in particular 
increased the proportion of relapsing 
patients within a year to 84.6%. We 
hypothesize that the seasonal 
influence may be a proxy for an 
increased risk of infections, which 
may serve as a second hit. 
Alternatively, during follow-up we 
observed lower levels of vitamin D, an 
important immunodulator, in 
relapsing patients, but not in patients 
who remained in remission. 
In Chapter 3, we reviewed the current 
literature regarding potential 
strategies to guide maintenance 
therapy in patients with GPA or MPA, 
with an emphasis on patient 
classifications and the role of serial 
ANCA measurements. In this review, 
we hypothesize that a classification 
model that is focused on the biologic 
behavior of the disease may in the 
future be used to guide maintenance 
therapy in patients with AAV. To 
substantiate this hypothesis, we 
analysed additional biomarkers in 
serum samples that were previously 
obtained for clinical purposes during 
follow-up. To reduce heterogeneity in 
our cohort, we limited our studies to 
patients with Granulomatosis with 
Polyangiitis that were PR3-ANCA 
positive. 
First, we investigated whether the 
avidity of PR3-ANCA changes during 
follow-up in different subgroups of 
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patients with Granulomatosis with 
Polyangiitis. In Chapter 4, we 
observed that avidity of PR3-ANCA 
increases after an ANCA rise during 
follow-up in renal relapsing patients 
but not after an ANCA rise in renal 
patients who remain in remission or in 
non-renal relapsing patients. The 
findings of our pilot study warrant a 
prospective study to investigate 
whether the avidity of PR3-ANCA at 
the time of an ANCA rise identifies 
patients that are at a risk of a relapse.  
In Chapter 5, we investigated the Fc 
glycosylation profiles of total IgG and 
PR3-ANCA as prognostic markers of a 
relapse. Most importantly, at the time 
of the ANCA rise, we observed that 
patients with low galactosylation or 
low sialylation in total IgG are more 
prone to relapse compared to patients 
with high galactosylation or sialylation 
in total IgG. Furthermore, we 
analysed a second sample after the 
ANCA rise taken at the time of the 
next disease activity in relapsing 
patients or time-matched in patients 
that remain in remission. The 
longitudinal analysis revealed a 
reduction in galactosylation, 
sialylation and bisection and an 
increase in fucosylation in total IgG of 
relapsing patients, while these 
glycosylation traits did not change 
significantly in patients who remain in 
remission. Our findings suggest that 
the glycosylation profile of total IgG 
during follow-up may be a useful 
marker to guide maintenance therapy 
in the future.
 
 
Limitations of our studies
Limitations of our studies have been 
extensively reported in the discussion 
of previous chapters and will be 
summarized next. Most importantly, 
our studies were performed in a 
single-centre cohort at a tertiary 
referral hospital using data from 
clinical practice that has been 
obtained in a retrospective manner. 
While such a cohort offers 
advantages, it is also associated with 
several limitations. As such, our 
cohort is limited in sample size and 
consists of a highly specific subset of 
patients as compared to cohorts 
originating from secondary care. 
Patient management in our cohort, 
while performed in accordance with 
appropriate guidelines123,266, is more 
heterogeneous as compared to 
patient management in a randomized 
clinical trial. Our physicians were not 
blinded to the ANCA values.71,101 Also, 
retrospective observational studies 
lag behind on new developments. 
Most of our patients are therefore 
treated with cyclophosphamide, which 
will continue to be relevant144,146, yet 
patients will more often receive 
rituximab in the future. Whether our 
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findings are applicable in patients 
treated with rituximab should be 
investigated. Last, our data are less 
reliable as compared to data obtained 
in a prospective manner. This is most 
evident when looking at the collection 
of serial ANCA measurements. In 
prospective trials71,101, serum samples 
are collected at a strict time interval 
(e.g. 1 month) and all samples are 
measured with the same ANCA 
method. This is in sharp contrast to 
clinical practice, in which the time 
interval is tailored to the preference of 
the patient and the method of ANCA 
testing may change throughout the 
years. In our studies, we had to 
implement several additional 
procedures to account for these 
limitations. Most importantly, we took 
the time between samples into 
consideration when defining the ANCA 
rise. In addition, samples were 
measured with both ANCA methods 
during the period in which the ANCA 
method was changed.  
 
Recommendations for future research
Future studies should take the 
limitations that have been described 
above into account. Most importantly, 
our findings need to be replicated in a 
prospective multi-centre cohort study 
with sufficient power. Because serial 
ANCA measurements are performed 
in daily practice, population-based 
observational studies are ideal to 
further investigate the clinical 
usefulness of serial ANCA 
measurements. However, the quality 
of data in this kind of studies are often 
low, as relevant data are not obtained 
in a standardized and well-defined 
manner.267 In the following 
paragraphs, we will discuss how 
standardized data collection in daily 
practice may lead to high quality 
observational studies regarding the 
prediction of relapses. The results of 
these studies can be directly 
implemented in clinical practice using 
clinical decision support systems. In 
addition, we will discuss how patient 
data may be automatically evaluated 
using machine learning. The 
transformation of electronic medical 
record systems by standardized data 
collection, clinical decision support 
and machine learning may in the 
future lead to a new approach in 
predicting relapses in ANCA 
associated vasculitis.  
 
Standardized data collection  
Electronic medical record (EMR) 
systems have been highly debated 
since their introduction. This is most 
apparent after the rejection of a 
legislative proposal to implement a 
national EMR by the Senate on the 5th 
of April, 2011, due to concerns 
regarding the security and privacy 
protection (‘voorstel tot Wijziging van 
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de Wet gebruik burgerservicenummer 
in de zorg in verband met de 
elektronische informatieuitwisseling 
in de zorg’). Nevertheless, hospitals 
have independently been working on 
local EMRs. In the current state, 
however, these EMRs offer insufficient 
possibilities to adapt the database to 
a specific patient group such as ANCA 
associated vasculitis. EMRs often only 
provide one text field in which the 
clinician can write his findings, which 
does not allow for automated 
processing and analysis of the patient 
data. Instead, patient data should be 
stored in a standardized manner and 
data should be well defined. Examples 
of patient input are clinical 
characteristics, such as the 
Birmingham Vasculitis Activity Score 
and the Vasculitis Damage Index, 
outcome registration such as 
relapses, adverse events (e.g. 
infections, malignancies and 
thrombosis) and patient reported 
outcomes268 such as the 36-item 
Short Form Health Survey.121,269 
Active involvement of the patient 
should also be encouraged, as it has 
been shown that his own assessment 
is useful in the prediction of disease 
reactivation.202 
 
The usefulness of standardized data 
collection has been shown by the 
advent of population-based 
observational studies.267,270 While 
randomized controlled trials are the 
cornerstone to investigate new 
interventions, observational studies 
are essential in the evaluation of 
interventions and diagnostic 
approaches that have already been 
introduced in clinical healthcare.270 
Population-based observational 
studies offer large datasets unrivalled 
in size by randomized clinical trials 
that are capable to detect associations 
that were previously unidentified. In 
addition, they are capable of 
monitoring adverse events that rarely 
occur. These datasets make precision 
medicine possible, a strategy that 
takes individual variability into 
account with regards to the 
prevention and treatment of 
diseases.271 Oncology in particular has 
seen a lot of interest in precision 
medicine, due to insights regarding 
the clinical impact of biological 
characteristics of the malignancy that 
have become available in the -omics 
era (e.g. genomics, metabolomics and 
glycomics). Precision medicine may 
also be possible in the field of ANCA 
associated vasculitis, as we have 
shown that genomics163 and glycomics 
(see Chapter 5) provide useful 
information regarding the prediction 
of disease reactivation.  
While oncology is ahead in the 
implementation of standardized data 
collection267, other specialties are 
picking up the pace. For instance, a 
workgroup statement has been issued 
regarding the optimization of 
administrative datasets to make 
registry-based observation studies 
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regarding acute kidney injury 
possible.272 The pivotal role of the 
integration of datasets has been 
appreciated and recommended in a 
consensus report for any form of 
biomedical research in the 21th-
century to facilitate a paradigm shift 
towards human biology-based 
models.273 In the field of ANCA 
associated vasculitis, several 
attempts have been made that can be 
regarded as standardized data 
collection.121,274-276 Recently, a case-
finding algorithm has been developed 
to accurately identify AAV patients in 
a large healthcare administrative 
database.275 While such an algorithm 
may in the future facilitate large 
observation studies, especially with 
regards to epidemiology, the 
possibilities are limited without 
standardized data collection.275 
 
Harmonization of definitions 
Standardized data collection may also 
help alleviate differences in definitions 
that are currently being used. The 
development of classification schemes 
have led to better comparability 
between different cohorts of patients 
with ANCA associated vasculitis, as 
described in the introduction of this 
thesis.21 Nevertheless, important 
differences are present between 
cohorts that should be taken into 
account when interpreting the results 
of the different studies.150 Most 
importantly, the definitions used for a 
relapse as the endpoint of studies are 
controversial. For example, the RAVE 
trial defines the primary endpoint as a 
relapse based on a BVAS score >0 
without the added requirement of a 
treatment change.151 This is in 
contrast to the MAINRITSAN trial, in 
which the primary endpoint is a major 
relapse and the secondary endpoint is 
a minor relapse, defined as a BVAS 
score >0 and, in addition, requiring 
mild treatment intensification.200  
 
Standardisation of ANCA detection  
So far, we have only discussed the 
opportunities to standardize data 
collection and the harmonization of 
definitions with regards to the clinical 
characteristics of the patient. In 
addition, ANCA detection may also 
greatly benefit from the 
standardization of immunoassays for 
PR3- and MPO-ANCA.105,204,277 
Currently, large differences are 
present between available antigen-
specific ELISAs with regards to their 
reference values, cut-off values and 
performance.278-281 In a recent multi-
centre study, the concordance 
between eight different 
immunoassays in controls, GPA and 
MPA was respectively 94%, 89% and 
91% for PR3-ANCA and respectively 
94%, 93% and 77% for MPO-ANCA.58 
While these concordance rates are 
relatively high, they are not absolute. 
In addition, only the qualitative 
results of the different immunoassays 
were compared (e.g. positive versus 
negative) and not the quantitative 
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value (e.g. 10 or 100 arbitrary units). 
While the qualitative result is of 
interest for diagnostic purposes, the 
quantitative result is of importance 
during follow-up.141,282 The 
comparability of the quantitative 
results is lacking, as demonstrated by 
Trevisin et al.281 Trevisin analysed a 
PR3-ANCA positive serum standard, 
with a reported value of 101 U/ml, 
using 8 different commercial ELISAs 
and observed values ranging from 4 
to 102 U/ml.281 The authors note 
differences in the used testing 
dilutions, methods of PR3 purification, 
binding properties of the ELISA plates, 
buffers used for coating and 
incubation, negative and positive 
controls and methods used to 
construct standard curves and 
calculate PR3-ANCA binding.281 
Importantly, these methodological 
differences could be standardized to 
align test results between different 
ELISA-based immunoassays. 
Importantly, it was shown that this 
objective could be achieved by using 
a commutable reference material for 
calibration.283 Therefore, the Institute 
for Reference Materials and 
Measurements (IRMM), in 
collaboration with the Working Group 
Harmonisation of Autoantibody Tests 
(WG-HAT), developed a serum 
Certified Reference Material (CRM) 
that can be used as a common 
calibrant for immunoassays targeted 
against IgG MPO-ANCA.284 The 
standardisation of immunoassays is 
not only important to detect MPO-
ANCA, but is also for other 
autoantibodies, which will be 
developed in the future.204,284  
The benefits from standardisation are 
highlighted by the success of the EU-
supported EuroFlow Consortium, 
which has developed laboratory 
protocols and software tools to 
standardize flow cytometric 
immunophenotyping of leukocytes.285  
The lack of standardisation of ANCA 
testing is evident in our studies, as 
the method of ANCA detection was 
replaced during follow-up and the 
results of the new method could not 
be compared with the old method (see 
Chapter 1). The impact of the 
standardisation of immunoassays on 
the predictive value of serial ANCA 
measurements for disease 
reactivation will be of great interest in 
the future. 
 
Integration of data sources 
Next to standardized data collection, 
the underlying database 
infrastructure should be unified across 
healthcare providers to allow for 
straightforward exchange of patient 
data upon patient’s consent to 
facilitate second opinions. Currently, 
the electronic record of a patient is 
printed at the secondary hospital and 
faxed to the tertiary hospital, which 
subsequently scans the paper records 
to add the data to their EMR. This 
process is highly inefficient, time-
consuming and prone to mistakes. 
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The importance of integration 
between healthcare providers is most 
evident in the field of ANCA associated 
vasculitis since most patients are 
treated in expert centres after referral 
from primary or secondary 
healthcare. Seamless integration of 
patient data may in the future 
promote management collaboration 
between primary, secondary and 
tertiary healthcare providers. In such 
a collaboration, patients could be seen 
more often by their local specialist or 
even using any digital device at 
home286, while expert centres 
continue to supervise the 
management plan to provide the most 
optimal healthcare.  
Integration of anonymized datasets 
for research purposes should not only 
be limited to national healthcare 
providers but should be done globally. 
This is essential in orphan diseases 
such as ANCA associated vasculitis.287 
The integration of datasets on a global 
level can be achieved by one universal 
database, or by the use of common 
templates and universal ontologies 
that allow for automated integration 
when future research questions are 
formulated. The first approach would 
face several difficulties to implement, 
which includes aligning the vision of 
collaborators, overcoming differences 
in cross-border legislation and 
assuring the publication rights of 
contributing collaborators. These 
obstacles are problematic in the entire 
field of medicine and are often 
discussed in the renowned New 
England Journal of Medicine.288-292 In 
the field of ANCA associated 
vasculitis, most research databases 
are currently maintained by individual 
expert centres, with recent efforts to 
expand to a national level.293,294 In 
this fragmented environment, with a 
limited number of patients and 
restricted financial possibilities, the 
latter approach may be more practical 
to implement. 
 
Clinical decision support 
Clinical decision support (CDS), also 
known as computer-assisted medical 
decision making or artificial 
assistance, utilizes computer 
generated data to assist the physician 
to provide optimal healthcare. 
Systems that apply CDS have become 
available after the introduction of EMR 
systems, which enable automated 
processing of patient data. While 
several definitions for CDS systems 
have been described, the term 
generally refer to “any electronic 
system designed to aid directly in 
clinical decision making, in which 
characteristics of individual patients 
are used to generate patient specific 
assessments or recommendations 
that are then presented to clinicians 
for consideration.”295,296 Importantly, 
no medical decision is made 
independently by the system, the 
physician remains responsible for the 
decision. Interest in CDS systems was 
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sparked by the observation that about 
28% of adverse drug events among 
hospitalized patients were 
preventable.297 A British study 
observed that 11% of admitted 
patients experience adverse events, 
of which 8% were fatal and 48% were 
retrospectively judged to be 
preventable.298 In the United States, 
physicians and hospitals are obliged 
to implement CDS in order to 
demonstrate meaningful use of EMR 
systems according to the 2009 Health 
Information Technology for Economic 
and Clinical Health (HITECH) Act. 
While the clinical rules that form the 
basis of CDS systems are available in 
clinical practice guidelines, the 
adoption and adherence to these 
guidelines are far from perfect.299,300 
This is not surprising, since physicians 
would require at least 21.7 hours per 
day if they wish to adhere to these 
recommendations!301 Several barriers 
are present regarding the 
implementation and adherence 
thereof, which may in part be resolved 
by the use of CDS systems.299,302 
 
Examples of clinical decision support 
The implementation of CDS can range 
from simple calculations to adjust the 
medication dose based on the 
patient’s age or weight, providing 
likelihood ratios with test results197, to 
complex algorithms that combine a 
multitude of patient characteristics.303 
The principle can be implemented on 
clinical features to accurately 
diagnose pre-defined diseases, as has 
been proven in the case of sepsis303 
and urticaria.304 Another well-known 
example of artificial assistance is the 
evaluation of newly prescribed 
medicine for potential drug-drug 
interactions with the patient’s current 
medication, which notifies the 
physicians when a potentially life-
threatening interaction may 
occur.305,306 Artificial assistance has 
also been applied to prevent venous 
thromboembolism to correctly identify 
patients that require 
thromboprophylaxis.307,308 In a 
different approach, physicians were 
assisted in the decision whether blood 
transfusion was necessary based on 
haemoglobin values in order to 
significantly reduce inappropriate 
blood transfusions.309 A systematic 
review in 2012 described CDS 
systems in topics that addressed 
pharmacotherapy, diagnosis, chronic 
disease management, laboratory test 
ordering and interpretation310, 
preventive care, immunizations and 
initiating discussions with patients.296 
The review concluded that CDS 
systems improve health care process 
outcomes, e.g. adherence of 
physicians to local 
recommendations296, and a slight 
reduction in morbidity was 
noted.296,311 No evidence was 
observed that suggests that CDS 
systems directly reduce mortality, 
although included studies were 
heterogenous in methodology and 
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underpowered to show improvements 
in this outcome, as this was not the 
primary outcome.296,311 Currently, 
efforts to implement CDS are often 
not well-regarded as physicians 
become alert fatigue by an overflow of 
alerts that are incorrect or of low 
clinical importance, a shortcoming 
that can be addressed in future 
iterations of CDS 
systems.295,303,305,306,312 
 
Clinical decision support in ANCA 
associated vasculitis 
Clinical management in patients with 
ANCA associated vasculitis may in 
particular benefit from clinical 
decision support systems due to the 
complexity of patient care and the low 
incidence of the disease. A simple 
implementation would be the 
standardisation and automation of 
induction protocols according to the 
published trials. Currently, each 
separate medication and dose is 
manually prescribed, which is both 
time-consuming and prone to 
mistakes. This is also the case with 
regard to the monitoring of side-
effects during follow-up, as each 
laboratory test needs to be manually 
ordered. Automation of prescribing 
induction protocols could potentially 
reduce the risk of unnecessary 
exposure to immunosuppressive 
therapy and ensure that prophylaxis 
therapy is prescribed if applicable 
(e.g. osteoporosis prophylaxis during 
corticosteroid therapy313,314 and 
Pneumocystis pneumonia prophylaxis 
during cyclophosphamide therapy). 
Importantly, physicians will save time 
that was otherwise spent on manually 
prescribing and ordering standard 
protocols, so they can focus on the 
patient instead. 
Diagnostic delay, a glaring problem 
despite the introduction of ANCA 
testing, may be challenged by 
implementing a CDS system which 
alerts physicians on the possibility of 
orphan diseases based on clinical 
features. For instance, in patients with 
bloody nasal discharge and persisting 
pulmonary infiltrates or nodules on x-
ray despite appropriate antibiotic 
therapy, the physician may be 
advised to refer the patient to a centre 
with expertise in ANCA management, 
especially if surrogate markers for 
renal involvement are present. Such a 
system would mostly assist general 
practitioners who would generally 
only see an AAV patient once in their 
career, thereby alleviating disparities 
in healthcare outcomes based on the 
individual physicians’ knowledge.  
In this thesis, we report findings that 
can be implemented as clinical 
decision support to assist physicians 
in the maintenance of remission in 
patients with ANCA associated 
vasculitis. In Chapter 1, we report an 
algorithm that alerts physician about 
the occurrence of an ANCA rise. The 
algorithm automatically calculates 
whether a fluctuation in ANCA values 
fulfils the definition of an ANCA rise. 
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The most optimal cut-off value of an 
ANCA rise is derived from an ROC 
curve on previous patient data to 
increase sensitivity and specificity for 
a relapse. In addition, the algorithm is 
capable of presenting the relapse risk 
based on clinical features at the time 
of the ANCA rise, as reported in 
Chapter 2. These risk factors are real-
time updated based on clinical data of 
all included patients with available 
serial ANCA measurements in an 
anonymized manner. The system can 
be further extended by including other 
risk factors, such as patient 
characteristics at the time of 
diagnosis, genetics and previous 
therapeutic interventions. Whether 
the implementation of such a system 
decreases the occurrence of vasculitic 
damage and/or therapeutic 
complications and increases the 
quality of life of patients with ANCA 
associated vasculitis should be further 
investigated.  
 
Machine learning 
Standardized data collection in 
healthcare will lead to vast amounts 
of structured and well-defined data, 
which ushers in a new era of big 
data.315 However, big data will be of 
little use if we do not have advanced 
analytical tools that can translate the 
data to useful findings that can impact 
clinical healthcare.316 Due to recent 
advances in processing power of 
computers, machines are now capable 
of learning from large datasets, also 
known as machine learning. Using 
intricate statistical methods, 
machines are capable of deriving 
patterns and rules from these 
datasets, with which they can 
subsequently solve complex tasks 
with minimal human intervention. 
There are two approaches in machine 
learning: (1) supervised learning is 
possible in data that is labelled by a 
gold standard (e.g. a tumor is 
malignant or benign), and (2) 
unsupervised learning in data sets 
that are not labelled. These 
approaches have different purposes, 
wherein a supervised learning 
algorithm is capable of classifying and 
predicting new instances of data, 
while an unsupervised learning 
algorithm is capable of finding 
patterns in data that were previously 
unidentified. 
 
Machine learning has become popular 
due to the successes it has achieved 
in mastering (video) games, such as 
the defeat of world chess champion 
Gary Kasparov in 1997 (Deep Blue, 
IBM), the mastering of classic Atari 
2600 computer games (Google 
Deepmind)317 and the recent victories 
in Go (AlphaGo, Google Deepmind)318 
and no-limit Texas hold'em poker 
(Libratus, Carnegie Mellon 
University). However, it has also been 
successful in the field of healthcare. 
Recently it has been shown that the 
prognosis of patients with non-small 
General discussion 
130 
cell lung cancer can be accurately 
predicted based on microscopic 
pathology image features that are 
processed by a machine learning 
algorithm.319 Importantly, the 
algorithm that was used in this study 
can also be applied to other 
specimens and diseases, provided 
that a sufficient number of digital 
images is available. In another 
setting, it is also capable of 
diagnosing skin cancer from a picture 
taken with a mobile phone with similar 
accuracy as expert dermatologists, 
who even had a slight edge because 
they were allowed to use 
dermatoscopes.320 Such an algorithm 
has also been applied to retinal fundus 
photographs to detect diabetic 
retinopathy and diabetic macular 
edema.321 Machines can also learn 
from radiology images322, for example 
to diagnose and characterize thyroid 
nodules on ultrasound.323 
Impressively, machines can learn 
from intracortically recorded signals 
to restore cortical control of functional 
movement in quadriplegia.324 
 
In ANCA associated vasculitis, 
machine learning can be implemented 
in various ways. First, it can be 
implemented to enhance pattern 
recognition in indirect 
immunofluorescence. Second, it can 
be utilized to diagnose patients on the 
basis of clinical characteristics, 
including serology, imaging and 
histology. In addition, such a system 
may better predict the prognosis on 
the basis of these characteristics as 
compared to conventional 
classification models. The main 
advantage of machine learning is the 
ability to evaluate an unprecedented 
amount of data that is impossible with 
conventional statistical methods. 
Therefore, a predictive model of an 
ANCA rise for a relapse that is created 
using conventional methods (see 
Chapter 1 and Chapter 2) will in the 
future most likely be improved by a 
model that is created using machine 
learning. 
 
However, current implementations of 
machine learning suffer from several 
limitations.325 For instance, current 
algorithms are not yet capable of 
survival analysis.325 It should also be 
emphasized that the effectiveness of 
machine learning is dependent on the 
quality of the data (“garbage in is 
garbage out”). Therefore, 
standardized data collection is of 
utmost importance. Moreover, 
machine learning can only be 
functional if it can learn from large 
datasets, which is difficult to obtain in 
a disease that seldom occurs. For 
instance, the algorithm that predicts 
the prognosis of non-small cell lung 
cancer required thousands of 
histopathology whole-slide images325, 
while renal biopsy registries are 
limited to merely hundreds of cases of 
crescentic 
glomerulonephritis.118,131,326 This 
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further emphasizes the need of 
integration of data on a global manner 
in orphan diseases such as ANCA 
associated vasculitis.287 Last, the rules 
and patterns that have been learned 
by machine learning appear as a black 
box to the physician. While machine 
learning may indeed predict more 
accurately the prognosis of a patient 
with non-small cell lung cancer, a 
physician and decision makers may 
want to know on what features the 
prognosis was made. These 
algorithms analyse images of 
histology in far greater detail than 
humanly possible, but at the same 
time the translation to the 
pathophysiology is lost, nor can it 
infer causality in the correlations it 
has observed. Therefore, machine 
learning will complement but not 
replace current research methods. 
 
Toward a model that predicts disease 
activity 
As described in the introduction, 
classification models have had 
different purposes throughout the 
years. The initial reports sought 
similarities in patients to make 
research regarding potential 
treatment options possible.12,14 After 
the successful introduction of 
cyclophosphamide, classification 
schemes focused on patient 
characteristics that stratified the need 
for immunosuppressive induction 
therapy according to the disease 
severity at the time of diagnosis.327 
Due to the success of these 
classification schemes, ANCA 
associated vasculitis is no longer a 
fatal diagnosis and several treatment 
modalities with different side-effect 
profiles are available to effectively 
induce remission. This success has 
lead researchers to focus on the 
maintenance of remission, an aspect 
that was previously unimaginable. 
Researchers are now looking for 
strategies to prevent comorbidities 
from active disease while reducing 
treatment-related side-effects by 
personalizing maintenance therapy. 
Personalized maintenance therapy 
would entail increasing therapy in 
patients who are at risk of a relapse, 
while reducing therapy for those who 
are not. However, current 
classification schemes are of limited 
use to guide maintenance therapy 
because the current schemes are 
based on patient characteristics at the 
time of diagnosis and do not take 
follow-up into account. Therefore, in 
Chapter 3 we propose a new model 
that is focused on the biologic 
behavior of the disease that may in 
the future be used to guide 
maintenance therapy in patients with 
AAV.  
 
Which factors should be included in 
such a prediction model? In Chapter 1 
and Chapter 2, we investigate the role 
of serial ANCA measurements in such 
a model. In Chapter 4 and Chapter 5 
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we analyse whether other qualities of 
the autoantibody may contribute to 
the predictive value of serial ANCA 
measurements. While it is tempting to 
conclude that these factors should all 
be included in a future model, it 
should be emphasized that our 
findings need to be replicated in other 
cohorts. These studies should be of 
sufficient power to not only test the 
predictive value of the factors that we 
have identified, they may also identify 
new factors that were previously 
undetected. In addition, these studies 
require well-defined and high-quality 
data, which often cannot be extracted 
from retrospective data and should 
therefore be prospectively gathered. 
Prospective studies should include the 
systematic collection of samples (e.g. 
serum and urine samples, but also 
plasma dialysate during 
plasmapheresis and histologic 
samples) to make genomic, 
proteinomic and glycomic studies 
possible. The samples should be 
gathered according to standardized 
protocols at the time of active disease 
and during follow-up to study the 
onset of disease activity. Given the 
association with disease activity, 
ANCA rises may guide the collection of 
these samples. For instance, samples 
could be collected every (two) 
month(s) after an ANCA rise until the 
relapse occurs.  
 
While reading the seminal papers in 
the field of ANCA associated vasculitis 
(see A historical perspective), the 
high quality of these investigations is 
evident by the level of detail of the 
description of patient characteristics 
and histopathologic features. 
Interestingly, even the patient initials 
were reported, which would not be 
accepted today due to privacy issues. 
The current classification schemes 
have led to greater homogeneity in 
patient cohorts, but as a consequence 
they have also led to a diminished 
attention to detail. In order to realize 
the full potential of personalized 
medicine, we will most likely have to 
establish a similar level of detail as the 
seminal papers. Not only should the 
clinical and histologic characteristics 
be included in greater detail, several 
other biomarkers could be included, 
which we will discuss hereafter. 
 
New targets for biomarkers 
In this thesis, several novel markers 
were investigated for their potential 
predictive value for disease 
reactivation. A biomarker should 
indicate a characteristic that is 
objectively measured and evaluated 
as an indicator of normal biological 
processes, pathogenic processes, or 
pharmacologic responses to a 
therapeutic intervention.328 In 
particular, we focused on several 
qualities of the autoantibody. Our 
studies have shown that these 
qualities offer important prognostic 
information and should be further 
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investigated, as extensively discussed 
in the appropriate chapters. Most 
importantly, a prospective study 
should analyse the combined 
predictive value of a panel of these 
qualities at the time of an ANCA rise. 
In addition, in vitro studies should be 
performed to demonstrate the 
pathogenic process of these qualities 
of the autoantibody. In vitro studies 
include the ability of ANCA to prime 
neutrophils, consecutively leading to 
respiratory burst, increased adhesion 
and injury to endothelial cells and 
subsequent migration of neutrophils, 
as well as the ability to induce 
neutrophil extracellular traps.329-334 
Furthermore, our hypothesis that 
ANCA rises are associated with 
vasculitic and not granulomatous 
disease activity should be further 
investigated. A consensus 
classification of disease 
manifestations into “granulomatous” 
or “vasculitic” without the need of 
histologic evidence199 could be utilized 
to further substantiate our 
hypothesis.  
However, research regarding 
biomarkers that objectively measure 
disease activity should not only be 
limited to ANCA. In the next 
paragraphs, we will discuss potential 
biomarkers that could be of value to 
predict relapses in ANCA-associated 
vasculitis.  
 
Assessing disease activity with a 
panel of protein markers 
Using serum samples that were 
systematically obtained by the RAVE 
trial, a panel of 28 markers reflecting 
inflammation, injury and repair were 
tested to discriminate active disease 
from remission.206 The authors 
concluded that three biomarkers in 
particular were of interest for future 
studies: matrix metalloproteinase-3 
(MMP-3), tissue inhibitor of 
metalloproteinases-1 (TIMP-1) and 
chemokine CXCL13 (BCA-1). These 
biomarkers did not only distinguish 
active vasculitis from remission, but 
they were also capable of 
differentiating remission from 
grumbling disease. In a different 
study, it was shown that MMP-3 levels 
are higher in patients with renal 
involvement compared to patients 
with non-renal disease.335 In addition, 
MMP-3 and TIMP-1 levels were higher 
in patients with AAV compared to 
healthy controls, reflecting increased 
systemic inflammation and enhanced 
vascular remodeling.336,337 Given the 
promising results of these 
biomarkers, they are merited as 
promising candidates for future 
studies in staging vasculitis activity 
and predicting the risk of relapse. 
Another marker that has shown 
significant potential to predict 
relapses is serum calprotectin 
(S100A8/A9).207,338 In 2013, Pepper 
et al. identified high levels of 
calprotectin at 1 and 6 months after 
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treatment as a highly predictive risk 
factor for a relapse (a positive 
likelihood ratio of 10.3 at month 1).207 
More recently, using samples from the 
RAVE trial, it was shown that higher 
levels of calprotectin at 2 months after 
the induction therapy was predictive 
for a relapse in PR3-ANCA positive 
patients, but not in MPO-ANCA 
positive patients.338 
 
Urinary biomarkers of renal vasculitis 
A multi-centre cohort study with 
systematic collection of samples will 
allow for the investigation of the 
predictive value of a complete panel 
of biomarkers in serum or urine 
samples. Such an investigation has 
already been performed in (juvenile) 
lupus nephritis, which revealed a good 
correlation of several urinary 
markers, such as monocyte 
chemoattractant protein 1 (MCP-1), 
kidney injury molecule-1 (KIM-1) and 
neutrophil gelatinase-associated 
lipocalin (NGAL), with disease activity 
determined by a kidney biopsy.339-341 
This lead to the development of a 
novel renal activity index of lupus 
nephritis, which accurately identifies 
active lupus nephritis without the 
need of a biopsy.340 In ANCA 
associated vasculitis, a similar study 
has been performed with a limited 
number of patients.342 While these 
results are less convincing than the 
results in lupus nephritis, they 
warrant further investigation, 
especially regarding the 
discriminatory capacity of urinary 
MCP-1 to assess active disease. Using 
a different approach, a metabolomics 
profile that reflects renal disease 
activity was delineated by inducing 
MPO-ANCA associated vasculitis in 
Wistar-Kyoto rats and analysing 
urinary metabolites using nuclear 
magnetic resonance spectroscopy.343 
This metabolomics profile, with a 
prominent role for the myo-
inositol/citrate ratio, was then applied 
on a retrospective cohort of patients 
and accurately identified patients with 
active renal disease. The diagnostic 
accuracy of existing markers (CRP, 
eGFR and protein to creatinine ratio) 
was increased by adding the results of 
metabolomics profile (from 89.6% to 
95.8%, respectively).343  
Another urinary marker that has 
recently received a lot of interest is 
soluble CD163.205 This marker, shed 
by monocytes and macrophages, is 
highly specific for active renal disease 
in AAV patients (positive likelihood 
ratio of 20.8) and has been confirmed 
in internal and external validation 
cohorts.205 
 
Leukocyte subsets 
After the successful introduction of 
rituximab, B-cell subsets have 
received a lot of attention once they 
return after B-cell depletion. In 
particular, the return of B-cells with a 
low proportion of anti-inflammatory 
IL-10+ regulatory B cells344, CD5+ 
regulatory B-cells345,346 and naïve B-
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cells347 may predict a future relapse. 
The impact of the presence or 
absence of specific subsets of 
leukocytes is not only limited to B-
cells. T-cells also play an important 
role104,348, including CD8+ T-effector 
cells349, CD4+ T-helper cells350, IL-17-
secreting T-cells351-353, regulatory 
CD4+ T-cells354,355 and CD4+ effector 
memory T-cells355, especially when 
expressing CD134 and GITR.356 Last, 
low-density granulocyte357 and 
hypogranular granulocyte358 subsets 
may also prove to be effective 
biomarkers to assess disease activity 
in patients with ANCA associated 
vasculitis. 
 
Infections and vasculitis – in search 
for the second hit 
Since the first description of cases 
with Granulomatosis with Polyangiitis, 
the aetiology of the disease was 
associated with infections. In fact, one 
of the first descriptions of ANCA were 
linked to a possible Ross River virus 
infection.52 Nasal carriage of 
staphylococcus aureus is a risk factor 
for a relapse116,157 and maintenance 
therapy with high-dose co-
trimoxazole decreases the risk of a 
relapse.137 In animal studies, 
lipopolysaccharide aggravates MPO-
ANCA induced vasculitis64 and is 
required for PR3-ANCA induced 
vasculitis.63 Immunisation of rats with 
bacterial protein from Staphylococcus 
ureus and Escherichia coli lead to a 
positive C-ANCA titer, but not PR3- or 
MPO-ANCA positivity, and some 
evidence of vasculitis, but not 
convincing.359 In a recent study, mice 
were immunized with a trypsin-like 
protease of Saccharomonospora 
viridis, which shares 30% homology 
with proteinase 3. PR3-ANCA 
positivity was induced, as well as 
granulomatous inflammation, 
although the latter can also be 
attributed to the use of complete 
Freund’s adjuvant.360 Also, a LAMP-2 
epitope shares 100% homology with 
an amino-acid sequence from FimH, 
an adhesion molecule found in gram-
negative pathogens such as 
Escherichia coli, Klebsiella 
pneumoniae and Proteus mirabilis.361 
Rats immunized with FimH develop 
antibodies to LAMP-2 and subsequent 
necrotizing glomerulonephritis via a 
mechanism named molecular 
mimicry.361 In another model, PR3-
ANCA but no signs of vasculitis were 
induced in mice immunized with 
recombinant complementary (anti-
sense) PR3, a protein that may be 
derived from exogenous DNA or RNA 
brought in by pathogens.362 However, 
this mechanism has neither been 
completely elucidated nor confirmed. 
With regard to serial ANCA 
measurements, infections have been 
suggested as a potential second hit 
that creates a pro-inflammatory 
environment that enables the ANCA to 
become pathogenic. In the “second 
hit” hypothesis, ANCA-induced 
General discussion 
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(severe) disease reactivation is 
enabled by or aggravated by an as yet 
unidentified “second hit”. As 
described above, infections have been 
hinted as a potential candidate of a 
second hit, but this has never been 
fully elucidated, nor has it been 
thoroughly investigated. Therefore, 
signs of infections should be 
prospectively monitored during 
follow-up and the association with 
serial ANCA measurements and 
disease activity should be 
investigated. In addition, the impact 
of the pro-inflammatory stimulus of 
an influenza vaccination could also be 
of interest to investigate in relation to 
the presence of ANCA. While an 
influenza vaccination does not 
increase relapse rate143, it has 
previously been shown that it leads to 
a pro-inflammatory glycosylation 
profile of anti-vaccine IgG but not of 
total IgG.363 Whether a potential spill-
over effect occurs in antibodies 
targeted against MPO or PR3 could be 
further investigated. 
 
Research regarding infections and 
active vasculitis is not only warranted 
in order to understand the role of 
infections as an aggravator of 
vasculitis, it is also important in order 
to better differentiate symptoms 
caused by infections from symptoms 
caused by active vasculitis. This 
differentiation can in particular be 
difficult during induction 
immunosuppressive therapy, in which 
patients are prone to infections and 
conventional diagnostic methods may 
sometimes be inconclusive. 
Procalcitonin has been investigated as 
a potential marker to differentiate 
infections from active disease.364 In 
this study, the receiver operating 
characteristics curve for procalcitonin 
to differentiate AAV patients with an 
intercurrent bacterial infection (n=10) 
from AAV patients with a relapse 
(n=36) was 0.75 [95% CI 0.55-0.94], 
slightly higher than C-reactive protein 
(0.67 [95% CI 0.46-0.88]).364 
Whether other markers are valuable 
in differentiating infection from active 
vasculitis should be prospectively 
studied. 
 
Fine-tuning maintenance therapy 
A prediction model of disease activity, 
as proposed above, is only of value if 
the results have clinical 
consequences. Therefore, future 
prospective studies should investigate 
the ability of such a prediction model 
to guide maintenance therapy. While 
mortality and the occurrence of 
(major) relapses should be the 
primary research question, secondary 
questions should include the 
prevention of vasculitic or treatment-
related damage, a reduction of 
cumulative treatment exposure and 
quality of life indicators, as well as the 
economic impact in terms of 
hospitalization rate and a possible 
cost reduction.  
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Several strategies of maintenance 
therapy guided by ANCA rises have 
been investigated, as described in 
Chapter 3. Most importantly, 
cyclophosphamide at the time of an 
ANCA rise has proven to be effective 
in the prevention of relapses, but this 
strategy is heavily debated because 
cyclophosphamide is a potentially 
harmful drug.74,365 Lengthening the 
duration of azathioprine therapy 
based on the ANCA titer at the time 
that induction therapy is switched to 
maintenance therapy does not seem 
to protect against relapses, nor does 
it lower the severity of relapses that 
occur.176 Pre-emptive treatment at 
the time of an ANCA rise with 
azathioprine is not sufficient 
(unpublished data).365 Strategies that 
guide corticosteroid therapy based on 
serial ANCA measurements require 
further investigation.178 With the 
advent of rituximab 
therapy46,151,192,200, novel strategies 
are investigated to guide rituximab 
maintenance therapy. In particular, 
the timing of repeating Rituximab 
cycles is at present unknown and is 
being investigated in the 
MAINRITSAN2 trial (ClinicalTrials.gov 
Identifier: NCT01731561), in which 
individually timed retreatment based 
on ANCA rise or B cell reconstitution is 
compared with fixed interval dosing of 
Rituximab. Future studies that utilize 
advanced prediction models to guide 
maintenance therapy will in the future 
harbour exciting results that will 
further reduce the burden of the 
disease in patients with ANCA 
associated vasculitis.  
 
In summary, we have shown the 
predictive value of several biomarkers 
in this thesis. We propose a new 
prediction model that is focused on 
the biologic behavior of the disease 
that may in the future be used to 
guide maintenance therapy in 
patients with AAV. An effective 
method to achieve this objective is 
using data obtained from clinical 
healthcare once high-quality data is 
ensured by standardized data 
collection. Several markers have been 
proposed that may be of added value 
to accurately predict disease activity, 
which should also be analysed 
according to standardized protocols. 
Promising markers include a panel of 
protein markers, urinary markers, 
serial ANCA measurements, including 
characteristics of ANCA, as well as an 
increased vigilance for infections as a 
potential second hit. Future research 
regarding these biomarkers will 
potentially lead to a prediction model 
of disease activity that can be used to 
guide maintenance therapy to reduce 
the morbidity caused by treatment-
related and vasculitic damage. Clinical 
decision support will ensure that novel 
findings will be successfully 
implemented in clinical healthcare. 
Last, machine learning could in the 
future be introduced to further 
improve the accuracy of the model.
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Dutch summary 
- 
Nederlandse samenvatting 
 
Het afweersysteem
Het afweersysteem beschermt de 
mens tegen de gevaren van de 
buitenwereld. Zo werken de 
verschillende cellen van dit systeem 
nauw samen om schadelijke bacteriën 
en virussen te vernietigen. Daarnaast 
controleert het afweersysteem, ook 
wel het immuun systeem genoemd, of 
onze eigen cellen niet ongeremd 
vermenigvuldigen om kanker te 
voorkomen. Het afweersysteem is 
niet alleen in staat om ons te 
beschermen tegen nieuwe infecties, 
het kan ook een herinfectie goed 
voorkomen. Dit doet het door eiwitten 
genaamd “antilichamen” te maken 
tegen specifieke herkenningspunten 
van deze bedreigingen, zogenaamde 
“antigenen”. Deze antilichamen 
circuleren rond in ons bloed en 
plakken aan de antigenen bij een 
herinfectie, waardoor het 
afweersysteem direct in actie komt. 
Dit onderdeel van het immuun 
systeem wordt onder andere gebruikt 
om toekomstige infecties te 
voorkomen door middel van 
vaccinaties. Bij een vaccinatie worden 
antigenen van een virus of bacterie 
aangeboden aan het afweersysteem, 
waarop het antilichamen aanmaakt 
die een toekomstige infectie 
ongevaarlijk maken. 
Geen enkel systeem in de biologie is 
echter zonder fouten. Zo complex als 
het afweersysteem is, zo veel kan er 
fout gaan. Het systeem kan 
bijvoorbeeld minder goed werken, 
waardoor iemand zich niet goed kan 
beschermen tegen infecties (een 
“afweerstoornis”). Het kan echter ook 
te aggressief of ongecontroleerd 
reageren, waardoor de eigen, 
gezonde, cellen beschadigd raken 
(een “auto-immuun aandoening”). 
Het kan ook misgaan bij antilichamen. 
Sommige mensen maken 
antilichamen aan tegen 
herkenningspunten van onze eigen 
cellen en eiwitten. Deze antilichamen, 
auto-antilichamen genaamd, 
veroorzaken daardoor onstekingen in 
het lichaam waar dat niet nodig is, 
zoals we gaan zien bij vasculitis.
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Vasculitis – ontstekingen van de vaten
Ontsteking aan de vaten (“vasculitis” 
in het Latijn) werd al in de achtiende 
eeuw opgemerkt bij patiënten die met 
een grote verscheidenheid aan 
klachten bij de dokter kwamen. Deze 
klachten verergerden na verloop van 
tijd en vrijwel allen overleden binnen 
een jaar. Destijds werden bij de 
eerste onderzoeken afwijkingen van 
de grote vaten gezien met het blote 
oog. De vaten waren hierbij op 
verschillende plaatsen verwijd en 
verlittekend. Later zagen 
onderzoekers met behulp van een 
microscoop dat ook de kleine 
bloedvaten aangetast waren door een 
actieve ontsteking. Doordat de kleine 
vaten overal in het lichaam aanwezig 
zijn, kan het allerlei klachten 
veroorzaken – van de huid, de neus 
en de ogen tot en met de longen, de 
zenuwen en de nieren. Veel patiënten 
overleden uiteindelijk aan het 
uitvallen van dit laatste orgaan, 
aangezien nierfunctie vervangende 
behandelingen nog niet beschikbaar 
waren.  
Midden in de negentiende eeuw werd 
duidelijk dat afweerremmende 
medicijnen verbetering gaven voor 
deze patiënten. Deze medicatie wordt 
ook wel immunosuppressiva 
genoemd. Dit was destijds een grote 
doorbraak aangezien patiënten niet 
meer stierven door deze aandoening. 
De patiënten hadden na behandeling 
geen klachten meer en zijn dan “in 
remissie”. De afweerremmende 
medicatie, zoals cyclofosfamide en 
prednison, zijn echter niet zonder 
bijwerkingen. Doordat deze 
medicijnen het afweersysteem 
onderdrukken kunnen de patiënten 
zich minder goed beschermen tegen 
infecties. Daarnaast ontwikkelen 
patiënten na verloop van tijd vaker 
kanker bij langdurig gebruik. Volledig 
afbouwen van de medicatie is echter 
ook niet zonder risico’s, aangezien de 
aandoening vervolgens weer 
terugkomt in een groot gedeelte van 
de patiënten. Meerdere termen 
worden gebruikt voor de terugkeer 
van de ziekte, zoals een “relapse”, 
een “flare”, of een “chute”. De voor- 
en nadelen van de behandeling 
moeten dus tegen elkaar worden 
afgewogen. De perfecte balans is 
echter tot op heden niet duidelijk. 
In de jaren zestig werd een tweede 
belangrijke ontdekking gedaan. 
Destijds werden er auto-antilichamen 
ontdekt die vastplakten op 
neutrofielen, lichaamseigen cellen van 
de mens die onderdeel zijn van ons 
afweersysteem. Deze auto-
antilichamen werden alleen gevonden 
in het bloed van patiënten met 
vasculitis van de allerkleinste vaten 
en niet in het bloed van gezonde 
mensen. Onder de microscoop was te 
zien dat deze auto-antilichamen 
vastplakten binnen de cel van de 
neutrofiel, in het zogenaamde 
cytoplasma (zie Figure 5-6). Na deze 
bevinding werden de gevonden auto-
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antilichamen dan ook omgedoopt tot 
‘anti-neutrofiel cytoplasmatische 
antilichamen’, afgekort ANCA. De 
term ANCA geassocieerde vasculitis 
wordt vervolgens gebruikt bij 
patiënten met ontstekingen rondom 
de kleine vaten bij wie deze auto-
antilichamen gedetecteerd worden. 
Verder onderzoek liet zien dat deze 
antilichamen specifiek zijn gericht op 
de eiwitten proteinase 3 (PR3) en 
myeloperoxidase (MPO). In een klein 
gedeelte van de patiënten worden 
deze auto-antistoffen niet 
aangetroffen maar is er wel sprake 
van vasculitis in de kleine vaten. De 
ziekte in deze ANCA negatieve 
patiënten is meestal gelimiteerd tot 
de neus en longen, terwijl vrijwel alle 
patiënten met betrokkenheid van de 
nieren ANCA positief zijn.
 
 
Figure 5-6. Auto-antilichamen gericht op de neutrofiel kunnen zichtbaar gemaakt 
worden onder de microscoop (licht groene kleur). Aan de linkerkant is te zien hoe ze 
vastplakken rondom de celkern, terwijl ze aan de rechterkant vastplakken in het 
cytoplasma.  
 
Wat betekenen deze auto-
antilichamen? Onderzoekers hebben 
aangetoond dat het toedienen van 
ANCA in muizen leidt tot vasculitis in 
de nieren en longen. Dit onderzoek 
laat zien dat de auto-antilichamen 
gevaarlijk kunnen zijn in muizen, hoe 
zit dit echter in de mens? In het bloed 
van patiënten met ANCA 
geassocieerde vasculitis werd gezien 
dat de ANCA in hoge mate aanwezig 
waren op het moment dat de ziekte 
voor het eerst tot uiting kwam (bij 
diagnose). De hoeveelheid ANCA nam 
na de behandeling met 
afweerremmende medicatie af en 
verdween zelfs volledig in een deel 
van de patiënten. Bij sommige 
patiënten kwamen echter de ANCA 
weer terug in het bloed. Hoewel deze 
patiënten op het moment van zo’n 
ANCA stijging klachtenvrij waren, 
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kregen zij na verloop van tijd weer 
terugkeer van de klachten. Zo’n ANCA 
stijging werd dus gezien als een 
alarmsignaal voor een toekomstige 
relapse (zie Figure 5-7).  
Op basis van bovenstaande 
bevindingen werd daarom 
beredeneerd dat de afweerremmende 
medicatie gegeven kon worden op 
geleide van de ANCA waarden. Zo zou 
de medicatie volledig afgebouwd 
kunnen worden bij patiënten waarbij 
de ANCA niet meer detecteerbaar is 
en zou de medicatie voortijdig 
opgehoogd kunnen worden bij een 
ANCA stijging. Het verband tussen 
een stijging van de ANCA waarde en 
terugkeer van de ziekte is echter niet 
absoluut, aangezien niet elke patiënt 
terugkeer van de ziekte krijgt na een 
ANCA stijging en de ANCA niet in elke 
patiënt volledig verdwijnt wanneer zij 
langdurig geen klachten meer 
hebben. Tot op heden wordt daarom 
niet geadviseerd om de medicatie aan 
te passen op basis van de ANCA 
waarden. 
 
Dit proefschrift
Het doel van dit proefschrift is om de 
terugkeer van ziekte te voorspellen in 
patiënten met ANCA geassocieerde 
vasculitis die in remissie zijn. De 
relatie tussen de ANCA waarden in het 
bloed en de ziekte activiteit speelt 
hierbij een centrale rol. Waarom leidt 
een ANCA stijging in de ene patiënt 
wel tot terugkeer van de ziekte, maar 
niet in een ander? Kunnen wij op het 
moment van zo’n ANCA stijging 
voorspellen wie wel een relapse krijgt 
en wie niet? Indien wij nauwkeurig 
kunnen voorspellen wie een relapse 
krijgt, kunnen wij namelijk preventief 
beginnen met het ophogen van 
afweerremmende medicatie om de 
terugkeer van de ziekte te 
voorkomen.  
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Figure 5-7. Een voorbeeld van het beloop van een denkbeeldige patiënt met ANCA 
geassocieerde vasculitis. Bij het vaststellen van de ziekte wordt afweerremmende 
medicatie gestart, waarna de klachten van de patiënt verdwijnen. Vanwege de 
bijwerkingen van de medicatie wordt de medicatie langzaam afgebouwd. Echter, 
sommige patiënten krijgen daarna weer terugkeer van de klachten. De ANCA waarde 
is bij diagnose hoog en neemt af na het starten van de medicatie. In sommige 
patiënten stijgt de ANCA waarde voordat de klachten terugkomen. Indien dit het 
geval is, kan medicatie preventief gestart worden om een toekomstige relapse te 
voorkomen.  
 
Om dit doel te bereiken, onderzochten 
wij alle patiënten met ANCA 
geassocieerde vasculitis die 
behandeld werden bij de afdeling 
immunologie van het Maastricht 
University Medical Center. Dit 
centrum is gespecialiseerd in 
zeldzame aandoeningen van het 
afweersysteem en er worden 
daardoor veel patiënten met vasculitis 
doorverwezen door andere 
specialisten uit de zuidelijke regio van 
Nederland.  
In de periode van januari 2000 tot en 
met november 2011 werden 166 
patiënten behandeld voor ANCA 
geassocieerde vasculitis in Maastricht 
die na behandeling in remissie 
kwamen. Van deze 166 patiënten 
hadden er 104 patiënten ook 
betrokkenheid van de nieren in het 
verleden. In het beloop van de studie 
zijn 7 patiënten komen te overlijden, 
voornamelijk aan de gevolgen van 
hart- en vaatziekten, kanker of een 
infectie. Bij 74 patiënten vond er een 
relapse plaats tijdens het beloop van 
de studie, wat inhoud dat de kans op 
een relapse gemiddeld 17% per jaar 
is. In 26 gevallen was de relapse 
ernstig en levensbedreigend, 
bijvoorbeeld doordat de nieren 
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betrokken waren. In de overige 48 
relapses waren de klachten mild, 
bijvoorbeeld doordat de klachten 
gelimiteerd waren tot de gewrichten, 
de neus of de longen. 
 
Tijdens de studie verdween de ANCA 
in 116 patiënten. In totaal werd een 
ANCA stijging gezien in 89 patiënten. 
Een belangrijke bevinding is dat geen 
van onze patiënten die ANCA negatief 
bleven een ernstige relapse kregen 
tijdens onze studie. In andere 
woorden, als de ANCA verdwijnt, dan 
is de kans op een levensbedreigende 
terugkeer van de ziekte minimaal. 
Tweeënvijftig van de 89 patiënten 
met een ANCA stijging kregen 
uiteindelijk terugkeer van de ziekte 
(58.4%). Echter, deze relapse vond 
slechts in 35 patiënten (39.5%) plaats 
binnen een half jaar na de ANCA 
stijging. 
 
Wij hadden het vermoeden dat een 
ANCA stijging wel gerelateerd was 
met terugkeer van de ziekte in 
patiënten met nierbetrokkenheid, 
maar niet in patiënten waarbij dit niet 
het geval was (Chapter 1). Bij de 
ziekte worden namelijk twee 
verschillende beelden gezien onder de 
microscoop: ten eerste ontsteking 
van de vaten (vasculitis) en ten 
tweede een opeenstapeling van 
ontstekingscellen. Dit laatste wordt 
ook wel granulomateuze ontsteking 
genoemd (zie Figure 5-8). In de 
nieren is vrijwel altijd sprake van 
vasculitis en maar zelden van 
granulomateuze ontsteking. Vasculitis 
wordt ook gezien bij andere 
levensbedreigende uitingen van de 
ziekte, zoals bloedingen in de longen 
en zenuwbetrokkenheid. 
Granulomateuze ziekte is vaak 
zichtbaar in de neus, de luchtpijp en 
als knobbels in de longen. Over het 
algemeen zijn uitingen van de 
granulomateuze ziekte minder 
ernstig, maar het kan nog steeds 
levensbedreigend zijn. Bij patiënten 
waarin vasculitis wordt gezien onder 
de microscoop, wordt bijna altijd een 
ANCA waarde in het bloed gevonden. 
Dit in tegenstelling tot patiënten met 
enkel granulomateuze ontsteking, 
waarbij net iets meer dan de helft 
ANCA positief zijn. In muizen zijn 
onderzoekers enkel in staat om 
vasculitis uit te lokken na de 
toediening van ANCA, terwijl 
granulomateuze onsteking zelden 
wordt gezien.  
Om ons vermoeden te bevestigen, 
verdeelden wij onze groep patiënten 
in twee groepen: een groep met 
nierbetrokkenheid en een groep 
zonder nierbetrokkenheid. Om de 
relatie tussen een ANCA stijging en 
een relapse te meten, maakten wij 
gebruik van een wiskundige analyse. 
Deze analyse geeft een waarde aan 
het verband tussen een ANCA stijging 
en een relapse, genaamd de hazard 
ratio (HR). Hoe hoger de HR, hoe 
groter de kans op een relapse na de 
ANCA stijging, terwijl een HR van 1 
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aangeeft dat de kans op een relapse 
niet veranderd. In de gehele groep 
van patiënten is de hazard ratio 5.8. 
De kans op een relapse is dus 5.8 keer 
groter nadat een ANCA stijging heeft 
plaatsgevonden. In de groep van 
patiënten met nierbetrokkenheid is de 
hazard ratio 11.1, terwijl deze slechts 
2.8 is in de groep met patiënten 
zonder nierbetrokkenheid. Met andere 
woorden, de kans op een relapse is 
sterk verhoogd na een ANCA stijging 
in patiënten wanneer de nieren 
betrokken zijn. Dit in tegenstelling tot 
patiënten met gelimiteerde ziekte, 
waarbij een ANCA stijging weinig 
vertelt over een toekomstige relapse.
 
 
Figure 5-8. Twee verschillende beelden onder de microscoop. Aan de linkerkant is 
een biopt getoond van een nier van een patiënt met ANCA geassocieerde vasculitis. 
Door de uitgebreide ontsteking in de vaten is het nierfilter volledig verwoest. Aan de 
rechterkant is een voorbeeld van een granuloom te zien. Dit granuloom bestaat uit 
immuuncellen die bij een langdurige ontsteking opeenhopen. 
 
Na de bevestiging dat de ANCA 
waarden gerelateerd zijn met 
ziekteactiviteit in patiënten met 
nierbetrokkenheid en niet in andere 
patiënten, gingen wij op zoek naar 
andere factoren die voorspellend zijn 
voor een relapse ten tijde van een 
ANCA stijging (Chapter 2). Om dit te 
onderzoeken, analyseerden wij alle 
patiënten met nierbetrokkenheid en 
een ANCA stijging. Dit waren 60 
patiënten in totaal, waarvan 36 
patiënten een relapse kregen na 
verloop van tijd (60%). Zestien 
patiënten daarvan hadden een 
relapse binnen een half jaar (31.7%). 
In totaal vonden wij drie 
risicofactoren voor een relapse ten 
tijde van een ANCA stijging. Ten 
eerste hebben patiënten die 
behandeld zijn met milde 
afweerremmende medicatie een 
grotere kans op een relapse 
vergeleken met patiënten die 
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behandeld werden met zwaardere 
medicatie, zoals cyclofosfamide en 
rituximab. Ten tweede hebben 
patiënten een hogere kans op een 
relapse wanneer de ANCA door blijft 
stijgen na de eerste ANCA stijging. 
Patiënten waarbij de ANCA waarde 
weer daalt of stabiel blijft na de ANCA 
stijging, krijgen dus minder snel een 
relapse. Als laatste vonden wij dat een 
ANCA stijging tijdens de herfst vaker 
wordt gevolgd door een relapse dan 
tijdens de andere seizoenen. Wij 
vermoeden dat dit komt doordat er in 
de periode na de herfst vaker een 
infectie plaatsvindt ten opzichte van 
de lente en de zomer. Wij denken dat 
een infectie ervoor zorgt dat het 
afweersysteem geactiveerd wordt en 
zo de ANCA in staat stelt om schade 
te doen. Bovendien daalt de vitamine 
D waarde in de herfst en winter, een 
vitamine die wordt aangemaakt in de 
huid bij zonlicht en een belangrijke 
sturende werking heeft op het 
afweersysteem.  
Slechts 16 van de 60 patiënten 
hadden (31.7%) een relapse binnen 
een halfjaar na een ANCA stijging. 
Van alle patiënten die een ANCA 
stijging in de herfst hadden, hadden 9 
van de 13 patiënten een relapse 
(69.2%). De kans voor een relapse 
binnen een half jaar is nog groter 
wanneer de ANCA waarde blijft stijgen 
na de ANCA stijging (77.8%). In 
patiënten met deze risicofactoren is 
de kans op een relapse zo groot, dat 
de voordelen van preventieve 
ophoging van afweerremmende 
medicatie mogelijk opwegen ten 
opzichte van de nadelen.  
 
In een uitgebreide analyse van alle 
voorgaande onderzoeken naar de 
relatie tussen een ANCA stijging en 
een relapse (Chapter 3), concluderen 
wij dat er ruimte is voor een 
behandeling op basis van de ANCA 
waarden in een specifieke groep van 
patiënten bij specifieke 
omstandigheden. Wij stellen voor dat 
patiënten ingedeeld behoren te 
worden op basis van risicofactoren 
voor een relapse. De 
afweerremmende medicatie kan op 
basis van deze indeling gedoseerd 
worden. Zo kan de medicatie 
gepersonaliseerd worden naar elke 
individuele patiënt. De risicofactoren 
die wij hebben gevonden (Chapter 1 
en Chapter 2), kunnen hierbij een rol 
spelen. Deze factoren moeten echter 
ook door andere onderzoekers 
onderzocht worden om onze 
bevindingen te bevestigen. Daarnaast 
verwachten wij dat een aantal andere 
factoren ook een rol kunnen spelen. 
Een aantal factoren hebben wij in de 
volgende hoofdstukken onderzocht. 
 
Wij hadden het vermoeden dat niet 
elke auto-antilichaam hetzelfde is als 
het ander. Zo verwachten wij dat 
bepaalde ANCA minder snel leiden tot 
een relapse dan andere ANCA. Auto-
antilichamen kunnen onderscheiden 
worden op bepaalde kwaliteiten. Een 
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van die kwaliteiten is de mate waarop 
de auto-antilichaam blijft vastplakken 
aan het antigeen. Waarschijnlijk zal 
een ANCA die beter vastplakt vaker 
leiden tot een relapse dan een ANCA 
die nauwelijks vastplakt. De sterkte 
van deze binding wordt ook wel de 
aviditeit genoemd; hoe hoger de 
aviditeit, hoe sterker het auto-
antilichaam vastplakt aan het antigen. 
Om de invloed van de aviditeit te 
onderzoeken, analyseerde wij de 
aviditeit van PR3-ANCA in 30 
patiënten met een ANCA stijging 
(Chapter 4). Wij konden niet 
bevestigen dat ANCA met een hoge 
aviditeit vaker leidde tot een relapse 
dan ANCA die minder goed 
vastplakten. Wij vonden echter wel 
dat de aviditeit van ANCA na verloop 
van tijd hoger werd in patiënten met 
nierbetrokkenheid die een relapse 
kregen. Dit was niet het geval in 
patiënten zonder nierbetrokkenheid 
met een relapse. Ook in patiënten met 
nierbetrokkenheid die in remissie 
bleven, bleef de aviditeit stabiel.  
 
Een ander eigenschap van een 
antilichaam is het glycosylatie profiel. 
Dit profiel bestaat uit een aantal 
suikergroepen die aan het antilichaam 
vastzitten. De hoeveelheid 
suikergroepen heeft invloed op de 
vorm van het antilichaam en bepaalt 
daardoor hoe andere cellen van het 
afweersysteem erop reageren. 
Bijvoorbeeld, hoe minder galactose 
groepen vastzitten aan het 
antilichaam, hoe sterker de 
afweercellen worden geactiveerd. 
Anderzijds wordt het afweersysteem 
afgeremd wanneer antilichamen veel 
galactose of siaal groepen bevatten. 
Je kunt het vergelijken als vlaggetjes 
die aangeven hoe sterk het 
afweersysteem moet reageren. Deze 
eigenschap wordt gebruikt door het 
afweersysteem om zich beter te 
kunnen beschermen tegen 
bedreigingen van buitenaf. Wanneer 
patiënten bijvoorbeeld gevaccineerd 
worden tegen een infectie, maakt het 
afweersysteem de antilichamen 
sterker door galactose groepen te 
verwijderen.  
Om de invloed van het glycosylatie 
profiel op de kans van een relapse te 
bepalen, analyseerden wij het profiel 
in alle PR3-ANCA positieve patiënten 
met een ANCA stijging (Chapter 5). 
Uit de resultaten van de analyse bleek 
dat het glycosylatie profiel inderdaad 
voorspellend is voor een relapse. Op 
het moment van de ANCA stijging 
hebben patiënten met weinig 
galactose of siaal groepen aan de 
antilichamen een hogere kans op 
terugkeer van de ziekte. Met andere 
woorden, patiënten met antilichamen 
met veel galactose of siaal groepen 
aan de antilichamen zijn beschermd 
tegen een relapse. Na de ANCA 
stijging neemt de hoeveelheid 
galactose en siaal groepen verder af 
in patiënten die een relapse krijgen en 
niet in patiënten die in remissie 
blijven. Deze bevinding ondersteunt 
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onze conclusie dat het glycosylatie 
profiel voorspellend is voor een 
relapse. In de toekomst kan deze 
analyse gebruikt worden om de 
behandeling aan te passen aan het 
risico op een relapse. 
Naast het glycosylatie profiel van alle 
antilichamen in het bloed, hebben wij 
ook het profiel geanalyseerd van de 
specifieke auto-antilichamen tegen 
proteinase 3. Uit deze analyse blijkt 
dat de PR3-ANCA minder galactose en 
siaal groepen krijgen in alle patiënten 
die wij onderzocht hadden. Het auto-
antilichaam wordt dus nog effectiever 
in het activeren van het 
afweersysteem, ongeacht of de ziekte 
terugkomt of niet. Hieruit concluderen 
wij dat een andere factor aanleiding 
geeft tot een relapse, gereflecteerd 
door het glycosylatie profiel van alle 
antilichamen bij elkaar. Deze tweede 
factor activeert het immuun systeem 
en stelt daardoor waarschijnlijk de 
PR3-ANCA in staat om schade aan te 
brengen. Wat deze tweede factor 
precies is, weten wij tot op heden nog 
niet. Wij vermoeden dat het een 
infectie is, maar het kan ook een 
andere factor zijn die het 
afweersysteem activeert, zoals silica. 
Onderzoek naar de tweede factor is 
noodzakelijk.
 
Conclusie en discussie
In dit proefschrift hebben wij 
aangetoond dat een ANCA stijging 
voorspellend is voor een relapse in 
patiënten met nierbetrokkenheid 
maar niet in patiënten zonder 
betrokkenheid van de nieren. In 
patiënten met nierbetrokkenheid is de 
kans op een relapse 11 keer groter 
nadat een ANCA stijging heeft 
plaatsgevonden. Daarnaast is de kans 
op een levensbedreigende relapse 
minimaal wanneer de ANCA negatief 
is geworden tijdens remissie en er 
geen ANCA stijging heeft 
plaatsgevonden. Drie risico factoren 
voor een relapse op het moment van 
een ANCA stijging werden 
geïdentificeerd: (1) voorgaande 
behandeling met milde 
afweerremmende medicatie, (2) 
wanneer de ANCA blijft doorstijgen na 
de initiele ANCA stijging en (3) 
wanneer de ANCA stijging plaatsvindt 
tijdens de herfst.  
Daarnaast onderzochten wij de 
invloed van de eigenschappen van het 
antilichaam. De kracht van de binding 
tussen het antilichaam en het 
antigeen neemt toe in patiënten met 
nierbetrokkenheid die een relapse 
krijgen, maar niet in andere 
subgroepen. Een andere eigenschap 
van het antilichaam is het glycosylatie 
profiel. Uit ons onderzoek bleek dat 
patiënten met weinig galactose of 
siaal groepen aan antilichamen meer 
risico lopen op een relapse ten tijde 
van een ANCA stijging.  
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Wij concluderen uit ons onderzoek dat 
er voldoende mogelijkheden zijn om 
ziekte activiteit te voorspellen in 
patiënten met ANCA geassocieerde 
vasculitis. Wij stellen een model voor 
die de kans op een relapse voorspelt 
ten tijde van remissie. Dit model geeft 
op basis van de eigenschappen van de 
patiënt de kans aan op een relapse. 
Middels het voorgestelde model kan 
de afweerremmende medicatie 
gepersonaliseerd worden voor elke 
individuele patiënt. Zo kan de 
medicatie opgehoogd worden in 
patiënten met een hoog risico, om 
toekomstige ziekte activiteit te 
voorkomen. In patiënten met een lage 
kans op ziekte activiteit zou de 
medicatie juist gestaakt kunnen 
worden, om bijwerkingen van de 
medicatie te voorkomen. 
Uit ons onderzoek zijn meerdere 
risicofactoren geïdentificeerd die 
opgenomen kunnen worden in dit 
model. Echter, onze resultaten zijn 
gebaseerd op de patiënten die 
behandeld zijn in Maastricht. Onze 
bevindingen dienen getoetst te 
worden in andere onderzoeksgroepen 
om onze conclusies te bevestigen.  
Wij verwachten dat het voorgestelde 
model het beste gerealiseerd kan 
worden door een grote 
onderzoekspopulatie te analyseren. 
Dit kan mogelijk gemaakt worden 
door gebruik te maken van de data 
van alle patiënten die klinisch 
behandeld worden. Door data op 
gestandardiseerde wijze te 
verzamelen zijn complexe wiskundige 
methoden mogelijk, zoals het gebruik 
van kunstmatige intelligentie. Door de 
rekenkracht van de huidige 
computers te gebruiken, kan de arts 
in staat gesteld worden om de 
behandeling te personaliseren voor 
elke indivuele patiënt. ANCA 
geassocieerde vasculitis komt zelden 
voor, het is daarom van cruciaal 
belang dat er op internationaal gebied 
samengewerkt wordt om dit doel te 
bereiken. 
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Valorisation addendum 
 
Relevantie
ANCA geassocieerde vasculitis komt 
zelden voor en is door het European 
Medicines Agency (EMA) aangewezen 
als weesziekte. Per definitie is 
onderzoek in ANCA geassocieerde 
vasculitis daardoor gelimiteerd om 
kennis beschikbaar te maken voor 
maatschappelijke benutting ten 
opzichte van onderzoek in meer 
prevalente aandoeningen. Het klein 
aantal patiënten met de aandoening 
leidt ertoe dat er een minimale 
financiële prikkel is om onderzoek in 
ANCA geassocieerde vasculitis 
mogelijk te maken. Het onderzoek is 
echter niet minder relevant, 
aangezien het een grote impact kan 
hebben voor de specifieke doelgroep. 
Een overzicht van het onderzoek naar 
ANCA geassocieerde vasculitis van de 
afgelopen eeuw bevestigd de 
aanzienlijke impact, zoals beschreven 
in de introductie. Aan het begin van 
de 20ste eeuw overleed elke patiënt 
binnen een jaar na het vaststellen van 
de diagnose, terwijl de aandoening 
tegenwoordig goed behandeld kan 
worden. Ook het onderzoek van de 
laatste decennia heeft een grote 
impact gehad op de mortaliteit, zoals 
geconstateerd uit een 
cohortonderzoek van Maastricht 
University. Uit dit onderzoek is 
gebleken dat patiënten behandeld in 
het eerste decennium van de 21ste 
eeuw 4 keer minder vaak kwamen te 
overlijden dan patiënten behandeld in 
de tachtiger jaren. 
De aandoening wordt tegenwoordig 
gezien als een chronische ziekte in 
plaats van een fatale diagnose. 
Toekomstig onderzoek richt zich 
daarom voornamelijk op de lange 
termijn. Een belangrijk 
aandachtspunt is de optimale 
onderhoudsbehandeling om terugkeer 
van de ziekte te voorkomen en 
tegelijkertijd de kans op bijwerkingen 
door de medicatie te minimaliseren. 
Het onderzoek beschreven in dit 
proefschrift sluit goed aan bij de 
onderzoeksagenda’s opgesteld door 
internationale verbanden zoals de 
European Vasculitis Society (EUVAS) 
en de OMERACT Vasculitis Working 
Group.  
Een belangrijk onderdeel van het 
valorisatie traject is de minimale 
kosten van het onderzoek dat is 
beschreven in dit proefschrift. Dit 
onderzoek is tot stand gekomen door 
de klinische data van patiënten die 
reeds behandeld werden in het 
academisch ziekenhuis in Maastricht 
op structurele wijze te verzamelen om 
statistische analyses mogelijk te 
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maken. Dit onderzoek is verwezenlijkt 
zonder structurele, noch substantiële 
financiering en heeft desondanks 
meerdere wetenschappelijke 
publicaties geproduceerd in 
vooraanstaande medische vakbladen.
 
Innovatie
Het onderzoek uit dit proefschrift is 
innoverend in meerdere opzichten. In 
Chapter 1 werden nieuwe inzichten 
gegeven in de vraag of het 
systematisch meten van de ANCA 
waarden na de diagnose van ANCA 
geassocieerde vasculitis voorspellend 
is voor ziekte activiteit. Deze 
onderzoeksvraag is sinds de 
introductie van ANCA relevant is 
gebleven, zoals uiteengezet in 
Chapter 3. De vraagstelling werd op 
een wiskundige manier benaderd om 
rekening te houden met zowel de 
stijging van de ANCA waarde als de 
tijd tussen de ANCA bepalingen. Het 
onderzoek heeft nieuwe inzichten 
gegeven in de relevantie van seriele 
ANCA bepalingen door het verband 
met bepaalde histologische beelden te 
leggen. Het resultaat draagt hierdoor 
bij aan het paradigma dat het verschil 
tussen granulomateuze en vasculitis 
activiteit relevant is, ook al ligt de 
nadruk de laatste jaren voornamelijk 
op het verschil in de serologische 
klassificatie tussen PR3- en MPO-
ANCA. Dit onderzoek heeft tevens 
laten zien dat er geen toegevoegde 
waarde is om de ANCA te bepalen met 
zowel de antigeen specifieke ELISA’s 
als de indirecte immunofluorescentie, 
waardoor onnodige kosten bespaard 
kan worden. 
Tot dusver werd alleen gekeken naar 
de eerste ANCA stijging, zonder 
rekening te houden met de 
veranderingen na de ANCA stijging. In 
Chapter 2 onderzoeken wij als eerste 
onderzoeksgroep wat risicofactoren 
voor terugkeer van de ziekte zijn op 
het moment van de ANCA stijging. 
Een verdere stijging van de ANCA 
waarde zorgt voor een verhoogde 
kans op ziekte activiteit, daarnaast 
wordt er een associatie gevonden met 
seizoensgebondenheid. We leveren 
hiermee een belangrijke bijdrage aan 
het paradigma dat een tweede ‘hit’ 
nodig is, welke waarschijnlijk 
seizoensgebonden is. Dit onderzoek 
laat zien dat het mogelijk is om een 
voorspellend model te ontwikkelen 
om terugkeer van de ziekte te 
voorspellen.  
Na het beschrijven en het analyseren 
van het cohort van patiënten met 
ANCA geassocieerde vasculitis, zijn de 
daaropvolgende onderzoeken gericht 
op het identificeren van nieuwe 
biomarkers die voorspellend zijn voor 
een relapse op het moment van de 
ANCA stijging. In Chapter 4 
onderzochten wij het beloop van de 
bindingskracht van het antilichaam 
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tijdens de followup. Hoewel de 
aviditeit van het antilichaam op 
theoretische gronden van belang kan 
zijn, zijn tot op heden nog weinig 
indicaties om de aviditeit te bepalen in 
een klinische setting. De aviditeit van 
PR3-ANCA stijgt in patiënten met 
renale betrokkenheid waarbij de 
ziekte in de toekomst terugkeert.  
In Chapter 5 onderzochten wij de 
voorspellende waarde van het 
glycosylatie profiel van PR3-ANCA 
voor een relapse. Het onderzoek naar 
het glycosylatie profiel is een 
veelbelovend onderzoeksveld, ook 
wel glycomics genoemd. Tot nu toe 
zijn er echter enkel associaties 
gevonden met bepaalde 
aandoeningen, zoals de ernst van de 
ziekte activiteit in reumatoide 
arthritis. Ons onderzoek heeft 
aangetoond dat het glycosylatie 
profiel ten tijde van een PR3-ANCA 
stijging voorspellend is voor de 
terugkeer van de ziekte in ANCA 
geassocieerde vasculitis. Deze 
bevindingen tonen voor het eerst de 
klinische relevantie aan van het 
bepalen van het glycosylatie profiel.
 
Planning en realisatie
Onze bevindingen dienen bevestigd te 
worden in andere cohorten voordat ze 
toegepast kunnen worden in de 
kliniek. De risicofactoren die zijn 
geidentificeerd in onze studies dienen 
in een prospectieve studie onderzocht 
worden in een cohort met een groot 
aantal patiënten. Om dit te 
verwezenlijken is een database intern 
ontwikkeld waarmee de klinische data 
op systematische en 
gestandardiseerde wijze verzameld 
kan worden om automatische analyse 
mogelijk te maken. Om een 
voldoende aantal patiënten te 
analyseren dient daarnaast 
samengewerkt te worden in een 
internationaal verband om genoeg 
power te hebben om het individuele 
effect van alle risicofactoren te 
bepalen. Op basis van de resultant 
van zo’n toekomstige studie kan een 
predictie model ontwikkeld worden 
toekomstige ziekte activiteit accuraat 
te voorspellen. Wanneer dit predictie 
model is ontwikkeld, kan vervolgens 
onderzocht worden of het geleiden 
van de onderhoudsbehandeling op 
basis van dit model leidt tot het 
voorkomen van zowel toekomstige 
ziekte activiteit als vasculitis schade 
als bijwerkingen van de medicatie. 
Daarnaast dient in een toekomstige 
studie onderzocht te worden of zo’n 
strategie leidt tot een verbetering van 
de kwaliteit van leven.  
 
 
  
Two roads diverged in a yellow wood, 
And sorry I could not travel both 
And be one traveler, long I stood 
And looked down one as far as I could 
To where it bent in the undergrowth; 
 
Then took the other, as just as fair, 
And having perhaps the better claim, 
Because it was grassy and wanted wear; 
Though as for that the passing there 
Had worn them really about the same, 
 
And both that morning equally lay 
In leaves no step had trodden black. 
Oh, I kept the first for another day! 
Yet knowing how way leads on to way, 
I doubted if I should ever come back. 
 
I shall be telling this with a sigh 
Somewhere ages and ages hence: 
Two roads diverged in a wood, and I— 
I took the one less traveled by, 
And that has made all the difference. 
 
The road not taken 
Robert Frost (1874 – 1963) 
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